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ABSTRACT 
 
Dilated cardiomyopathy (DCM) is the third most common cause of heart failure, 
often associated with arrhythmias and sudden cardiac death if not controlled.  Metabolic 
and/or environmental factors, such as alcohol abuse, obesity, diabetes and Chagas disease, 
alter glycoprotein glycosylation, can lead to DCM. Inherited genetic disease, such as the 
human congenital disorders of glycosylation (CDG), causes multi-system manifestations 
including DCM. Non-congenital changes in glycosylation are also occurred in humans 
with and in animal models of DCM and heart failure. However, mechanisms responsible 
for glyco-dependent DCM are not understood. Here we sought to investigate the impact 
of sialylation and N-glycosylation in cardiac function.  
Partial reduction of N-α2,3-sialylation achieved through ST3Gal4 deletion 
(ST3Gal4
-/-
) led to adult late-onset DCM. The DCM symptoms progressed gradually, 
developing thinner left ventricular walls and dilation of all four chambers by 18-month 
old, but with preserved systolic function. Transverse aortic constriction (TAC) was used 
as a chronic stressor on 16-20 week old mice to determine whether the ability of the 
ST3Gal4
-/-
 heart to compensate against pathologic insult is compromised.  TAC’d 
ST3Gal4
-/-
 mice presented with insufficient hypertrophy and reduced systolic function 
that deteriorated into congestive HF within six weeks post-surgery, while constricted WT 
hearts remained well-adapted throughout (ejection fraction, ST3Gal4
-/- 
=34±5.2%; WT 
ix 
 
=53.8±7.4%; p<0.05). Calcineurin expression was decreased in ST3Gal4
-/-
 (compared to 
TAC’d WT), contributed to the maladaptation of TAC’d ST3Gal4-/-.  
In order to better understand the role of glycosylation on cardiac function, we 
generated a cardiomyocyte specific knockout (αMHC-Cre) of glycosyltransferase 
responsible for synthesizing complex and hybrid N-glycans, Mgat1, (Mgat1CKO). 
Similar to but much more severe than that observed in ST3Gal4
-/-
, Mgat1CKO developed 
early-onset of DCM, late adult mortality, severely impaired cardiac systolic and diastolic 
function and frequent arrhythmias. Marked sex-difference in cardiac phenotype was 
observed in this autosomal gene (Mgat1) deletion, with male Mgat1CKO more severely 
affected. Both ST3Gal4 and Mgat1 did not participate in murine cardiogenesis, evidenced 
by normal litter size, Mendelian distribution of genotypes, no septal defect or vessel 
deformation under autopsy or echocardiography.   
In conclusion, we provided here the first and direct evidence of desialylation-
elicited idiopathic dilated cardiomyopathy (DCM), reporting the cardiac phenotype of 
ST3Gal4
-/-
and cardiac-specific knockout of Mgat1. Our data showed sialylation and 
complex N-glycosylation are essential for cardiac function, and reduced N-glycosylation 
or sialylation leads to DCM development, contractile dysfunction and arrhythmia.  
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CHAPTER ONE  
GENERAL INTRODUCTION 
 
Pathophysiology of Dilated Cardiomyopathy and Heart Failure  
Heart failure (HF) affects more than 23 million people worldwide 
[1]
, with dilated 
cardiomyopathy (DCM) the third most common cause of HF. In adults, DCM happens in men 
more than in women 
[2]
. The European Society of Cardiology defines DCM as, “left ventricular 
dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary 
artery disease sufficient to cause global systolic impairment; the right ventricle can also be 
involved 
[3].” Diagnosis is based on patient history, physical and clinical presentations, and 
echocardiography.  
Echocardiography of DCM typically shows left ventricular (LV) dilation and LV systolic 
dysfunction (e.g. reduced EF% and FS%) with or without mitral regurgitation 
[2]
. Adult coronary 
angiography should show no sign of coronary artery obstruction. Right ventricle (RV) can be 
affected too, presenting impaired RV function and right heart failure 
[2]
. Chest X-ray shows 
cardiomegaly and increased pulmonary vascular markings (signs of pulmonary edema). ECG 
typically shows sinus tachycardia, ST-T changes, and sometimes atrial and/or ventricular 
arrhythmia, bundle-branch block, low voltage and etc. 
[2]
. Thrombus formation is one of the 
common complications of DCM that can cause stroke.  Endomyocardial biopsy can be used to 
define the cause of the DCM 
[2]
. 
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Macroscopic examination of DCM heart shows the enlargement of all 4 chambers with 
ventricular dilation more obvious than atria. The valves and epicardial coronary arteries are 
usually normal 
[2]
. In some patients, intracavitary thrombi are present. Under microscope, 
cardiomyocyte size varies greatly with some atrophied cells and some hypertrophied cells. 
Ventricular wall often undergo extensive remodeling, displaying interstitial and perivascular 
fibrosis 
[2]
.  
Treatment of DCM is currently limited to treating HF symptoms, delaying disease 
progress, managing arrhythmia and preventing complications, including oral standard therapy 
(angiotensin-converting-enzyme inhibitor, β-blocker with or without diuretics), implantable 
cardioverter-defibrillators (ICD), ventricular-assist device, and heart transplantation 
[2]
. 
Variety of factors can cause DCM, including gene mutation, infection (viral myocarditis, 
Chagas disease), alcoholism, cardiotoxic agents, endocrine dysfunction and nutritional 
deficiencies. Approximately 30-48% of DCM is reported as familial due to different gene 
mutations 
[2]
.  However, approximately 70% of DCM is considered idiopathic, of unknown 
etiology and mechanism 
[4]
. Genes that can cause DCM usually encode cytoskeletal and 
sarcomeric proteins with predominantly autosomal-dominant inheritance pattern 
[2]
. The 
cytoskeletal gene mutations identified so far are: dystrophin, desmin, lamin A/C, sarcoglycan, 
metavinculin and etc. 
[2]
. Dystrophin is an X chromosomal gene and the mutation in dystrophin 
causes Duchenne muscular dystrophy, Becker muscular dystrophy, or X-linked dilated 
cardiomyopathy, preferably in male 
[5]
. Another cytoskeletal protein lamins are located at the 
nuclear lamina. Lamin A and C are expressed exclusively in heart and skeletal muscle cells. 
Lamin A/C mutation causes the autosomal-dominant form of Emery-Dreifuss muscular 
dystrophy, manifests AV block and skeletal myopathy with associated DCM 
[2]
. Mutations in 
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sarcomeric proteins, however, cause both hypertrophic and dilated cardiomyopathy phenotypes, 
such as β-myosin heavy chain (thick filament) and cardiac actin (thin filament)and etc. [2]. 
Furthermore, phospholamban and sodium-channel SCN5A mutations are also reported in DCM. 
For cytoskeletal and sarcomere protein mutations, defects of force transmission and /or force 
generation are thought to cause DCM. For phospholamban mutation, disturbed calcium 
homeostasis is thought to cause DCM 
[2]
. 
 Infection that can induce DCM includes viral carditis, Chagas’ cardiomyopathy and etc. 
Chagas disease is caused by the protozoan Trypanosoma cruzi, the leading cause of chronic heart 
failure in Latin America. Chagas’ cardiomyopathy is characterized as DCM, heart failure, 
conduction disease, malignant arrhythmia and sudden cardiac death 
[2]
.  
Heart failure is defined as “an abnormality of cardiac structure or function leading to 
failure of the heart to deliver oxygen at a rate commensurate with the requirements of the 
metabolizing tissues, despite normal filling pressures (or only at the expense of increased filling 
pressures)” [6]. Typical signs of heart failure include breathlessness, ankle swelling, fatigue, 
elevated jugular venous pressure, pulmonary crackles, displaced apex beat and etc. 
[6]
. 
Traditionally, LV EF%≤35% is considered severe heart failure (normal EF%>50%). In mice, 
normal EF% range from 55% to 85%.  
Heart failure is graded according to New York Heart Association functional classification 
based on the severity of symptoms and physical activity 
[7]
:  
Class I:  No limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea (shortness of breath). 
Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea (shortness of breath). 
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Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, or dyspnea. 
Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure 
at rest.  If any physical activity is undertaken, discomfort increases. 
Identifying the underlying causes for heart failure is critical for its treatment. There is 
rising evidence showing activated calcineurin/NFAT pathway can cause heart failure. This 
mechanism will be described in detail later in this chapter. 
 
Cardiac Ion Channel Operation During Action Potential and ECG  
In human, ventricular cardiomyocyte action potential (AP) consists of the following 
phases (See Figure 1.1B-C): Phase 4 is at baseline where inward rectifier K
+
 current (IK1) effuses 
the K
+
 out of the cell to maintain the resting membrane potential. When membrane potential 
reaches the threshold, a rapid upstroke rises from the influx of Na
+
 (INa) through fast voltage-
gated Na
+
 channel (Phase 0). This is then followed by a brief and transient decline (Phase 1), 
mostly due to the inactivation of voltage-gated Na
+
 channel and the opening of the transient 
outward K
+
 channel that effuse the K
+
 out of the cell (Ito). Phase 2 is the plateau phase when 
voltage-gated L-type Ca
2+
 channel opens and Ca
2+
 influx (ICa, L) initiates myocytes contraction. 
In the meantime, Na
+
/Ca
2+
 exchanger acts by moving 3 Na
+
 in for exchange of 1 Ca
2+ 
out, 
helping maintaining the plateau phase. Other delayed rectifier K
+
 currents are also involved in 
the plateau phase, namely IKs and IKr. The influx of Ca
2+
 through L-type Ca
2+
 channel leads to 
Ca
2+
 -induced Ca
2+
 release (CICR) from sarcoplasmic reticulum, which in turn triggers 
excitation-contraction coupling (E-C coupling), resulting in the contraction of the myocytes 
[8]
. 
After phase 2, the ventricular AP ends with a relatively rapid return to the resting membrane 
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potential (Phase 3) that involves the gradual inactivation of L-type Ca
2+
 channel, gradual 
increase of the delayed rectifier K
+
 currents (e.g. IKs and IKr), and  increase of IK1 current to draw 
the membrane potential towards resting potential.   
        In comparison, ventricular AP waveform in mice is triangular with a large phase 1 
repolarization and the lack of distinctive plateau phase (See Figure 1.1B) 
[9]
. This is probably due 
to the different ionic currents that are responsible for shaping AP waveform. The rapid 
depolarization phase (Phase 0) is similar in both mice and human and is caused by fast INa 
[10]
. 
The main difference between murine and human AP lies in the repolarization phase. In human, 
two main repolarizing currents, IKr and IKs account for the repolarization in AP. But in mice, it is 
Ito and IK, slow 
[11]
. IKs and IKr are negligible in mice (See Figure 1.1C) 
[8]
.  In addition, the steady 
state non-inactivating current, Iss, also contributes to the mice ventricular repolarization. 
Moreover, in human, Ito only briefly activates and exclusively contributes to transient 
repolarization of phase 1. No IK, slow and Iss is detected in human ventricular cardiomyocyte 
[8]
. 
As a result, in mice, a large early repolarization (phase 1) arise from both Ito and IK, slow currents 
causes a large J wave immediately after QRS complex (ventricular depolarization) (See  
A) 
[8]
. ST segment represents the plateau phase (phase 2) in human. Because plateau phase in 
mice is indistinctive, ST segment is absent. T wave in human represents the heterogeneity of 
repolarization throughout the heart and is usually concordant with QRS complex. In mice, there 
is a negative and relatively small T wave after J wave (See Figure 1.1A). Other differences 
include the much faster resting heart rate in mice (450–750bpm) [12], about 10 times faster than 
that in human (60-100bpm). As a consequence, AP duration in mice is much shorter than that in 
human (See Figure 1.1B). Since QT interval is mostly determined by AP duration, this leads to 
much shorter murine QT interval which is only 50-100ms, when compared to human QT interval  
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Figure 1.1. The comparison of ECG, action potential and ionic currents between mice and 
human. (Continued on Next Page) 
                                                                                                                                                          
A. 
B. 
C. 
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Figure 1.1 (Continued) 
Only ventricular cardiomyocyte’s activities are shown here. A. The representative lead II ECG 
waveform from human (left) and mouse (right). When compared to human, mice have a large J 
wave immediately after QRS complex (ventricular depolarization), representing the large early 
repolarization phase in mice (phase 1) 
[8]
.  ST segment is absent, and T wave is negative and 
relatively small in mice. In addition, the resting heart rate is 450–750bpm in mice [12], about 10 
times faster than that in human (60-100bpm). As a consequence, the action potential duration in 
mice is much shorter than that in human (B). This also leads to much shorter murine QT interval 
which is only 50-100ms, when compared to human QT interval (about 400ms) 
[11]
. B. The 
representative action potential (AP) waveform from ventricular cardiomyocytes in human (left) 
and in mice (right). When compared to human, ventricular AP waveform in mice is triangular 
with a large phase 1 repolarization and the lack of distinctive plateau phase 
[9]
. Scale bar (left), 
100ms; scale bar (right), 25ms. C. The rapid depolarization phase (Phase 0) is similar in both 
mice and human and is caused by fast INa 
[10]
. The main difference between murine and human 
AP lies in the repolarization phase. In human, two main repolarizing currents, IKr and IKs account 
for the repolarization in AP. But in mice, it is Ito and IK, slow 
[11]
. IKs and IKr are negligible in mice 
[8]
.  In addition, the steady state non-inactivating current, Iss, also contributes to the mice 
ventricular repolarization. Moreover, in human, Ito only briefly activates and exclusively 
contributes to transient repolarization of phase 1. No IK, slow and Iss is detected in human 
ventricular cardiomyocyte 
[8]
.  
 
* Figure is adapted from Boukens, B.J. et al., 2014 and reprinted from Nerbonne, J.M. et al., 
2001 with permission (See Appendix 2-3). 
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(about 400ms) (See Figure 1.1A) 
[11]
. It is also very difficult to provoke ventricular or atrial 
arrhythmia in mice. For example, murine AV node refractory period is relatively long, it is much 
harder to induce atrioventricular reentry in mice.     
The excitation-contraction coupling (E-C coupling) starts at phase 2 when the influx of 
Ca
2+
 through L-type Ca
2+
 channel causes a small local increase in intracellular [Ca
2+
]. This small 
increase of local [Ca
2+
] then binds to the nearby ryanodine receptors on sarcoplasmic reticulum 
(SR) and triggers a much larger Ca
2+
 -induced Ca
2+
 release (CICR). The released Ca
2+
 then binds 
to troponin and initiates the myofibril contraction, producing the movement necessary to pump 
the blood out. During the repolarization phase, about 70% of intracellular Ca
2+
 is re-uptaken by 
sarcoendoplasmic reticulum calcium transport ATPase (SERCA) residing on SR, and the rest of 
intracellular Ca
2+
 is excreted by Na
+
/Ca
2+
 exchanger on plasma membrane 
[13]
. The reduction of 
intracellular [Ca
2+
] relaxes the myofibrils (See Figure 1.2). The main regulator for SERCA pump 
is phospholamban (PLB) which acts by inhibiting SERCA’s activity. Phosphorylation of PLB 
releases this inhibition, and in turn activates the re-uptake of Ca
2+
 into SR.  In SR, Ca
2+
 is mainly 
stored by binding to calsequestrin (CSQ) and/ or other calcium binding proteins 
[13]
.  
 
Cardiac Channelopathy  
Cardiac channelopathy is a group of disease caused by disruption of ion channel function 
or its regulatory proteins. So far, the discovered channelopathies include: long QT syndrome, J 
wave syndromes (e.g. Brugada syndrome, early repolarization syndrome and etc.), short QT 
syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), familial atrial 
fibrillation and etc. (See Figure 1.3) 
[14]
. 
Long QT syndrome (LQTS) is characterized by QT prolongation with syncope and  
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 SERCA PLB 
  
(CSQ) 
  
 
Figure 1.2. Excitation-contraction coupling in cardiomyocyte. 
The excitation-contraction coupling (E-C coupling) starts at phase 2 when the influx of Ca
2+
 
through L-type Ca
2+
 channel causes a small local increase in intracellular [Ca
2+
]. This small 
increase of local [Ca
2+
] then binds to the nearby ryanodine receptors on sarcoplasmic reticulum 
(SR) and triggers a much larger Ca
2+
 -induced Ca
2+
 release (CICR). The released Ca
2+
 then binds 
to troponin and initiates the myofibril contraction, producing the movement necessary to pump 
the blood out. During the repolarization phase, about 70% of intracellular Ca
2+
 is re-uptaken by 
sarcoendoplasmic reticulum calcium transport ATPase (SERCA) residing on SR, and the rest of 
intracellular Ca
2+
 is excreted by Na
+
/Ca
2+
 exchanger on plasma membrane. The reduction of 
intracellular [Ca
2+
] relaxes the myofibrils. The main regulator for SERCA pump is 
phospholamban (PLB) which acts by inhibiting SERCA’s activity. Phosphorylation of PLB 
releases this inhibition, and in turn activates the re-uptake of Ca
2+
 into SR. In SR, Ca
2+
 is stored 
mainly by binding to calsequestrin (CSQ) and/ or other calcium binding proteins 
[13]
.  
 
* Figure is adapted from Silverthorn, D.U. al., 2004 with permission. 
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sudden cardiac death secondary to Torsades de Pointes and ventricular fibrillation, in the absence 
of structural heart disease or other causes of QT prolongation 
[15, 16]
. About 90% of LQTS results 
from loss-of-function mutations in IKs, Ikr or IK1, or gain-of-function mutations in INa or ICa, L (See 
Figure 1.3) 
[17]
. The excessive prolongation of repolarization leading to prolonged relative 
refractory period is thought to be the cause for torsades de pointes in LQTS 
[17]
. 
J-wave syndrome has a J wave immediately after QRS complex in ECG 
[17]
. J-wave 
syndrome includes Brugada syndrome (BrS), early repolarization syndrome and etc. 
[17]
. BrS 
occurs predominantly in men 
[15, 17]
 and is characterized by abnormal right ventricular conduction 
and coved-type ST elevation in V1-V3 leads without the structural heart disease or secondary 
causes (e.g. pharmacological agents) known to cause Brugada-like ECG (See Figure 1.3A). BrS 
is caused by loss-of-function mutations in INa or  ICa, L or gain-of-function mutations in Ito or  
IKATP 
[15]
. BrS AP exhibits a prominent and unopposed Ito in the right ventricular epicardium, 
which leads to an abnormal J wave, ST segment elevation and initiation of ventricular fibrillation 
(See Figure 1.3) 
[15]
. Another J-wave syndrome, early repolarization syndrome, also displays an 
enhanced Ito current in ventricular epicardial AP, resulting in the abnormal J wave and high 
susceptibility to ventricular fibrillation 
[14]
.  
Short QT syndrome (SQTS) is a rare disease and is characterized by short QT interval, 
sudden cardiac death and high risk of ventricular & atrial arrhythmia (due to short absolute 
refractory period) on an otherwise structurally normal heart (See Figure 1.3A) 
[15]
. In contrast to 
LQT, SQTS has increased K
+
 currents due to gain-of-function mutations in IKr, IKs or IK1, which 
causes short QT interval (See Figure 1.3) 
[14, 17]
.  
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is another rare disease 
characterized by early-onset adrenergically mediated fatal arrhythmias that leads to syncope and 
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sudden cardiac death 
[17]
. Surface ECG of CPVT patients is usually unremarkable. Diagnosis is 
made upon detection of stress-induced arrhythmia during exercise stress test or Holter recording 
showing bidirectional ventricular tachycardia (beat-to-beat 180° rotation of the QRS complex) 
[17]
. CPVT is caused by gain-of-function mutations in ryanodine receptor-2 (RyR2) or 
calsequestrin-2 mutation 
[14]
. Increased intracellular [Na
+
] producing intracellular Ca
2+
 overload 
is thought to be the mechanism triggers bidirectional ventricular tachycardia in CPVT 
[17]
.  
Cardiac channelopathies can also result from altered ion channel membrane trafficking, 
posttranslational modifications, and dysfunctional ion channel regulatory proteins 
[18]
.  For 
example, Ankryin B facilitates the membrane protein targeting, and the loss-of-function 
mutations in ankyrin B causes long QT syndrome 4 (LQT4). It is thought that Ankryin B 
mutation leads to the improper localization of Na/Ca exchanger, Na/K ATPase and IP3 receptor, 
which can cause an increase in intracellular [Na
+
], leads to LQTS 
[17]
. Caveolin-3 is a major 
component of caveolae and involves in membrane microdomain formation and endocytosis of 
NaV channel. Mutation in caveolin-3 increases INa current and causes LQT9. α1-syntrophin is a 
part of cardiac dystrophin associated protein complex. α1-syntrophin mutation leads to released 
inhibition of associated neuronal nitric oxide synthase, and in turn causes an increase in INa 
current and LQT12 
[17]
. In addition, mutations in the β subunit of KV channels (the regulatory 
protein of KV channel) that conduct IKs and IKr leads to LQT5 and LQT6 
[17]
.  
Voltage-gated ion channels are also heavily glycosylated with glycans comprise up to 30% 
of total channel mass 
[19, 20] 
. The reported voltage-gated ion channels that are affected by 
glycosylation are: NaV, KV, CaV, hyperpolarization-activated cyclic nucleotide gated channel 
(HCN), calcium-activated potassium (KCa), transient receptor potential channels (TRP) and etc.
 
[21-24]
. For example, sialic acid is the negatively charged monosaccharide that often terminates N-  
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Figure 1.3. Examples of cardiac channelopathy. 
Three cardiac channelopathies are presented here: long QT syndrome, short QT syndrome and 
Brugada syndrome. A. The representative lead II or lead V2 ECG from normal (black, upper 
panel) or diseased (red, lower panel) is shown here. ECG of long QT syndrome (LQTS) showed 
prolonged QT interval. Short QT syndrome (SQTS) has shortened QT interval. And Brugada 
syndrome (BrS) exhibited an abnormal J wave with coved-type ST segment elevation in right 
precordial leads (V1-V3). B. The representative ventricular myocytes’ AP waveforms from 
normal (black) and diseased (red). LQTS displayed a prolonged AP waveform in epicardial 
ventricular myocytes. SQTS showed a shortened AP waveform. And BrS exhibited the 
transmural gradient between the endocardial (dotted red line) and epicardial (solid red line), 
which leads to the abnormal J wave in ECG. C. The ionic mechanisms of LQTS, SQTS and BrS. 
Downwards arrow means loss-of-function and upwards arrow means gain-of-function. APD, 
action potential duration.   
 
* Figure is adapted from Giudicessi, J.R. al., 2012 with permission (See Appendix 4). 
 
Lead II Lead II Lead V2 
epicardial 
myocytes 
with transmural 
gradient 
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and O-glycan chains. These negative charges of sialic acids contribute to the effective external 
surface charge of ion channels. Previous studies showed that experimental prevention or removal 
of sialic acids markedly altered the voltage sensitivity of NaV and KV gating, through direct, 
isoform-specific, electrostatic mechanisms 
[25-31]
. 
Moreover, increasing number of channel mutations has been reported to associate with 
DCM development. For example, SCN5A mutation has been linked to DCM. DCM-causing 
SCN5A mutations usually do not disrupt sarcolemmal NaV channel expression, but via the loss-
of-function or gain-of-function changes in NaV gating. It is also speculated that such SCN5A 
mutations in DCM disrupt the NaV interaction with intracellular cytoskeleton or ECM and lead to 
DCM formation 
[32]
. Mutation in phospholamban, who plays an essential role in Ca
2+
 
homeostasis via regulating SERCA pump, can also lead to DCM. Another ion channel linked to 
DCM is the sulfonylurea receptor 2A which is the regulatory subunit of cardiac KATP channel 
[33]
. 
 
Glycosylation as Post-Translational Modification  
Glycosylation is one of the most important post-translational modifications, responsible 
for producing glycoproteins, glycolipids (mostly glycosphingolipids), hyaluronan (hyaluronic 
acid) and proteoglycans in mammalian cells (See Figure 1.4). Membrane proteins and secreted 
proteins are often heavily glycosylated, as well as extracellular matrices (ECMs). Glycosylation 
has significant clinical impact, for example, human A, B, and O blood group antigens are 
glycans of surface glycoproteins and glycolipids on the red blood cell and other types of cells. 
[34]
. 
The anti-thrombotic agents, heparin and its derivatives, are among the most commonly used 
drugs in the world 
[35]
. 
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Figure 1.4. Major classes of glycosylation and their nomenclature. 
Glycosylation is an important post-translational modification in mammalian cells, responsible for 
producing glycoproteins, glycolipids (mostly glycosphingolipids), hyaluronan, proteoglycans and 
etc. Two main types of protein glycosylation: N-glycosylation and O-glycosylation. N-
glycosylation assembles glycan on the nitrogen atom of the amide group of Asparagine (Asn). 
And O-glycosylation assembles glycan on the oxygen atom of the hydroxyl group of serine 
(Ser)/threonines (Thr) 
[35]
. Hyaluronan (hyaluronic acid) is a nonsulfated glycosaminoglycan 
composed of the repeating N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA) (GlcNAc-
GlcA)n. Hyaluronan is the largest polysaccharide in mammals and usually forms hydrated  
matrices (e.g. vitreous humor in the eye) 
[36]
. Proteoglycan is a protein that carries one or more 
glycosaminoglycan chains such as heparin sulfate, chondroitin sulfate and etc. Proteoglycan is 
abundant in ECM (such as basement membrane, cartilage and etc.) and intracellular secretory 
granules. The cell membrane bound proteoglycans are able to transmit signals from ECM to 
intracellular cytoskeleton 
[37]
. The core structure of the glycan chain (gray region) is conserved 
among all cell types. For example, the core structure of N-glycan is composed of 2 GlcNAc + 3 
mannoses in mammal. However, the pattern of the branching and terminal oligosaccharides (e.g. 
sialic acid) is regulated in a tissue- or cell lineage-specific manner during development. 
Glycosylation has significant clinical impact. For example, human A, B, and O blood group 
antigens are glycans of glycoproteins and glycolipids on the red blood cell surface and other cell 
types 
[34]
. The anti-thrombotic agents, heparin and its derivatives, are among the most commonly 
used drugs in the world 
[35]
. Gal, galactose; Glc, glucose; Man, mannose; NeuAc, N-acetyl 
neuraminic acid (also known as sialic acid); GlcA, glucuronic acid; IdoA, iduronic acid; Fuc, 
fucose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine. 
  
 
                (Sialic Acid) 
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Figure 1.4 (Continued) 
* Figure is reprinted from Rillahan, C.D. et al., 2011 with permission (See Appendix 5). 
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Mammalian glycosylation typically go through ER-Golgi pathway. In Golgi apparatus, 
this process is catalyzed by  the enzymes called glycosyltransferases 
[38]
. Golgi 
glycosyltransferases that participate in the early steps of glycosylation are often located at cis- 
and medial Golgi, such as N-acetylglucosaminyltransferase I (Mgat1) who catalyzes the 
formation of hybrid and complex N-glycosylation. Whereas glycosyltransferases that catalyze 
the later steps of glycosylation are usually located at trans-Golgi, such as ST3Gal 
sialyltransferase that catalyzes the terminal sialylation, the last step of glycosylation. Golgi 
glycosyltransferases are usually type II transmembrane proteins and are composed of a single 
transmembrane domain, an intraluminal large C-terminal containing enzymatic sites, and a short 
N-terminal as an anchor segment 
[38]
.  
Two major types of protein glycosylation occur in mammalian cells: N-glycosylation and 
O-glycosylation. N-glycosylation assembles glycan on nitrogen atom of the amide group of 
Asparagine (Asn) (often the Asn of Asn-X-Ser/Thr sequon). And O-glycosylation assembles 
glycan on the oxygen atom of the hydroxyl group of serine (Ser)/threonines (Thr) 
[35]
 (See Figure 
1.4). For N-glycosylation, the process starts on a lipid-like molecule, dolichol phosphate, linked 
to ER membrane where the oligosaccharide is synthesized at the cytosolic side of ER (See Figure 
1.5). When 2 N-acetylglucosamines (GlcNAc) and 5 mannoses are added to the dolichol 
phosphate, the dolichol-linked precursor oligosaccharide is flipped inside the ER lumen and 7 
more monosaccharides are added 
[39]
. The whole precursor oligosaccharide (14 monosaccarides: 
2 GlcNAc + 9 mannose + 3 glucose) is then transferred “en bloc” to the Asn residue of the 
growing nascent polypeptide, undergoes initial trimming and processing (such as the calnexin-
calreticulin cycle of ER quality control) until the protein is properly folded. Protein is then 
transferred to cis-Golgi and medial Golgi for further trimming (e.g. Mgat1), and trans-Golgi for 
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terminal glycosylation (e.g. ST3Gal4) (See Figure 1.5). Disruption of this process leads to 
reduced/ de-glycosylation, resulting in a group of diseases called congenital disorders of 
glycosylation (CDGs) (See Figure 1.5). 
The core structure of the glycan chain is conserved among all cell types, for example, the 
core structure of N-glycan is 2 N-acetylglucosamiens + 3 mannoses in mammal. However, the 
pattern of the branching and terminal oligosaccharides (e.g. sialic acid) is regulated in a tissue- or 
cell lineage-specific manner during development. The change of terminal glycan structures is 
also related to malignant transformation in cancer 
[34]
. Glycosylation is important for 
glycoprotein’s functions, including promoting proper protein folding, glycoprotein quality 
control, targeting proteins to the correct cellular compartments, contributing to ligand 
recognition processes, and modifying the charge and isoelectric point of proteins 
[21-23, 40-47]
. 
 
Glycosylation in Cardiovascular Disease 
Human congenital disorders of glycosylation (CDG) are a family of diseases result in 
reduced glycoprotein/ glycolipid glycosylation. There are more than 40 subtypes of CDG, 
afflicting 1/50,000 to 1/100,000 newborns worldwide 
[48-54]
.  CDG leads to high infant mortality 
and diverse clinical symptoms, including delayed brain development, GI and immune system 
defects and etc. The same gene mutation can result in wide variety of phenotypic expressions, 
probably due to the differences in the genetic background among patients as well as the dietary 
and environmental factors 
[55]
. Almost all CDGs have reduced or de-sialylation, evidenced by 
isoelectric focusing (IEF) electrophoresis of serum glycoprotein’s sialylation status such as 
transferrin 
[55]
.  Because sialylation is typically the last step in glycosylation process, and the  
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Figure 1.5. The process of N-glycosylation in mammalian cells. 
N-glycosylation starts on a lipid-like molecule, dolichol phosphate, linked to ER membrane 
where the oligosaccharide is synthesized at the cytosolic side of ER. When 2 N-
acetylglucosamines (GlcNAc) and 5 mannoses are added to the dolichol phosphate, the dolichol-
linked precursor oligosaccharide is flipped inside the ER lumen and 7 more monosaccharides 
are added 
[39]
. The whole precursor oligosaccharide (14 monosaccarides: 2 GlcNAc + 9 mannose 
+ 3 glucose) is then transferred “en bloc” to the Asn residue of Asn-X-Ser/Thr sequon of the 
growing nascent polypeptide, undergoes initial trimming and processing (e.g. calnexin- 
calreticulin cycle, CCC, an ER quality control mechanism) until the protein is properly folded. 
Protein is then imported to cis-Golgi and medial Golgi for further trimming (e.g. Mgat1), and 
trans-Golgi for terminal glycosylation (e.g. ST3Gal4). Only one of many terminal glycosylation 
patterns is shown here. Finally, the mature glycoprotein is transported out of Golgi apparatus to 
its destination. Disruption of this process results in a group of disease called congenital disorders 
of glycosylation (CDGs). Mgat1, N-Acetylglucosaminyltransferase I; ST3Gal4, β-galactoside 
α2,3-sialyltransferase 4. 
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Figure 1.5 (Continued) 
* Figure is adapted from Helenius A, Aebi M. Intracellular functions of n-linked glycans. 
Science. 2001;291:2364-2369. Reprinted with permission from AAAS (See Appendix 6). 
 
 
20 
 
mutation leads to truncated glycosylation in either at or proximal to the point of sialylation in the 
Golgi 
[50]
. Therapeutics are not widely available. The increased realization of cardiac dysfunction 
associated with young CDG patients has led physician scientists to recommend that all young 
patients suffering from idiopathic cardiomyopathy be screened for CDG, and all young CDG 
patients be monitored for cardiac dysfunction 
[51, 56-58]
.   
There is a group of CDGs presenting with muscular dystrophy and dilated 
cardiomyopathy (DCM), including mutations in protein O-mannosyltransferase-1 or -2 
(POMT1/2, walker-warburg syndrome), protein O-mannose β-1,2-N-
acetylglucosaminyltransferase (POMGNT1, muscle-eye-brain disease), dolichol kinase (DOLK, 
dilated cardiomyopathy), Dol-P-Man synthase complex (DPM1-3, dystroglycanopathy), fukutin 
(Fukuyama muscular dystrophy), fukutin-related protein (FKRP, congenital muscular dystrophy 
type 1C), acetylglucosaminyltransferase-like protein (LARGE, congenital muscular dystrophy 
type 1D), UDP-GlcNAc –epimerase/N-acetylmannosamine kinase (GNE, hereditary inclusion 
body myopathy II) and etc. 
[49, 55, 59]
. POMT1/2 and POMGNT1 encode glycosyltransferases of 
O-mannosylation in ER and Golgi. αDG is the only carrier identified for these glycans. DOLK 
encodes dolichol kinase that synthesizes dolichol-phosphate. Mutation in DOLK results in 
deficient N-glycosylation and O-mannosylation, especially in αDG, leading to DCM phenotype 
[60-62]
. Dol-P-Man synthase complex catalyzes the addition of mannose to dolichol-phosphate for 
precursor oligosaccharide formation on ER (See Figure 1.5), and is composed of DPM1 (the 
catalytic subunit), DPM2 (the stabilizing subunit), and DPM3 (the ER-targeting subunit) 
[59]
. 
Mutation in DPM complex results in deficient N-glycosylation and O-mannosylation, leading to 
dystroglycanopathy and DCM 
[59, 63]
. In addition, GNE encodes the enzyme that catalyzes the de 
novo biosynthesis of CMP-sialic acid 
[64]
. Almost all of those mutations have disrupted 
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glycosylation in α-dystroglycan (αDG) [59-63, 65]. No mutation in αDG itself has been found in 
those diseases 
[55]
. Because αDG binds to the laminin-2 of ECM via its glycan-containing 
extracellular domain 
[55]
, deficient glycosylation causes dissociation of  αDG from ECM, leading 
to muscular dystrophy and DCM. Overexpression of glycosyltransferases can rescue the above 
phenotype, as it created novel glycans in αDG of mdx mice, a Duchenne’s muscular dystrophy 
mice model 
[66, 67]
. 
Several DCM risk factors, including smoking, alcohol abuse, obesity, and diabetes, cause 
changes in protein glycosylation, and data show glycosylation is altered in DCM 
[56, 68-71]
. 
Relevant examples in human DCM include measurement of reduced mRNA levels of the DPM1, 
CMP sialic acid transporter, and a putative sialyltransferase 
[69, 70]
. The microarray analysis of 
idiopathic DCM patients’ LV tissues also revealed a significant reduction in expression (nearly 2 
fold reduction) of the glycosyltransferase responsible for production of complex and hybrid N-
glycans, Mgat1, when compared to the non-failing hearts 
[69, 70]
. In addition, patients suffering 
from heart failure secondary to idiopathic DCM have reduced α2,3-sialylation but not α2,6-sialic 
acid in their cardiac tissues 
[72]
.  
         Furthermore, infection can also change protein glycosylation. Chagas disease is caused by 
the infection of protozoan Trypanosoma cruzi (T. Cruzi) often via blood-sucking reduviid bugs 
Triatoma 
[73]
. In 2001, there were approximately 10 million people infected and 13,000 deaths 
associated with Chagas disease in Latin America alone 
[74, 75] 
. The characteristic of this disease is 
the parasitic secretion of the trans-sialidase that transfers α2,3-sialic acid specifically from host 
cell surface to parasitic mucins due to  the incapacity of producing sialic acid by the parasite 
itself 
[76]
. Cardiomyocyte is its primary target 
[76]
. Patients typically present with dilated 
cardiomyopathy, fatal arrhythmia, LV apical aneurysm and etc. 
[73, 77]
. ECG typically shows 
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bundle branch block, ventricular premature beats, low voltage of QRS and etc. 2/3 of these 
patients die of cardiac sudden death caused by arrhythmias 
[73]
, suggesting a causal relationship 
linking α2,3-sialylation to DCM, fatal arrhythmia and sudden cardiac death.  
 
Dystrophin-Associated Protein Complex  
Dystrophin-associated protein complex (DAPC) is a collection of proteins/ glycoproteins 
located in between the extracellular matrix (ECM) and intracellular cytoskeleton 
[78]
, essential for 
stabilizing the sarcolemma during repeated cycles of contraction and relaxation, transmitting 
force generated in the muscle sarcomeres to the ECM, forming neuromuscular synapses and 
transducing extracellular-mediated signals to the muscle cytoskeleton 
[78, 79]
. DAPC is composed 
of dystroglycans, sarcoglycans, sacospan, dystrobrevins, dystrophin and syntrophin 
[80]
. In 
muscular cells, filamentous actin (F-actin) of the cytoskeleton links to sarcolemmal β-
dystroglycan (β-DG) via dystrophin. The extracellular domain of the β-DG binds to α-DG, which 
in turn binds to ECM via its glycan-containing domain (See Figure 1.6) 
[78]
.   
Dystrophin is an X chromosome encoded protein, linking β-DG with cytoskeleton (F-
actin). Mutations in dystrophin cause Duchenne muscular dystrophy, Becker muscular dystrophy, 
or X-linked dilated cardiomyopathy, preferably in male 
[5]
.  
A single dystroglycan (DG) gene encodes the precursor protein that undergoes 
posttranslational proteolytic cleavage, produces two non-covalently associated subunits: α-DG 
and β-DG [80, 81]. The dumbbell-shaped α-DG is extensively glycosylated, containing two 
globular domains and connected by a mucin-like portion rich in O-glycans. The O-mannosyl 
glycans of α-DG mediate the binding of α-DG to laminin globular domain (LG domain) of ECM 
ligands such as laminin-2, agrin and perlecan 
[55, 82]
.  Disruption of this O-mannosylation, but not 
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its core protein, renders α-DG unable to bind ECM, causing congenital muscular dystrophy and 
other dystroglycanopathies 
[79, 82]
. Overexpression of LARGE, synaptic cytotoxic T cell GalNAc 
transferase and other glycosyltransferases hyperglycosylate α-DG and resume α-DG’s binding 
capability 
[66, 67]
. α-DG then binds to β-DG (a transmembrane glycoprotein), which in turn binds 
to dystrophin 
[80]
. Besides of O-glycosylation, there are also three potential N-glycosylation sites 
on α-DG and one N-glycosylation site on β-DG (See Figure 1.6) [81].  
Sarcoglycans are transmembrane glycoproteins and appear to strengthen the interactions 
between β-DG  and α-DG,  β-DG  and dystrophin (See Figure 1.6) [80]. It includes α-, β-, γ- and 
δ-sarcoglycans. Mutations in any of those sarcoglycans can lead to limb girdle muscular 
dystrophy 
[79]
.  
In addition, syntrophin involves in cell signaling transduction of DAPC. It functions via 
recruiting and organizing various signaling proteins such as nNOS, G protein-coupled receptor, 
calmodulin and ion channels (e.g. NaV, TRPC and sarcolemmal Ca
2+
 pump) into a signalplex 
anchored to dystrophin scaffold 
[80]
.  
 
Calcineurin/ NFAT As One of the Major Cardiac Pathological Hypertrophy Pathways  
Physiological cardiac hypertrophy induced by exercise, pregnancy or growth hormones 
typically entails the activation of insulin-like growth factor 1 (IGF-1)/ phosphatidylinositol 3 
kinase alpha (PI3Kα) / protein kinase B (AKT) -dependent pathway, mammalian target of 
rapamycin (mTOR) pathway or mitogen-activated protein kinase/ERK kinase 1 (MEK1)/ 
extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway 
[83, 84]
. In contrast, pathological 
cardiac hypertrophy involves many overlapping steps.  
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Figure 1.6. Dystrophin-associated protein complex in striated muscles. 
Dystrophin-associated protein complex (DAPC) is composed of dystroglycans, sarcoglycans, 
sacospan, dystrobrevins, dystrophin and syntrophin 
[80]
, located in between the extracellular 
matrix (ECM) and intracellular cytoskeleton 
[78]
. DAPC is essential for stabilizing the 
sarcolemma during repeated cycles of contraction and relaxation, transmitting force generated in 
the muscle sarcomeres to the ECM, forming neuromuscular synapses and transducing 
extracellular-mediated signals to the muscle cytoskeleton In muscular cells, filamentous actin (F- 
actin) of the cytoskeleton links to sarcolemmal β-dystroglycan (β-DG) via dystrophin. The 
extracellular domain of the β-DG binds to α-DG, which in turn binds to ECM via its glycan-
containing domain 
[78]
.   
Dystrophin is an X chromosome encoded protein, linking β-DG with cytoskeleton (F-
actin). The dumbbell-shaped α-DG is extensively glycosylated, containing two globular domains 
and connected by a mucin-like portion rich in O-glycans. The O-mannosyl glycans of α-DG 
                                                                                                                                                          
N-glycan 
O-glycan 
Cytosol 
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Figure 1.6 (Continued) 
mediate the binding of α-DG to laminin globular domain (LG domain) of ECM ligands such as 
laminin-2, agrin and perlecan 
[55, 82]
.  By contrast, biglycan, a proteoglycan found in ECM, binds 
to the C-terminus of α-DG protein core structure [81]. α-DG then binds to β-DG (a 
transmembrane glycoprotein), which in turn binds to dystrophin 
[80]
. Disruption of this O-
mannosylation, renders α-DG unable to bind ECM, causing congenital muscular dystrophy and 
other dystroglycanopathies 
[79, 82]
. Besides of O-glycosylation, there are also three potential N-
glycosylation sites on α-DG and one N-glycosylation site on β-DG [81]. Sarcoglycans are 
transmembrane glycoproteins and appear to strengthen the interactions between β-DG  and α-
DG,  β-DG  and dystrophin [80]. It includes α-, β-, γ- and δ-sarcoglycans. Biglycan can also bind 
to α- and γ-sarcoglycans [80]. In addition, syntrophin involves in cell signaling transduction of 
DAPC. It functions via recruiting and organizing various signaling proteins such as nNOS, G 
protein-coupled receptor, calmodulin and ion channels (e.g. NaV, TRPC and sarcolemmal Ca
2+
 
pump) into a signalplex anchored to dystrophin scaffold 
[80]
. 
 
* Figure is adapted from Mercuri E. et al., 2013 with permission (See Appendix 7). 
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The main pathological cardiac hypertrophy signaling pathways include 
[83]
: 1) activation 
of cell membrane receptors, such as G protein coupled receptor (GPCR), lead to the activation(s) 
of phospholipase C (PLC), protein kinase A (PKA), or mitogen-activated protein kinases 
(MAPKs), which in turn initiate the pro-hypertrophic programs. 2) Sustained increase of 
intracellular [Ca
2+
] activates calcineurin, which in turn, activates the nuclear factor of activated T 
cells (NFAT) that turns on the hypertrophic genes. 3) MAPK cascade phosphorylates and 
activates p38 and/or c-Jun N-terminal kinase (JNK) which switches on the target gene 
expressions 
[84]
. It is acknowledged that calcineurin/NFAT acts as one of the common cardiac 
hypertrophic mechanisms in response to the pathological stimuli such as pressure overload, 
alpha-adrenergic agonist infusions and etc. 
Calcineurin is a serine/threonine-specific phosphatase, and composed of a catalytic 
subunit A (CnA) and a regulatory subunit B (CnB) (See Figure 1.7) 
[85]
. Calcineurin is uniquely 
activated by sustained elevation of intracellular [Ca
2+
] in cardiomyocytes 
[85]
. Upon activation, 
calcineurin dephosphorylates cytosolic NFAT, which in turn translocates into the nucleus and 
activates hypertrophic gene expressions (See Figure 1.7) 
[85, 86]
. Persistent activation of 
calcineurin by Ca
2+
 is required to prevent NFAT exit from the nucleus in order to maintain 
hypertrophic gene expression 
[87]
.  
Inhibition of Calcineurin/NFAT pathway prevents cardiac hypertrophy. For example, 
calcineurin catalytic activity is inhibited by immunosuppressive drugs cyclosporine A and 
FK506 
[85, 86]
. Administration of cyclosporine A or FK506 significantly reduced the hypertrophic 
response. Cardiac-specific expression of non-competitive calcineurin inhibitory domains from 
Cabin-1or A-kinase anchoring protein 79 (AKAP79) blocks calcineurin activity and attenuates 
cardiac hypertrophy phenotype 
[85, 86]
. In addition, calcineurin dominant negative mutant mice or  
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Figure 1.7. Calcineurin/ NFAT is one of the major cardiac pathological hypertrophy 
pathways. 
It is acknowledged that calcineurin/NFAT acts as one of the common cardiac hypertrophic 
mechanisms in response to the pathological stimuli such as pressure overload, alpha-adrenergic 
agonist infusions and etc. Calcineurin is a serine/threonine-specific phosphatase, and composed 
of a catalytic subunit A (CnA) and a regulatory subunit B (CnB) 
[85]
. Calcineurin is uniquely 
activated by sustained elevation of intracellular [Ca
2+
] in cardiomyocytes 
[85]
. Upon activation, 
calcineurin dephosphorylates cytosolic NFAT, which in turn translocates into the nucleus and 
activates hypertrophic gene expressions 
[85, 86]
. Persistent activation of calcineurin by Ca
2+
 is 
required to prevent NFAT exit from the nucleus in order to maintain hypertrophic gene 
expression 
[87]
. Calcineurin catalytic activity is inhibited by immunosuppressive drugs 
cyclosporine A (CsA) and FK506 
[85, 86]
. MAPK/ERK can also interact with Calcineurin/NFAT 
pathway 
[85]
. Cam, calmodulin; CyA, cyclophilin A; FKBP12, FK506 binding protein 12; P, 
phosphate.  
 
* Figure is adapted from Molkentin J.D. et al., 2004 with permission (See Appendix 8). 
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CnAβ-/- mice show reduced cardiac hypertrophic response to pressure-overload, isoproterenol or 
angiotensin II infusion 
[85, 86]
, whereas overexpression of calcineurin recaptured the hypertrophy 
phenotype 
[88-90]
.  
Some studies also suggest that calcineurin may promote pro-survival signaling in hearts 
[85]
. It is a loose consensus that JNK and p38 kinases function as mediators in DCM 
[85]
. 
Activation of GSK3β, JNK or p38 inhibits NFAT nuclear translocation by directly 
phosphorylates NFAT, and thus reduces calcineurin’s effect in hearts [85, 86]. Recent studies 
utilizing MLP
-/-
/ CnAβ-/- double knockout mice demonstrated the exacerbated DCM formation in 
addition to the deficient cardiac hypertrophic response to pathological stimuli (e.g. pressure 
overload, isoproterenol infusion and etc) 
[90, 91]
. Both too much and too little calcineurin 
adversely affect heart function 
[92]
.  
 
Transverse Aortic Constriction Surgical Model 
Cardiovascular disease is the number one cause of death in United States and the number 
of afflicted is still rapidly growing. In order to study the mechanisms underlying left ventricular 
(LV) hypertrophy and heart failure, transverse aortic constriction (TAC) surgical model is 
introduced 
[93, 94]
. TAC was
 
first established by Dr. Rockman in 1991 
[95]
. The surgery is 
performed by placing a partial constriction on aortic arch between right innominate and left 
common carotid arteries to create a reliable pressure overload (See Figure 2.5). The result is a 
consistent and reproducible LV afterload, mimics chronic systemic hypertension in human 
[93]
. 
The initial cardiac response to this pressure-overload can be compensatory, producing concentric 
LV hypertrophy. When pressure-overload persists, however, heart becomes maladaptive, 
develops eccentric LV hypertrophy and heart failure. Thus, upon imposing the equivalent amount  
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of pressure-overload, this surgical model can serve as a valuable tool to imitate cardiovascular 
diseases in human for mechanism discovery, treatment design and drug invention 
[94]
. 
 
Previous Studies of ST3Gal4 and Mgat1  
Sialic acid is a negatively charged monosaccharide attached by sialyltransferase, often to 
galactose residue of glycans via α2,3- or α2,6-linkage. β-galactoside α2, 3-sialyltransferase 
(ST3Gal) is a glycosyltransferase residing in Golgi apparatus that catalyzes the transfer of α2, 3-
sialic acid to the terminal galactose. Six ST3Gal are identified in mouse and human so far, 
ST3Gal1 to 6. ST3Gal4 is one of the ST3Gal that transfers α2, 3-sialic acid linkage to N-
glycoproteins preferentially 
[96]
. Because of its negative charge, sialic acid is needed in variety of 
developmental stage- and tissue-specific glycoproteins
[97]
. For example, most of the CDGs has 
varied degree of reduced or de-sialylation because sialylation is the terminal step of the 
glycosylation. One of such example is the hereditary inclusion body myopathy caused by GNE 
mutation 
[98]
. ST3Gal4 is also required in viral infection of the host. Lassa virus, which spreads 
from rodents to humans, can cause lethal hemorrhagic fever. Lassa virus readily engaged its cell-
surface receptor α-DG in avian cells, but virus entry in susceptible species involved a pH-
dependent switch to an intracellular receptor, the lysosome-resident protein (LAMP1) 
[99]
. The 
sialyltransferase ST3GAL4 was required for the interaction of the virus glycoprotein with 
LAMP1 
[99]
. A single glycosylated residue in LAMP1 was essential for interaction with the Lassa 
virus envelope protein and subsequent infection 
[99]
.  
ST3Gal4 gene is located on chromosome 9 in mouse and on chromosome 11 in human 
[97]
. Mouse ST3Gal4 gene comprises 11 exons that translates 333 amino acids (See Figure 1.8A) 
[97]
. Sialyltransferase ST3Gal4 is a type II transmembrane protein and shares a common domain 
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structures with other glycosyltransferases (See Figure 1.8B-C). It contains a large C-terminal 
catalytic domain and  an extended stem region in Golgi lumen, followed by a 18-amino acid 
transmembrane domain and a short N-terminal cytoplasmic tail (See Figure 1.8B-C) 
[100]
.   The 
stem region serves as a flexible tether, allowing catalytic domain to glycosylate its substrates 
[100]
. 
ST3Gal4 is uniformly expressed in almost all tissues and organ types throughout all 
developmental stages in both human and mouse, including heart (See Figure 1.9) 
[96, 97, 101, 102]
.  
ST3Gal4
-/-
 mice were first generated in 2002 by Dr. Marth’s laboratory [101]. Briefly, the 
exons 5-7 of ST3Gal4 gene, which encodes the functional enzymatic motif, was replaced by a 
LoxP site,  resulting in a translational frameshift within exon 8 and the subsequent loss of 
ST3Gal4 RNA (See Figure 2.1A). No ST3Gal4 RNA was detected in ST3Gal4
-/-
 mice 
[101]
. 
Lectin binding assays showed that ST3Gal4
-/-
 has reduced α2,3 sialylation and increased 
galactose exposure on N-glycans of von Willebrand factor (vWF) (See Figure 1.10) 
[101]
.  
Previous studies reported that ST3Gal4
-/-
 has increased bleeding time, decreased vWF 
and platelet counts, decreased L-selectin binding and L-selectin-dependent leukocyte rolling, as 
well as the increased terminal galactose residue exposure 
[101] [103]
. It is thought that the 
unmasked galactose linkages (implicated as asialoglycoprotein receptor) via ST3Gal4 deletion 
promoted asialoglycoprotein clearance mechanisms (probably by the Ashwell receptors 
[104]
) 
resulting in a reduction in plasma levels of vWF and platelets 
[101]
. Our lab is the first to show 
that the cardiac glycome is variable and changes differentially during development of atria and 
ventricles 
[105]
. The negative charges of sialic acids contribute to the effective external surface 
charge of ion channels. Previous studies showed that experimental prevention or removal of 
sialic acids markedly altered the voltage sensitivity of NaV and KV gating, through direct, 
isoform-specific, electrostatic mechanisms 
[25-31, 105-122]
. In isolated ventricular cardiomyocytes,  
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Figure 1.8. Murine ST3Gal4 genomic and topological structures. 
A. The representative view of ST3Gal4 gene. Mouse ST3Gal4 gene comprises 11 exons that 
translates 333 amino acids 
[97]
. Box, exons; open box, non-coding region; solid box, coding 
region; exons were labelled in arabic numbers; horizontal solid line, intron sequence; ATG, start 
codon; arrow, transcription direction. B. The representative murine ST3Gal4 protein domain 
structures. Previous studies and Uniprot search (http://www.uniprot.org/uniprot/Q91Y74) found 
that murine ST3Gal4 is a type II transmembrane protein and shares a common domain structures 
with other glycosyltransferases, containing a large C-terminal catalytic domain and  an extended 
stem region in Golgi lumen, followed by a 18 amino acids transmembrane domain and a short N-
terminal cytoplasmic tail 
[100]
.  The number of amino acids at the start of each domain is listed 
underneath. Corresponding amino acid sequences to its encoding region were depicted here. In 
particular, exons 7-8 encode the highly conserved sialyl motif L in catalytic domain, responsible 
for binding donor substrate CMP-Sia 
[97]
. Gray box, cytoplasmic domain; black box, 
transmembrane domain; open box, Gogi luminal domain. C. The predicted topological structure 
Transmembrane 
Domain 
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Figure 1.8 (Continued) 
of murine ST3Gal4. The stem region serves as a flexible tether, allowing the catalytic domain to 
glycosylate its substrates 
[100]
. 
 
* Figure is adapted from Paulson, J.C. et al., 1989 with permission (See Appendix 9).  
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A.  
 
 
 
 
 
 
B.  
 
Figure 1.9. ST3Gal4 is uniformly expressed in murine heart throughout developmental 
stages. 
A. Human N-linked α2,3-sialyltransferase (ST3N) is responsible for catalyzing N-linked α2,3-
sialylation, similar to the murine ST3Gal4 sialyltransferase counterpart. Northern blot shows that 
ST3N mRNA is expressed in both fetal and adult heart 
[102]
. B. ST3Gal4 mRNA is expressed 
uniformly in murine heart throughout developmental stages 
[96]
. Skel. muscle, skeletal muscle; 
S.G., salivary gland; G3PDH, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
  
* Figure is reprinted from Kitagawa H. et al., 1994 and Kono, M. et al., 1997 with permission 
(See Appendix 10-11). 
kb 
34 
 
 
 
 
 
 
 
 
 
Figure 1.10. Gene deletion of ST3Gal4 resulted in reduced N-α2,3-sialylation.  
Previous studies showed that the gene deletion of ST3Gal4 in mice (ST3Gal4
-/-
) resulted in the 
loss of terminal α2,3 sialic aicd and an increased galactose (Gal) exposure on N-glycans of 
plasma von villebrand factor (vWF), a sialoglycoprotein. Its O-glycan sialylation, however,  
was unaffected. These were evidenced by increased Ricinus communis agglutinin I (RCA-I) 
and Erythrina cristagalli lectin (ECL) (both recognize the terminal Galβ1,4GlcNAc [123, 124]) 
binding to vWF, and unchanged Peanut agglutinin (PNA, recognizes Galβ1,3GalNAc of O-
glycans) binding in ST3Gal4
-/- [101]
. Furthermore, the binding of Sambucus nigra (SNA, 
recognizes Sia2,6Gal) to vWF was also increased, suggesting a partial compensation from 
α2,6 sialic acid in ST3Gal4-/- [101]. The consistent sialylation status was also found in left 
ventricular tissues of ST3Gal4
-/-
 via lectin histochemistry (See Figure 3.1).  
 
* Figure is adapted from Ellies, L.G. et al., 2002 with permission. Copyright (2002) National 
Academy of Sciences, U.S.A (See Appendix 12). 
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ST3Gal4
-/-
 have altered AP waveforms, characterized by slow depolarization, extended 
repolarization and reduced refractory period (See Ednie A.R. et al., 2013 and 2015) 
[108, 110]
. 
These AP waveform changes were attributed to the depolarizing shift in NaV, Ito and IK, slow 
gating; a 29% significant increased rate of NaV recovery from fast inactivation; and the rightward 
shift of NaV window current. All of which contributed to the observed decrease in cellular 
refractory periods, prolonged QT interval and increased susceptibility to arrhythmia 
[108, 110]
. 
These data provided initial insight into a possible novel mechanism for controlling/ modulating 
excitability. However, little is known about whether and how sialylation modulates cardiac 
function in vivo.  
Human Mgat1 is a medial-Golgi enzyme (type II transmembrane protein) initiates the 
synthesis of hybrid and complex N-glycans and is expressed in all tissues and organs 
[125]
. Mgat1 
shares the common structure of type II transmembrane protein (See Figure 1.8C) and is 
composed of a short N-terminal cytoplasmic tail, a transmembrane domain, an extended stem 
region and a large luminal catalytic domain 
[126]
.  
Mgat1 gene is highly conserved between human and mouse and is located on the 
autosome chromosome (Chr) (on mouse Chr 11 and on human Chr 5, respectively) 
[126]
. NCBI 
database search (http://www.ncbi.nlm.nih.gov/gene/17308) showed that mouse Mgat1 gene 
comprises 6 exons and transcribes 4 alternative splicing mRNAs (See Figure 1.11). The coding 
region of Mgat1 resides in a single exon in both human and mouse (i.e. in exon 6 of mouse 
Mgat1 gene) and share 84% identical DNA sequences (See Figure 1.11) 
[126]
. Previous studies 
reported that Mgat1 heterozygous knockout, Mgat1
-/+
, appeared normal, fully fertile and was 
indistinguishable from wildtype littermates 
[127]
. However, Mgat1 homozygous knockout, Mgat1
-
/-
, was embryonically lethal in mice, showing developmental retardation, open neuropore, 
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Figure 1.11. Murine Mgat1 gene. 
A. Mouse Mgat1 gene comprises 6 exons with the coding region resides solely in exon 6. B. 
NCBI database search showed that mouse Mgat1 gene transcribes at least 4 alternative splicing 
mRNAs with no change in its protein sequences (http://www.ncbi.nlm.nih.gov/gene/17308) 
[127]
. 
Box, exons, exons were labelled in arabic numbers; horizontal solid line, intron sequence; arrow, 
transcription direction.  
 
 
 
 
A. 
B. 
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 reduced somites, anemia and died between E9.5-E10.5 in gestation 
[127]
.   
Cre-lox system was derived from P1 bacteriophage and can induce site-specific 
recombination. Cre (cyclization recombination) recombinase is a 38KDa protein induces 
recombination at the loxP recognition sites. LoxP (locus of X(cross)-over in P1) is a 34bp 
sequences consisting of two palindromic 13bp sequences separated by an 8bp asymmetric core 
sequence, such as, ATAACTTCGTATA-GCATACAT-TATACGAAGTTAT. This asymmetric 
core sequence determines loxP’s directionality. When two loxP sites are in the same direction 
and located on the same DNA, Cre protein catalyze the recombination between these two loxP 
sites and the sequences between the loxP sites are excised. When placing Cre downstream of 
promoters that are active only in certain cell types, the Cre recombinase can be expressed in only 
those cell types. The mouse contains a Cre recombinase transgene under the direction of a tissue-
specific promoter can then be bred with the mouse contains two loxP sites that flank a genomic 
segment of interest (the "floxed" locus), mediating the recombination between loxP sites  in 
specified cell types. 
αMHC-Cre is a cardiomyocyte-specific Cre expression mouse strain obtained from the 
Jackson Laboratory. Database search from Mouse genome informatics 
(http://www.informatics.jax.org/allele/MGI:2386742?recomRibbon=open) showed that αMHC 
promoter driven Cre recombinase expresses throughout the entire development of the heart in 
both ventricle and atria 
[128-130]
. αMHC-Cre was detected in > 90% of cardiomyocytes and minute 
expression in pulmonary veins (See Figure 1.12) 
[130]
. Furthermore, αMHC-Cre does not elicit 
recombination in cardiac fibroblasts, valves, coronary vessels, aorta and other cell types in the 
heart (See Figure 1.12) 
[128-130]
. Thus, when combining Mgat1 floxed strain with αMHC-Cre 
strain, a cardiac-specific Mgat1 conditional knockout is achieved (See Figure 2.3).   
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Figure 1.12. α-myosin heavy chain driven Cre (αMHC-Cre) expresses specifically in 
cardiomyocytes.  
αMHC promoter driven Cre expresses throughout the entire development of the heart in both 
ventricle and atria 
[128-130]
 
(http://www.informatics.jax.org/allele/MGI:2386742?recomRibbon=open). αMHC-Cre 
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Figure 1.12 (Continued) 
expression was detected in > 90% of cardiomyocytes and minute expression in pulmonary veins 
[130]
. Furthermore, αMHC-Cre does not elicit recombination in cardiac fibroblasts, valves, 
coronary vessels, aorta and other cell types in the heart 
[128-130]
. 
 
* Figure is reprinted from Agah, R. et al., 1997 with permission (See Appendix 13). 
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Gene dosage is the copies of particular gene present in the cell. A decrease in gene 
dosage (by gene knockout for example) can result in reduced gene product formation, yielding 
phenotypical consequences. For example, missing two copies of the gene yields more severe 
phenotype than missing one copy of the gene. This is also known as gene-dosage dependent 
effect. 
The preliminary data of 9-week old Mgat1
fx/fx
 /αMHC-Cre+ ventricular myocytes showed 
similar but much more severe changes in AP waveform than ST3Gal4
-/-
, including a much more 
prolonged AP duration, marked depolarizing shift of NaV gating and NaV window current, and 
significantly increased NaV recovery rate. However, we still don’t know if N-glycosylation 
modulates cardiac function.  
In the next few chapters, we will ask the question of whether and how sialic acid and N-
glycosylation impact cardiac function in vivo.  
 
 
 
 
 
41 
 
CHAPTER TWO  
MATERIALS AND METHODS 
 
Introduction 
The following is a detailed description of the materials and methods used throughout the 
dissertation. The investigation conformed to the Guide for the Care and Use of Laboratory 
Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 
1985) and was approved by the University of South Florida Animal Care and Use Committee 
(See Appendix 1: IACUC Approval Letter for Animal Studies). Mice were housed in University 
of South Florida (USF) vivarium on a 12 hours light and dark cycle under pathogen-free 
conditions with food and water ad libitum. Animal tissues were used and disposed according to 
the guidelines of aforementioned organizations and committees. No human tissue or human 
subject was involved. Chemicals, antibodies and reagents were stored and disposed according to 
manufacturers’ material safety data sheets (MSDS).  
 
Generation of β-galactoside α2,3-sialyltransferase 4 (ST3Gal4) Null Mice 
The ST3Gal4 null mice were kindly provided by Dr. Jamey Marth 
[101]
. ST3Gal4 gene is 
located on chromosome 9 of mouse and on chromosome 11 in human 
[97]
. Mouse ST3Gal4 gene 
comprises 11 exons that translates 333 amino acids 
[97]
. In ST3Gal4
-/-
, the exons 5-7 of ST3Gal4 
gene, which encodes the functional enzymatic motif (See Figure 1.8), were flanked with loxP 
(locus of X(cross)-over in P1) sites and a neomycin cassette (neo) (See Figure 2.1 A).  Co-
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transfection of Cre recombinase deleted both exons 5-7 and the neo cassette, creating an 
additional subsequent translational frameshift within exon 8 that further destabilized ST3Gal4 
RNA. As a consequence, no ST3Gal4 mRNA was detected in ST3Gal4 null tissues by Northern 
blot, as described previously 
[101]
 (See Figure 2.1 B). Constructed ST3Gal4 null was then 
backcrossed into the C57BL/6 strain for at least 8 generations before usage 
[101]
. As described 
previously, ST3Gal4
-/-
 mice were produced by breeding between ST3Gal4
-/+
 strain (See Figure 
2.2 A) 
[101]
. Three genotypes with identical genetic background were therefore produced: wild-
type littermate, ST3Gal4
-/+
 and ST3Gal4
-/-
. The chance of obtaining ST3Gal4
-/-
 was 25%. 
ST3Gal4 null mice were produced in Mendelian ratios with both male and female mice fully 
fertile and appearing normal (See Figure 3.2). Genotyping polymerase chain reaction (PCR) 
(Sigma-Aldrich, MO) was conducted using mouse tail genomic DNA, according to Dr. Jamey 
Marth laboratory’s protocol [101]. Specifically, multiplex PCR was executed at the denaturing 
temperature of 94°C for 30 seconds, annealing temperature of 65⁰C for 1 minute and extension 
temperature of 72°C for 1 minute, using 3 primers: oIMR6890 (P1) (5’-GAC GCC ATC CAC 
CTA TGA G- 3’), oIMR6891 (P2) (5’-GGC TGC TCC CAT TCC ACT- 3’) and oIMR6892 (P3) 
(5’-GGC TCT TTG TGG GAC CAT CAG- 3’); and repeated for 35 cycles. Nucleotide BLAST 
search in National Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/) confirmed the location of P1 at exon 4, P2 at intron 4 and P3 at 
intron 7 region (See Figure 2.2 C) 
[101]
. The wild type allele resulted a 290bp PCR product via P1 
and P2 and the mutant allele yielded a 450bp fragment by P1 and P3 (See Figure 2.2 B). 
Heterozygote resulted both 290bp and 450bp fragments. Only male ST3Gal4
-/-
 and its WT 
littermates were investigated in this dissertation. 
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A.                                                                                                                       B. 
  
Figure 2.1. Generation of ST3Gal4
-/-
 mice.  
A. As described previously, to generate ST3Gal4
-/-
, the exons 5-7 of ST3Gal4 gene were firstly 
flanked with loxP sites and a neomycin cassette (neo), followed by deletion of exons 5-7 and neo 
via Cre recombination, creating a subsequent translational frameshift in exon 8 that further 
destabilized ST3Gal4 RNA 
[101]
. B. No ST3Gal4 RNA expression was detected in ST3Gal4
-/-
 
tissues by Northern blot * 
[101]
. Box, exons; open box, non-coding region; solid box, coding 
region; hatched box, translationally frameshifted coding region; exons were labelled in arabic 
numbers; horizontal solid line, intron sequence; , loxP;  , neomycin cassette; ATG, start 
codon; wt, wildtype; and ∆/∆, ST3Gal4-/-.   
 
* Figure 2.1B is reprinted from Ellies, L.G. et al., 2002 with permission (See Appendix 14). 
Copyright (2002) National Academy of Sciences, U.S.A 
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A.                                                                   B.                                C. 
 
 
 
 
 
 
 
 
Figure 2.2. Breeding scheme and genotyping methods of ST3Gal4
-/-
.  
A. ST3Gal4
-/-
 mice were produced by breeding between ST3Gal4
-/+
 strain, generating three 
genotypes with identical genetic background: wild-type littermate, ST3Gal4
-/+
 and ST3Gal4
-/-
, as 
described previously 
[101]
. The odds of obtaining ST3Gal4
-/-
 was 25%. B. Tail genomic DNA was 
used for genotyping PCR. Wild type allele resulted a 290bp fragment via primers P1 and P2, and 
the mutant allele yielded a 450bp fragment by primers P1 and P3, as described previously 
[101]
. 
C. Nucleotide BLAST confirmed the location of P1 at exon 4, P2 at intron 4 and P3 at intron 7 
regions respectively. WT, wildtype; solid box, coding region; hatched box, translationally 
frameshifted coding region; exons were labelled in arabic numbers; horizontal solid line, intron 
sequence; red arrow, primer; , loxP. 
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Generation of the Cardiac-Specific N-Acetylglucosaminyltransferase I (Mgat1) Conditional 
Knockout Mice 
 The floxed Mgat1 (Mgat1 
fx/fx
) mice were kindly provided by Dr. Jamey Marth 
[131]
. 
Mgat1 gene is located on the autosome chromosome (Chr) in both mouse and human (on Chr 11 
of mouse and on Chr 5 of human, respectively) 
[126, 132]
. The coding region of the mouse Mgat1 
gene resides solely on exon 6 which was flanked by loxP sites in Mgat1 
fx/fx
 strain, as described 
previously (See Figure 1.11 and Figure 2.3 A) 
[131]
. The cardiac specific alpha myosin-heavy 
chain Cre
+
 strain (αMHC-Cre+) was purchased from Jackson Laboratory. Briefly, αMHC-Cre 
was constructed by ligation of cardiac-specific murine αMHC promoter upstream from the Cre 
translational start codon, as described previously 
[130]
. The resulting αMHC promoter driven Cre 
recombinase expression was detected in > 90% of cardiomyocytes and minute expression in 
pulmonary veins (See Figure 1.12) 
[130]
. Furthermore, αMHC-Cre does not elicit recombination 
in cardiac fibroblasts, valves, coronary vessels, aorta and other cell types in the heart (See Figure 
1.12) 
[130]
. Both floxed Mgat1 and αMHC-Cre strains were backcrossed into the C57BL/6 strain 
for more than 6 generations before usage 
[130, 131]
. To generate the cardiac-specific Mgat1 
conditional knockout mice (Mgat1CKO), we utilized Cre/lox system, in which Mgat1
fx/fx
 was 
crossed with Mgat1
fx/+
 /αMHC-Cre+ to delete Mgat1 gene under transcriptional control of 
αMHC promoter (See Figure 2.3 A). Initial breeding and genotyping in our lab were developed 
and performed by A.E. Ednie, K-K. Horton, and E.S. Bennett. Four genotypes with identical 
genetic background were therefore produced: Mgat1
fx/fx
 /αMHC-Cre+ (Mgat1CKO), Mgat1fx/fx, 
Mgat1
fx/+
 and Mgat1
fx/+
 /αMHC-Cre+ (Mgat1Het) (See Figure 2.3 B). Mgat1CKO was produced 
in Mendelian ratios with normal litter size and sex ratios at birth. In addition, both male and 
female pups appear normal. The odds of obtaining Mgat1CKO were 25%.   
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A.                                                                                             C. 
 
 
 
 
 
B. 
 
 
 
Figure 2.3. Generation of cardiac-specific Mgat1 conditional knockout mice. 
A. We utilized Cre/lox system to create the cardiac-specific Mgat1 conditional knockout mice, 
by which αMHC driven Cre recombinase abolished Mgat1 coding gene specifically in mouse 
cardiomyocytes. B. This was achieved by crossing Mgat1
fx/fx
 with Mgat1
fx/+
 /αMHC-Cre+ that 
gave rise to four strains: Mgat1
fx/fx
 /αMHC-Cre+ (Mgat1CKO), Mgat1fx/fx, Mgat1fx/+ and 
Mgat1
fx/+
 /αMHC-Cre+ (Mgat1Het). The odds of obtaining Mgat1CKO were 25%. C. Tail 
genomic DNA was used for genotyping PCR of floxed Mgat1 and αMHC-Cre. Mgat1 wildtype 
allele produced a 421bp PCR product and the floxed allele yielded a 561bp fragment. αMHC-
Cre transgene amplified a 300bp fragment and the positive internal control produced a 200bp 
fragment. Solid box, coding region; open box, noncoding region; exon was labelled in arabic 
number; horizontal solid line, intron sequence; , loxP. 
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Age- and sex- matched littermate Mgat1
fx/fx
 or Mgat1
fx/+
 were served as controls.  Genotyping 
PCR (Sigma-Aldrich, MO) was performed using mouse tail genomic DNA, as described 
previously 
[130, 131]
. Specifically, Mgat1 floxed strain genotyping PCR was executed at the 
denaturing temperature of 94°C for 30 seconds, annealing temperature of 62⁰C for 45 seconds 
and extension temperature of 72°C for 45 seconds, using 2 primers: oIMR6865 (5’ -GAG ACC 
TGC TTA CTG CAG CC- 3’) and oIMR7025 (5’ -TGC AAG CCA ACA CTT GTG TC- 3’); 
and repeated for 35 cycles. The Mgat1 wildtype allele produced a 421bp PCR product and the 
floxed allele yielded a 561bp fragment (See Figure 2.3 C). αMHC-Cre strain genotyping 
multiplex PCR was  conducted at the denaturing temperature of 94°C for 30 seconds, annealing 
temperature of 58⁰C for 1 minute and extension temperature of 72°C for 1 minute, using 4 
primers: 9543 (P4) (5’ -ATG ACA GAC AGA TCC CTC CTA TCT CC- 3’), 9544 (P5) (5’ -
CTC ATC ACT CGT TGC ATC ATC GAC- 3’), oIMR8744 (P6) (5’-CAA ATG TTG CTT 
GTC TGG TG- 3’) and oIMR8745 (P7) (5’ -GTC AGT CGA GTG CAC AGT TT- 3’); and 
repeated for 35 cycles. Nucleotide BLAST search in NCBI database showed that P6 and P7 are 
located at mouse Chr 14, serving as an internal positive control for PCR reactions that produced 
a 200bp PCR product. P4 and P5 are located at the αMHC-Cre transgene, amplified a 300bp 
fragment. This PCR protocol does not distinguish αMHC-Cre hemizygote from homozygote.   
 
Murine Transthoracic Echocardiography 
Echocardiography is a non-invasive examination for cardiovascular structural and 
functional changes in vivo, providing a tool to assess heart repeatedly in chronological order on 
the same animal. Transthoracic echocardiography was performed using Vevo770 (VisualSonics, 
Canada) equipped with mechanical transducers centered on 30MHz ~ 25MHz, as described 
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previously 
[133, 134]
. Cardiac functions of wild-type (WT), ST3Gal4
-/-
 , Mgat1CKO, Mgat1Het or 
Mgat1 control mice were measured. Briefly, mouse was lightly anesthetized with 1.5% 
isoflurane/O2 and maintained body temperature at 37°C using rectal probe and an auto-regulatory 
heating pad. Core body temperature, ECG and respiration rate were monitored continuously 
during the procedure. Parasternal long-axis and shot-axis was visualized in brightness mode (B-
mode) (See Figure 2.4 A-C). From parasternal short-axis view, the two-dimension (2D) guided 
motion mode (M-mode) across the anterior and posterior wall at mid-papillary muscle level was 
imaged. Left ventricular anterior wall thickness at diastole and systole (LVAW;d and LVAW;s, 
mm), left ventricular internal dimension at diastole and systole (LVID;d and LVID;s, mm), left 
ventricular posterior wall thickness at diastole and systole (LVPW;d and LVPW;s, mm), heart 
rate (HR, bpm) and other parameters were measured from three consecutive cardiac cycles using 
the leading-edge to leading-edge convention following the guidelines of  American Society of 
Echocardiography 
[135]
. Ejection fraction (EF%), fractional shortening (FS%), end-diastolic 
volume (EDV, µl), end-systolic volume (ESV, µl), stroke volume (SV, µl), cardiac output (CO, 
ml/min), CO index (COi, ml/min/g), LV mass (LVM, mg) and LV mass index (LVMi, mg/g) 
were calculated: 𝐸𝐹% =
𝐸𝐷𝑉−𝐸𝑆𝑉
𝐸𝐷𝑉
 × 100%; 𝐹𝑆% =
𝐿𝑉𝐼𝐷;𝑑−𝐿𝑉𝐼𝐷;𝑠
𝐿𝑉𝐼𝐷;𝑑
× 100%; 𝐸𝑆𝑉 =
(
7
2.4+𝐿𝑉𝐼𝐷;𝑠
) × 𝐿𝑉𝐼𝐷; 𝑠3; 𝐸𝐷𝑉 = (
7
2.4+𝐿𝑉𝐼𝐷;𝑑
) × 𝐿𝑉𝐼𝐷; 𝑑3; 𝑆𝑉 = 𝐸𝐷𝑉 − 𝐸𝑆𝑉; 𝐶𝑂 = 𝑆𝑉 × 𝐻𝑅; 
𝐶𝑂 𝑖𝑛𝑑𝑒𝑥 =
𝐶𝑂
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
; 𝐿𝑉 𝑚𝑎𝑠𝑠 = 0.8 × 1.053 × [(𝐿𝑉𝐼𝐷; 𝑑 + 𝐿𝑉𝑃𝑊; 𝑑 + 𝐿𝑉𝐴𝑊; 𝑑)3 −
𝐿𝑉𝐼𝐷; 𝑑3] and 𝐿𝑉 𝑚𝑎𝑠𝑠 𝑖𝑛𝑑𝑒𝑥 =
𝐿𝑉 𝑚𝑎𝑠𝑠
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
 
[134]
. From parasternal long-axis view, left atrial 
anteroposterior diameter (LAd, mm) was measured via 2D guided M-mode, as described 
previously 
[135, 136]
. 2-D B mode, pulsed-wave Doppler (PW Doppler) and M-mode were used to 
assess pulmonary artery (PA) and right ventricle (RV). PA diameter (PAd, mm), pulmonary 
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acceleration time (PAT, ms), pulmonary ejection time (PET, ms), PA velocity time integral (PA 
VTI, cm) and RV free wall thickness (RVFW, mm) were measured 
[137]
. RV SV (µl) and RV CO 
(ml/min) were calculated as 𝑅𝑉 𝑆𝑉 = (
𝑃𝐴𝑑
2
)2𝜋 × 𝑃𝐴 𝑉𝑇𝐼 and 𝑅𝑉 𝐶𝑂 = 𝑅𝑉 𝑆𝑉 × 𝐻𝑅 [138]. From 
the apical four-chamber view, mitral valve (MV) inflow was also assessed. MV early filling 
velocity (E wave, mm/s), MV atrial filling velocity (A wave, mm/s), E wave deceleration time 
(DT, ms), left ventricular isovolumic relaxation time (IVRT, ms), left ventricular isovolumic 
contraction time (IVCT, ms), aortic ejection time (AET, ms) and left ventricular non-filling time 
(NFT, ms) were measured. Ratio of mitral valve E to A (E/A) and LV myocardial performance 
index (LV MPI, Tei index) were calculated: 𝐿𝑉 𝑀𝑃𝐼 =
𝐼𝑉𝐶𝑇+𝐼𝑉𝑅𝑇
𝐴𝐸𝑇
 
[139]
. The presence of the 
transverse aortic constriction (TAC) was first visualized in B mode (See Figure 2.4 E). PW 
Doppler was then used to assess the transconstriction peak velocity (V, mm/s) with the angle 
adjusted to the direction of the blood flow (generally 0-20 degrees) (See Figure 2.4 F). Aortic 
peak pressure gradient of aortic constriction (AoPg, mmHg) was calculated using the modified 
Bernoulli equation: 𝐴𝑜𝑃𝑔 = 4𝑉2 [134]. 
 
Minimally Invasive Transverse Aortic Constriction (TAC) 
Transverse aortic constriction (TAC) is an invaluable tool to study cardiac function and 
pathophysiology. The surgery itself produces very consistent and reproducible aortic constriction, 
allowing equivalent and significant LV afterload to be imposed on heart in vivo (See Figure 2.5 
A) 
[95]
. This mimics similar afterload induced hypertrophy and heart failure in human, thus 
allowing better understanding of the human disease mechanism to help advancing disease   
50 
 
TAC 
RV 
LV 
LA 
RBA 
LCCA 
LV 
RPA 
LV 
pm 
 A.                                               B.                                 C.                                               
 
D.                                                E.                                             F. 
 
Figure 2.4. Murine transthoracic echocardiography. 
Representative images of parasternal long- (A) and short-axis (B) view in B-mode. C. M-mode 
from the parasternal short-axis view at mid-papillary muscle level. Blue line, LV tracing. D. 
Representative images of aortic view in B-mode from a 16-20 week-old male wildtype mouse at 
baseline (D) and one week after TAC (E). F. AoPg was then assessed using PW Doppler-mode. 
LV, left ventricle; RV, right ventricle; LA, left atria; Asc Ao, ascending aorta; pm, papillary 
muscle; RPA, right pulmonary artery; RBA, right brachiocephalic artery; LCCA, left common 
carotid artery; LSA, left subclavian artery; TAC, transverse aortic constriction. 
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treatment and prevention. In this dissertation, 16-20 week-old male wildtype and ST3Gal4
-/-
 mice 
were used for the TAC study. Mice were first randomly assigned into four groups: sham WT, 
sham ST3Gal4
-/-
 , TAC’d WT and TAC’d ST3Gal4-/- (See Figure 2.5 B). Baseline 
echocardiography was then recorded blindly, 2 days before the surgery (See Figure 2.4 A-D). 
Minimally invasive transverse aortic constriction was performed as described previously to 
ensure minimal to no blood loss during surgery, and was successful in preventing any mortality 
among all cohorts throughout the six week experiment 
[94, 140, 141]
. Briefly, Ketoprofen (10mg/kg) 
was injected subcutaneously (s.c.) prior to the surgery. Mouse was then anesthetized with 
isoflurane (2-3%)/O2 and maintained body temperature at 37°C with a rectal probe on an auto-
regulatory heating pad. A partial left side thoracotomy was created followed by thymus 
retraction and aortic arch exposure. 7-0 silk suture was then ligated against 26-G cannula at the 
level of the aortic arch between the origin of the right innominate artery and left common carotid 
artery, followed by quick cannula removal. The sham operated groups received the sham surgery 
consisting of aortic arch exposure, but without ligation. After the surgery, mouse was allowed to 
recover in a warmed cage with soft food and water on the cage floor. Ketoprofen (10mg/kg) was 
injected s.c. again 12 hours after the surgery. One week after TAC (See Figure 2.4 E), AoPg was 
recorded under echocardiography (See Figure 2.4 F). Only mice with AoPg=85±5 mmHg were 
included in TAC’d group to ensure consistent pressure overload between groups. Mice were 
observed for six weeks after TAC, followed by euthanasia and tissue collection used for 
histological analysis and western blotting (See Figure 2.5 B). 
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Figure 2.5. Minimally invasive TAC animal model. 
A. An illustration of TAC surgery. Partial ligation (black) was placed between right innominate 
artery and left common carotid artery at aortic arch level, as described previously 
[94, 140, 141]
. B. 
Four groups were formed: sham wildtype, sham ST3Gal4
-/-, TAC’d wildtype and TAC’d 
ST3Gal4
-/-
. Baseline echocardiography was performed 2-3 days before surgery and at 1week, 
2week, 3week and 6week after TAC. Mice were observed up to six weeks, followed by 
euthanasia and tissue collection. WT, wildtype; KO, ST3Gal4
-/-
. 
 
* Figure 2.5 A is adapted from deAlmeida A. C.et al., 2010 with permission (See Appendix 15). 
 
 
 
Sham TAC 
WT Sham WT TAC WT 
KO Sham KO TAC KO 
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Murine Surface Electrocardiogram (ECG) 
PowerLab 16/35 data acquisition system and Bioamplifier FE136 (ADInstruments, New 
Zealand) configured with LabChart version 8.1 (ADInstruments, New Zealand) were used for 
lead II surface ECG recording from 18 month-old male wildtype and ST3Gal4
-/-
 or from  35 
week-old female Mgat1 control, Mgat1Het and Mgat1CKO respectively. Mouse was lightly 
anesthetized with 1.5% isoflurane/O2 and maintained body temperature at 37°C using a rectal 
probe and an auto-regulatory heating pad. The needle electrodes (29 gauge, ADInstruments) 
were inserted subcutaneously into the right forelimb (negative electrode), left hindlimb (positive 
electrode) and right hindlimb (reference electrode) (See Figure 2.6 A) and recorded for 2 minutes. 
Heart rate (HR, bpm), P wave duration (ms), PR duration (ms), QRS duration (ms), JT duration 
(ms), QT duration (ms), P wave amplitude (mV), J wave amplitude (mV) and R wave amplitude 
(mV) were measured. QTc duration (corrected QT interval for heart rate, ms) was calculated 
using Mitchell equation: 𝑄𝑇𝑐 =
𝑄𝑇
√𝑅𝑅 100⁄
 
[142]
. 
 
Telemetry ECG Recording 
For conscious long-term murine ECG recording, we implanted radiofrequency telemetry 
transmitter (TA10ETA-F20, Data Science International, MN) in 34~40 week-old male Mgat1 
controls and Mgat1CKOs, as described previously 
[143, 144]
. Briefly, Ketoprofen (10mg/kg) was 
injected subcutaneously (s.c.) prior to the surgery. Mouse was then anesthetized with isoflurane 
(2-3%)/O2 and maintained body temperature at 37°C with a rectal probe on an auto-regulatory 
heating pad. A midline 1.5-2.0cm incision on abdominal wall was performed and the transmitter 
device body was placed intraperitoneally. The biopotential leads were then tunneled under the 
skin in a modified lead II configuration (See Figure 2.6 B). Specifically, the negative lead was 
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placed at the right pectoral muscle of the mouse and the positive lead was positioned at the left 
caudal rib region approximately 1cm left to the xyphoid process (See Figure 2.6 B). After the 
surgery, mouse was allowed to recover in a warmed cage with soft food and water on the cage 
floor. Ketoprofen (10mg/kg) was injected s.c. again 12 hours after the surgery. All mice were 
housed in the same room under the same condition and synchronized to the same 12 hour- 12 
hour light-dark cycles. After one week of convalescence, telemetry transmitters were turned on 
magnetically and confirmed in AM 550kHz frequency. Individually housed mouse was then 
placed in close proximity on top of a RPC receiver (Data Science International, MN) linked to 
the data exchange matrix (Data Science International, MN) configured with Dataqueset A.R.T. 
software version 4.33 (Data Science International, MN). ECG, core body temperature and animal 
activity were recorded continuously in conscious mice till all recording Mgat1CKOs were 
deceased. The analysis was done by first select the simultaneous 24-hour recordings from both 
Mgat1 controls and Mgat1CKOs, as described previously 
[145-147]
. ECG was then analyzed using 
a simultaneous 60-second period in LabChart version 8.1 (ADInstruments, New Zealand). Heart 
rate (HR, bpm), P wave duration (ms), PR duration (ms), QRS duration (ms), JT duration (ms), 
QT duration (ms), P wave amplitude (mV), J wave amplitude (mV) and R wave amplitude (mV) 
were measured. QTc duration (corrected QT interval for heart rate, ms) was calculated using 
Mitchell equation: 𝑄𝑇𝑐 =
𝑄𝑇
√𝑅𝑅 100⁄
, as described above and previously 
[142]
. Next, heart rate 
variability (HRV) was assessed using HRV module version 2 (ADInstruments, New Zealand).   
Only the sinus beats without arrhythmia, ectopic beats or artifacts were included by manually 
scan the entire 24-hour recordings of both Mgat1 controls and Mgat1CKOs. The time-domain 
method was then used and the normal-to-normal interval (NN interval, ms), normal-to-normal 
heart rate (NN rate, bpm), the standard deviation of all NN interval (SDNN, ms), the square-root  
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Figure 2.6. Murine surface and telemetry ECG recording. 
A. The schematic illustration of murine surface ECG in lead II configuration.  The needle 
electrodes were inserted subcutaneously into the right forelimb (negative electrode), left 
hindlimb (positive electrode) and right hindlimb (reference electrode) respectively. The 
electrocardiogram signal was amplified via Animal Bio Amp (ADInstruments, New Zealand) 
and digitized using PowerLab (ADInstruments, New Zealand). B. The telemetry radio frequency 
transmitter (TA10ETA-F20, Data Science International, MN) was implanted intraperitoneally 
with the biopotential leads placed in the modified lead II configuration. Mice were allowed to 
recover for one week before telemetry recording, as described previously 
[143, 144]
. -, negative 
electrode; +, positive electrode; R, reference electrode; II, lead II configuration. 
 
* Figure 2.6 is adapted from Farraj, A. K. et al., 2011 with permission (See Appendix 16). 
                                                                       
 
 
                                                                                                                                                          
                                                                                                                                                          
Right                          Left  Right                      Left                              
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of the mean of square successive differences between successive NN intervals (RMSSD, ms), 
and percentage of normal consecutive NN intervals differing by >6 ms (pNN6, %) were reported, 
as described previously 
[145-147]
.  
 
Histological and Anatomical Analysis 
Mouse was injected with 100iu heparin intraperitoneally (i.p.) 20 minutes prior to the 
terminal anesthesia via 5% isoflurane/O2. In order to perform anatomical measurements, the 
whole heart, lungs and liver were immediately excised, rinsed in sterile saline (0.9% NaCl), 
blotted dry and weighed. The left ventricle, right ventricle, left atria and right atria were then 
dissected and weighed separately. Right tibia was carefully removed and defleshed. Tibia length 
(TL, mm) was measured using a micrometer caliper (Fisher Scientific, PA), as described 
previously 
[148]
.  
For histological analysis, hearts were arrested in KCl solution, retrogradely perfused and 
fixed in freshly prepared 4% paraformaldehyde solution (PFA, in 0.1M phosphate buffer, 
pH=7.4). Fixed hearts were then dehydrated in serial ethanol and infiltrated with paraffin (Fisher 
Scientific, PA). Tissue sections of 5μm thickness were obtained at room temperature via a rotary 
microtome (Leica, IL). Haematoxylin and eosin staining (H&E, Thermo Scientific, MA) was 
performed using the progressive method. Specifically, tissue slides were stained in modified 
Mayer’s hematoxylin (Thermo Scientific, MA), differentiated in an acid solution and stained 
with alcoholic eosin Y (Thermo Scientific, MA) until the nuclei turned blue and cytoplasm 
turned pink, as described previously 
[149]
. Masson’s trichrome (Sigma-Aldrich, MO) staining was 
performed according to the manufacturer’s instruction. Briefly, mordanted tissue slides (in 
Bouin’s solution) were counterstained with Weigert’s Iron haematoxylin first, followed by 
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staining in  Biebrich Scarlet-Acid Fucshin solution, differentiated in Phosphotungstic/ 
Phosphomolybdic acid, stained in Aniline Blue for collagenic fibers and differentiated in 1% 
acetic acid. Lastly, stained tissue sections were analyzed at the magnification of ×12.5 to ×1000 
under light microscope (Olympus BX53, PA). 
 
Lectin Histochemistry 
To determine the status of tissue sialylation and the expression pattern of α2,3-sialic acid, 
Maackia amurensis leukoagglutinin (MAL, Vector Lab, CA), Maackia amurensis hemagglutinin 
(MAH, Vector Lab, CA) and Erythrina cristagalli lectin (ECL, Vector Lab, CA) were used to 
probe murine left ventricular sections. Previous studies showed that MAL has very high affinity 
to N-linked Sialic acid α2,3 Galactose β1,4 N-acetylglucosamine (Siaα2,3Galβ1,4GlcNAc)  
oligosaccharide structure; MAH binds to O-linked Sialic acid α2,3 Galactose β1,3 N-
acetylgalactosamine (Siaα2,3Galβ1,3GalNAc); and ECL binds preferentially to terminal 
unsubstituted Galactose β1,4 N- acetylglucosamine (Galβ1,4GlcNAc) [150, 151]. Biotinylated lectin 
with avidin-biotin-fluorophore or avidin-biotin-peroxidase complex (ABC) systems was applied 
on PFA-fixed paraffin-embedded wildtype and ST3Gal4
-/- 
cardiac tissues, as described 
previously 
[150-154]
. Specifically, tissue sections were blocked for endogenous biotin 
(Streptavidin/Biotin blocking kit, Vector Lab, CA), endogenous peroxidase (3%H2O2) and non-
specific binding (Vector Lab, CA) before incubation with biotinylated lectin. Tissue sections 
were then incubated with fluorophore conjugated streptavidin (Thermo Scientific, MA) followed 
by 4, 6-diamidino-2-phenylindole (DAPI, Vector Lab, CA) counterstain or incubated with ABC 
system (Vector Lab, CA) followed by haematoxylin counterstain.  The following negative 
controls were used: 1) substitution of biotinylated lectin with blocking buffer alone, 2) staining 
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with blocking buffer only, and 3) staining with 3, 3 -diaminobenzidine (DAB) only when using 
the ABC system. Tissue slides were then examined under microscope (Olympus BX53, PA). 
 
Protein Extraction and Western Blotting 
Murine LV tissues were homogenized in radioimmunoprecipitation lysis buffer (RIPA) 
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.0004% sodium azide, 
phenylmethanesulfonyl fluoride (PMSF), sodium orthovanadate, protease inhibitor (Roche, IN) 
and phosphatase inhibitor (Thermo scientific, MA), as described previously 
[155]
. The 
concentrations of the protein extracts were colorimetrically assayed using bicinchoninic acid 
(BCA) method (Thermo scientific, MA) and detected in a spectrophotometer. Protein extracts 
were reduced and denatured in Laemmli sample buffer (32.9mM Tris-HCl, 13.15% glycerol, 
1.05% SDS, 0.005% bromophenol blue, 5% β-mercaptoethanol, pH=6.8). Equal amounts of 
proteins were then loaded and separated via Tris-Glycine SDS-Polyacrylamide gel 
electrophoresis (SDS-PAGE), and transferred to polyvinylidene difluoride (PVDF) membrane 
(Immobilon-P, Millipore, MA). The transfer efficiency was confirmed. Transferred blots were 
blocked for non-specific bindings (5% non-fat dry milk); probed with unconjugated primary 
antibodies against calcineurin A subunit (CnA, immunogen is the carboxyl terminal 349-
505amino acids of human CnA, BD Pharmingen, CA) 
[156]
, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, Santa Cruz, CA) or α-dystroglycan (Millipore, CA); and followed by 
incubation with HRP conjugated secondary antibodies. Blots were visualized in enhanced 
chemiluminescence (ECL, SuperSignal West Pico Chemiluminescent Substrate, Thermo 
Scientific, MA) via ChemiDoc XRS+ (Bio-Rad, CA) or exposed to autoradiography film. Finally, 
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densitometric analysis was performed using lane and band tool with background subtraction in 
Image Lab software version 5.2.1 (Bio-Rad, CA). And GAPDH was used as the protein loading 
control. 
 
Statistics 
Statistical analyses were performed in SPSS statistics software version 22 (IBM, NY). 
Survival time (week) was defined as the time until death and Kaplan-Meier with log-rank test 
was performed as described previously 
[157]
. P-value <0.05 was considered statistical significant. 
Except for the survival time, data were presented as mean ± S.E.M. For parametric data, 
Independent t-test (homogeneity of variances) or Welch t-test (heterogeneity of variances) was 
conducted when comparing two independent groups. One way ANOVA was performed when 
comparing more than 2 groups, followed by TukeyHSD (homogeneity of variances) or Games-
Howell (heterogeneity of variances) post hoc test. And two way ANOVA was executed by 
adjusting the significance using Bonferroni correction. For non-parametric data, Mann-Whitney 
U test was conducted when comparing two independent groups; and Kruskal-Wallis one way 
analysis of variance was performed when comparing more than two independent groups, 
followed by Dunn’s post hoc test with a Bonferroni correction for multiple comparisons. P-value 
<0.05 was considered statistical significant.  
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CHAPTER THREE  
PARTIAL REDUCTIONS OF SIALYLATION LEAD TO DILATED 
CARDIOMYOPATHY AND STRESS-INDUCED HEART FAILURE  
 
Introduction 
Sialic acids are negatively charged monosaccharides that often terminate N- and O-
glycan chains. Previous studies showed that experimental prevention of the addition of or 
following the removal of sialic acids markedly altered the voltage sensitivity of Nav and Kv 
gating, through direct, isoform-specific, electrostatic mechanisms 
[25-31, 106]
. Recent studies from 
our lab showed that the cardiac glycome is variable and changes differentially during 
development of atria and ventricles. The regulated expression of a single sialyltransferase was 
sufficient to modulate action potential waveforms and gating of less sialylated Nav consistently 
[105]
.  
Moreover, patients suffering from heart failure secondary to idiopathic dilated 
cardiomyopathy (DCM) have reduced α2,3- but not α2,6-sialylation in their cardiac tissues [72]. 
Some infectious diseases, such as Chagas Disease, selectively cleaving α2,3-sialic acid link, 
contribute to the subsequent severe DCM, fatal arrhythmia and cardiac sudden death.  
In order to investigate the physiological impact of α2,3-sialic acid on cardiac electrical 
signaling, ST3Gal4
-/-
 mice were obtained from Dr. Marth’s laboratory [101]. Previous studies of 
ST3Gal4
-/-
 showed that ST3Gal4
-/-
 has increased bleeding time, decreased von Willebrand factor 
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and platelet counts, decreased L-selectin binding and L-selectin-dependent leukocyte rolling, as 
well as the increased terminal galactose residue exposure 
[101] [103]
.  
Our laboratory is the first to report the cardiac phenotype of ST3Gal4
-/-
. That is, we found 
that isolated ventricular cardiomyocytes of ST3Gal4
-/-
 have altered AP waveforms, characterized 
by slow depolarization, extended repolarization and reduced refractory period (See Ednie A.R. et 
al., 2013 and 2015) 
[108, 110]
. These AP waveform changes were attributed to the depolarizing 
shift in Nav, Ito and IKslow gating; a 29% significant increased rate of Nav recovery from fast 
inactivation; and the rightward shift of Nav window current. All of which contributed to the 
observed decrease in cellular refractory periods, prolonged QT interval and increased 
susceptibility to arrhythmia 
[108, 110]
. These data provided initial insight into a possible novel 
mechanism for controlling/ modulating excitability.  However, little is known about whether and 
how sialylation modulates cardiac function in vivo. 
 
Methods 
The complete physiological and morphological examinations were performed on adult 
male ST3Gal4
-/-
 mice, including lectin histochemistry, PCR, western blotting, surface ECG, 
telemetry ECG, echocardiography, histology, minimally invasive TAC surgical animal model, 
anatomical studies and etc.   
 
Moderate Dilated Cardiomyopathy with Aberrant ECG in 18-Month Old ST3Gal4
-/-
 Heart 
α2,3-sialylation expression pattern was first examined via MAL, MAH and ECL lectin 
histochemistry as describe previously (See Chapter 2). MAL binds preferentially to N-linked 
Sialic acid α2,3 Galactose β1,4 N-acetylglucosamine (Siaα2,3Galβ1,4GlcNAc)  oligosaccharide 
62 
 
structure 
[150]
. MAH recognizes O-linked Sialic acid α2,3 Galactose β1,3 N-acetylgalactosamine 
(Siaα2,3Galβ1,3GalNAc) structure [150]. And ECL binds to terminal unsubstituted Galactose β1,4 
N- acetylglucosamine (Galβ1,4GlcNAc) [151]. ST3Gal4-/- showed reduced MAL staining when 
compared to wildtype, indicating a reduced N-linked α2,3-sialylation in ST3Gal4-/- hearts (See 
Figure 3.1A-B). ECL binding was increased in ST3Gal4
-/-
 due to the increased terminal galactose 
exposure in ST3Gal4
-/-
 hearts 
[101]
. However, MAH staining was indistinguishable between 
ST3Gal4
-/-
 and wildtype, suggesting a similar O-linked sialylation in their cardiac tissues. Hence, 
ST3Gal4
-/-
 exhibited a reduced N-linked but not O-linked α2,3-sialylation in their hearts, 
consistent with previous studies (also See Chapter 1 and Figure 1.10) 
[101]
. In addition, the strong 
MAL and MAH bindings were exhibited on the cardiomyocyte membrane, vascular endothelium 
& basement membrane and valve endothelium (See Figure 3.1A, E & H) of 18-month old 
wildtype cardiac tissues. No intracellular structure was stained. Negative controls were 
completely devoid of any stain (data not shown). Similar staining pattern was also exhibited on 
18- month old ST3Gal4
-/-
 cardiac tissues (See Figure 3.1B, F & I). It indicates that α2,3-
sialylation is primarily present on the glycoproteins residing on the cardiomyocyte sarcolemma, 
endothelium and basal lamina of  murine cardiac tissues, consistent with previous reports 
[152, 158]
.  
ST3Gal4
-/-
 mice appear normal afterbirth, fully fertile, active and well-nourished without 
increased mortality, consistent with the previous report 
[101]
. By 18-month of age, there was no 
significant difference in body size and body weight between ST3Gal4
-/-
 and wildtype littermates, 
weighing 49.3±1.7g (n=9) and 47.3±1.4g (n=8) respectively (See Figure 3.2). In order to 
determine how sialylation modulates cardiac function in vivo, echocardiography was performed 
chronologically at ages of 6-, 9-, 12- and 18-month old from the same animal (See Figure 3.3; 
Tables 3.1-3.4). Echocardiography revealed a progressively enlarged left ventricular end-  
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Figure 3.1. Lectin histochemistry of adult murine cardiac tissues.  
MAL, MAH and ECL lectin histochemistry was used to evaluate the cardiac sialylation of 18-
month old wildtype (A, C, E & G) and ST3Gal4
-/-
 (B, D, F & H) (magnification ×400). A-B. 
ST3Gal4
-/-
 hearts showed reduced MAL (green) staining when compared to wildtype hearts, 
indicating a reduced N-linked α2,3-sialylation upon gene deletion of ST3Gal4 on murine 
hearts, validated the ST3Gal4
-/-
 animal model. DAPI (blue) nuclear counterstain overlay. C-D. 
ECL binding (green) was almost devoid in wildtype, but was increased in ST3Gal4
-/-
 hearts. 
This is due to the increased terminal galactose exposure in ST3Gal4
-/-
 
[101]
. DAPI (blue) 
nuclear counterstain overlay. (E-H) However, MAH staining (purple in E-F or green in G-H) 
was indistinguishable between ST3Gal4
-/-
 and wildtype, suggesting the similar O-linked 
sialylation in ST3Gal4
-/-
 and wildtype cardiac tissues, consistent with previous studies 
[101]
. 
DAPI (blue) nuclear counterstain overlay. In addition, cardiomyocyte cell membrane (arrow) 
and capillary endothelium & basal lamina (open arrow) showed strong MAL and MAH 
stainings (A, E & G). No intracellular structure was stained. The same staining pattern was 
also exhibited on 18- month old ST3Gal4
-/-
 cardiac tissues (B, F & H). It suggests that α2,3-
sialylated glycoproteins are primarily expressed on the cardiomyocyte membrane and the 
vascular endothelium & basal lamina of murine cardiac tissues. Scale bar = 20µm. 
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diastolic volume (EDV), dilated left ventricular internal dimension at diastole (LVID;d) and 
thinner left ventricular posterior wall thickness at diastole (LVPW;d)  in male ST3Gal4
-/-
 mice 
(n=9) when compared to male wildtype littermates (n=8), with each parameter reaching 
significant difference by 18 months of age (See Figure 3.3B-D, at 18-month: EDV - WT = 
87.3±3.8µl, ST3Gal4
-/- 
= 106.5±5.0µl; LVID;d - WT = 4.37±0.09mm, ST3Gal4
-/- 
= 4.74±0.1mm; 
LVPW;d - WT = 0.94±0.05mm, ST3Gal4
-/- 
= 0.82±0.02mm. p<0.05). Although there was a 
slight reduction of EF% at 9-month in ST3Gal4
-/-
 (EF% of ST3Gal4
-/-
 = 61.7±1.6%, n=10 versus 
EF% of WT = 67±2.6%, n=10, p<0.05), cardiac systolic function of ST3Gal4
-/-
 was well 
preserved for 18 months when compared to age-matched wildtype littermates (See Figure 3.3A; 
Tables 3.1-3.4). No statistically significance was found in left ventricular mass (LVM, mg) 
between ST3Gal4
-/-
 and wildtype (See Figure 3.3E). And no septal defect or great vessel 
abnormality was observed under echocardiography. The gradual cardiac dilation with mostly 
preserved cardiac systolic function suggested a modest dilated cardiomyopathy (DCM) in 12- to 
18-month old male ST3Gal4
-/-
.  
In addition, lead II surface ECG was performed on 18-month old ST3Gal4
-/-
 and wildtype. 
Male ST3Gal4
-/-
 demonstrated a significantly depressed J peak (p<0.01), with a mild but not 
significantly prolonged PR interval (p>0.05) (See Figure 3.4;  Table 3.5). No statistical 
significance was detected in P, QRS, QT and QTc durations or P and R peak amplitudes between 
male 18-month ST3Gal4
-/-
 (n=9) and wildtype (n=6) (p>0.05). The aberrant ECG observed in 
ST3Gal4
-/-
 is consistent with the DCM phenotypes. 
Consistent with echocardiography, Haematoxylin & Eosin staining of 18-month old 
ST3Gal4
-/-
 hearts found a much thinner left ventricular free wall with all four cardiac chambers 
dilated, most obvious in left and right ventricles (See Figure 3.5B). No septal, valvular or 
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Figure 3.2. Gross appearance of ST3Gal4
-/-
 and wildtype at 18-month old.  
A. ST3Gal4
-/-
 mice appear normal afterbirth, fully fertile, active and well-nourished without 
increased mortality, consistent with previous report 
[101]
. By 18-month old, no statistical 
significant difference was observed in body size and body weight (B) between male WT and 
ST3Gal4
-/-
 littermates, weighing 47.3±1.4g (n=8) and 49.3±1.7g (n=9), respectively. Black bar, 
wildtype; red bar, ST3Gal4
-/-
; WT, wildtype; KO, ST3Gal4
-/-
. 
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Figure 3.3. Dilated cardiomyopathy with preserved cardiac systolic function in male 
ST3Gal4
-/- 
mice. (Continued on Next Page) 
 
 
 
 
E. 
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Figure 3.3 (Continued) 
A. Echocardiography was performed chronologically at ages 6-, 9-, 12- and 18-month from the 
same animal. Although there was a slight reduction of EF% at 9-month in ST3Gal4
-/-
 (EF% of 
WT = 67±2.6%, n=10 versus EF% of ST3Gal4
-/-
 = 61.7±1.6%, n=10, p<0.05), systolic function 
of ST3Gal4
-/-
 was well preserved for entire 18-month when compared to the wildtype littermates. 
Black bar, wildtype; red bar, ST3Gal4
-/-
. However, ST3Gal4
-/-
 (n=9) hearts showed progressively 
enlarged LVID;d (B), EDV (C) with thinner LVPW;d (D), reaching significance at 12- to 18-
month when compared to age-matched WT littermates (n=10). At 18-month: EDV - WT = 
87.3±3.8µl, ST3Gal4
-/- 
= 106.5±5.0µl; LVID;d - WT = 4.37±0.09mm, ST3Gal4
-/- 
= 4.74±0.1mm; 
LVPW;d - WT = 0.94±0.05mm, ST3Gal4
-/- 
= 0.82±0.02mm. E. LV mass of ST3Gal4
-/-
 and WT 
littermates were not significantly different (p>0.05). See Table 3.1-3.4 for raw echocardiography 
values from the chronological study.  *, p<0.05; **, p<0.01. WT, black circles/lines; ST3Gal4
-/-
, 
red squares/lines.   
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Table 3.1. Chronological echocardiography of wildtype and ST3Gal4
-/-
 at 6-month old. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
† Values are presented as mean ± SEM; *, p<0.05; **, p<0.01. 
n, number of mice in each group; HR, heart rate; LVID, left ventricular internal dimension; 
LVAW, left ventricular anterior wall thickness; LVPW, left ventricular posterior wall thickness; 
LVM, left ventricular mass; LVMi, left ventricular mass index; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, cardiac output; COi, cardiac output index; 
SV, stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-
systolic volume.   
                                                                                                                                                          
  WT ST3Gal4
-/-
   
n   10   
 
10 
  Body weight, g 38 ± 1 34 ± 2 
 HR, beats/min 513 ± 5 521 ± 5 
 Diastole   
 
  
                       LVID, mm 4.21 ± 0.09 4.17 ± 0.06 
                    LVAW, mm 0.93 ± 0.02 0.95 ± 0.03 
                    LVPW, mm 0.74 ± 0.02 0.71 ± 0.01 
 Systole   
 
  
                       LVID, mm 2.67 ± 0.13 2.60 ± 0.09 
                    LVAW, mm 1.46 ± 0.03 1.36 ± 0.03 * 
                   LVPW, mm 1.15 ± 0.04 1.15 ± 0.03 
 LVM, mg 105.7 ± 4.2 113.4 ± 3.6 
 LVMi, mg/g 2.8 ± 0.1 3.4 ± 0.2 ** 
EF, % 68.0 ± 2.7 69.4 ± 1.8 
 FS, % 38.1 ± 2.3 38.9 ± 1.5 
 SV, µl 54.7 ± 2.1 53.8 ± 1.3 
 CO, ml/min 28.1 ± 1.2 28.0 ± 0.7 
 COi, ml/min/g 0.74 ± 0.03 0.84 ± 0.06  
EDV, µl 81.4 ± 3.7 78.3 ± 2.5 
 ESV, µl 26.7 ± 2.8 24.0 ± 1.9   
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Table 3.2. Chronological echocardiography of wildtype and ST3Gal4
-/-
 at 9-month old. 
 
 
 
 
 
 
 
 
                                                                       
 
 
                                                                                                                                                          
 
 
† Values are presented as mean ± SEM; *, p<0.05; ***, p<0.001. 
n, number of mice in each group; HR, heart rate; LVID, left ventricular internal dimension; 
LVAW, left ventricular anterior wall thickness; LVPW, left ventricular posterior wall thickness; 
LVM, left ventricular mass; LVMi, left ventricular mass index; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, cardiac output; COi, cardiac output index; 
SV, stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-
systolic volume.    
                                                                                                                                                          
  WT ST3Gal4
-/-
   
n   10    10  
 Body weight, g 42 ± 1 41 ± 1 
 HR, beats/min 534 ± 6 524 ± 5 
 Diastole         
                    LVID, mm 4.33 ± 0.06 4.39 ± 0.08 
                    LVAW, mm 1.00 ± 0.04 0.89 ± 0.03 * 
                   LVPW, mm 0.77 ± 0.02 0.73 ± 0.02 
 Systole         
                    LVID, mm 2.80 ± 0.11 2.94 ± 0.09 
                    LVAW, mm 1.50 ± 0.04 1.30 ± 0.04 *** 
                   LVPW, mm 1.16 ± 0.06 1.18 ± 0.05  
LVM, mg 116.2 ± 2.6 110.6 ± 5.8  
LVMi, mg/g 2.8 ± 0.1 2.7 ± 0.1  
EF, % 66.8 ± 2.8 62.3 ± 1.6 * 
FS, % 37.2 ± 2.0 33.5 ± 1.2 
 SV, µl 57.2 ± 2.6 54.9 ± 1.9 
 CO, ml/min 30.2 ± 1.3 28.0 ± 1.5
 COi, ml/min/g 0.73 ± 0.04 0.68 ± 0.04  
EDV, µl 85.9 ± 2.6 88.5 ± 3.4 
 ESV, µl 28.7 ± 2.8 33.6 ± 2.3   
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Table 3.3. Chronological echocardiography of wildtype and ST3Gal4
-/-
 at 12-month old. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Values are presented as mean ± SEM; *, p<0.05; **, p<0.01. 
n, number of mice in each group; HR, heart rate; LVID, left ventricular internal dimension; 
LVAW, left ventricular anterior wall thickness; LVPW, left ventricular posterior wall thickness; 
LVM, left ventricular mass; LVMi, left ventricular mass index; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, cardiac output; COi, cardiac output index; 
SV, stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-
systolic volume.   
 
 
 
  WT ST3Gal4
-/-
   
n   9    10  
 Body weight, g 44 ± 1 45 ± 1 
 HR, beats/min 531 ± 6 509 ± 6 * 
Diastole         
                    LVID, mm 4.35 ± 0.08 4.58 ± 0.08 
                    LVAW, mm 0.99 ± 0.03 0.86 ± 0.03 ** 
                   LVPW, mm 0.86 ± 0.03 0.78 ± 0.02 * 
Systole         
                    LVID, mm 2.84 ± 0.11 3.08 ± 0.12 
                    LVAW, mm 1.45 ± 0.04 1.29 ± 0.04 * 
                   LVPW, mm 1.33 ± 0.06 1.21 ± 0.04  
LVM, mg 130.5 ± 6.6 120.5 ± 5.3  
LVMi, mg/g 3.0 ± 0.2 2.7 ± 0.1  
EF, % 65.5 ± 2.7 62.9 ± 2.2 
 FS, % 36.2 ± 2.2 34.2 ± 1.7 
 SV, µl 56.8 ± 3.2 61.4 ± 2.2 
 CO, ml/min 30.4 ± 1.8 31.0 ± 1.0 
 COi, ml/min/g 0.69 ± 0.05 0.69 ± 0.02  
EDV, µl 86.6 ± 3.3 98.4 ± 4.0 * 
ESV, µl 29.7 ± 2.4 37.0 ± 3.4   
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Table 3.4. Chronological echocardiography of wildtype and ST3Gal4
-/-
 at 18-month old. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Values are presented as mean ± SEM; *, p<0.05; **, p<0.01. 
n, number of mice in each group; HR, heart rate; LVID, left ventricular internal dimension; 
LVAW, left ventricular anterior wall thickness; LVPW, left ventricular posterior wall thickness; 
LVM, left ventricular mass; LVMi, left ventricular mass index; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, cardiac output; COi, cardiac output index; 
SV, stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-
systolic volume.    
 
  WT ST3Gal4
-/-
   
n   8    9  
 Body weight, g 47 ± 1 49 ± 2 
 HR, beats/min 535 ± 4 525 ± 5 
 Diastole         
                    LVID, mm 4.37 ± 0.09 4.74 ± 0.10 * 
                   LVAW, mm 0.95 ± 0.06 0.92 ± 0.03 
                    LVPW, mm 0.94 ± 0.05 0.82 ± 0.02 * 
Systole         
                    LVID, mm 2.89 ± 0.12 3.28 ± 0.09 * 
                   LVAW, mm 1.39 ± 0.08 1.34 ± 0.06  
                   LVPW, mm 1.31 ± 0.07 1.18 ± 0.02  
LVM, mg 135.2 ± 7.4 140.1 ± 6.6  
LVMi, mg/g 2.9 ± 0.1 2.9 ± 0.1  
EF, % 64.4 ± 2.8 61.3 ± 1.1 
 FS, % 35.3 ± 2.2 32.9 ± 0.7 
 SV, µl 56.2 ± 3.2 65.1 ± 2.9 
 CO, ml/min 30.0 ± 1.8 34.2 ± 1.6 
 COi, ml/min/g 0.64 ± 0.05 0.69 ± 0.02  
EDV, µl 87.3 ± 3.8 106.5 ± 5.0 ** 
ESV, µl 31.1 ± 2.8 41.4 ± 2.6 * 
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A. 
 
 
 
 
 
 
 
B.                                  C.                                              D. 
 
Figure 3.4. Aberrant lead II surface ECG on 18-month male ST3Gal4
-/-
mice. 
A. The representative lead II surface ECG waveform from an 18-month old wildtype and 
ST3Gal4
-/-
. B. RR intervals were similar between wildtype (n=6) and ST3Gal4
-/-
 mice (n=9) 
(p>0.05). C. However, ST3Gal4
-/-
 showed a significantly depressed J peak (p<0.01) with (D) a 
mild but not significantly prolonged PR interval (p>0.05). No statistical significance was 
detected in P, QRS, QT and QTc durations or P and R peak amplitudes between male 18-month 
ST3Gal4
-/-
 and wildtype (p>0.05). See  Table 3.5 for raw ECG values. Black bar, wildtype; red 
bar, ST3Gal4
-/-
. WT, wildtype; QTc, corrected QT interval for heart rate; **, p<0.01. 
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 Table 3.5. Quantitative comparison of lead II surface ECG from male 18-month wildtype 
and ST3Gal4
-/-
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
† Values are presented as mean ± SEM; ** p<0.01.  
n, number of mice in each group; WT, wildtype; QTc, corrected QT interval for heart rate. 
 
 
WT         ST3Gal4 
-/-
 
n   6 
 
  9 
  
Heart rate (bpm) 522 ± 10.6 532 ± 7.1 
 
RR interval (ms) 115 ± 2.4 113 ± 1.6 
 
PR interval (ms) 43 ± 0.8 47 ± 1.9 
 
P duration (ms) 11 ± 0.8 11 ± 0.3 
 
QRS interval (ms) 11 ± 0.2 10 ± 0.5 
 
QT interval (ms) 48 ± 2.2 48 ± 1.4 
 
QTc (ms) 44 ± 1.9 45 ± 1.3 
 
P amplitude (µV) 105 ± 10.7 93 ± 5.7 
 
R amplitude (µV) 742 ± 80.0 622 ± 47.7            
J  amplitude (µV) 178 ± 22.5 45 ± 22.7 ** 
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great vessel defect was observed. Under light microscope, ST3Gal4
-/-
 hearts exhibited reduced 
cardiomyocyte density and decreased width of myocardial fibers with fewer connections to the 
neighboring myocytes (See Figure 3.5B-D). Neither narrowing/ obstruction of the coronary 
artery lumen nor cell infiltration were found (See Figure 3.5). Masson’s trichrome staining did 
not detect any increased fibrosis in 18-month ST3Gal4
-/-
 hearts when compared to wildtype 
littermates (See Figure 3.6). Therefore, the mechanism of fibrosis-induced arrhythmogenesis or 
conductive abnormality in ST3Gal4
-/-
 was unlikely 
[159]
.  
Anatomical studies from 18-month ST3Gal4
-/-
 (n=5) and wildtype littermates (n=4) 
showed no statistical significance in tibia length, heart weight, left ventricular weight, right 
ventricular weight and left atrial weight (See Table 3.6), consistent with echocardiography data. 
Together, the echocardiography combined with histological and anatomical results concluded 
that 12- to 18-month old male ST3Gal4
-/- 
mice developed an adult late-onset modest idiopathic 
dilated cardiomyopathy (DCM). 
 
Pressure Overload Induced Rapid Cardiac Decompensation on 16~20-Week Old ST3Gal4
-/-
  
We showed above that ST3Gal4 gene deletion contributes to the later onset of a modest 
DCM, suggesting that the partial reduction in cardiac sialylation contributes to chronic cardiac 
dysfunction that slowly leads to altered cardiac structure and contractility.  This phenotype 
presented even under the most optimal conditions used to ensure the health of the animal.  That 
is, the mice were never exposed to chronic environmental or pathological cardiovascular 
stressors such as smoking, alcohol abuse, hypertension, intense exercise, obesity, and/or chronic 
generalized stress, all of which are risk factors for DCM and HF to which humans are often 
exposed 
[4, 160]
. Thus, to determine the impact of a partial reduction in cardiac sialylation on the  
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          D. 
 
 
 
 
 
 
 
  
 
Figure 3.5. Histological examination of 18-month male ST3Gal4
-/-
and wildtype hearts. 
A. 18 month-old wildtype and ST3Gal4
-/-
 hearts. Scale bar, 1mm. B. H&E staining (×12.5) 
revealed a thinner left ventricular free wall (bar) with all four chambers dilated, most obvious in 
ST3Gal4
-/-
 left and right ventricles, consistent with echocardiography studies (See Figure 3.3; 
Table 3.4). No septal, valvular or great vessel defect was found. Scale bar, 0.5mm. H&E staining 
at higher magnification of ×400 (C) and ×1000 (D) showed that ST3Gal4
-/-
 hearts had reduced 
cardiomyocyte density and decreased width of myocardial fibers with apparently fewer 
connections to the neighboring myocytes. Neither narrowing/ obstruction of the coronary artery 
lumen nor cell infiltration were observed. These experiments were repeated three times, with 
very similar results. Scale bar = 20µm in (C) and scale bar = 5µm in (D); WT, wildtype. 
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 A.  
 
 
 
 
 
 
 
 
 B. 
 
 
 
 
 
 
Figure 3.6. Lack of increased fibrosis in 18-month ST3Gal4
-/-
 hearts. 
A (×12.5) and B (×200). Masson’s trichrome staining did not detect any significantly increased 
fibrosis in 18-month ST3Gal4
-/-
 hearts when compared to wildtype littermates. These 
experiments were repeated three times, with very similar results. Therefore, the mechanism of 
fibrosis-dependent arrhythmogenesis or conductive abnormality in ST3Gal4
-/-
 was unlikely 
[159]
. 
Scale bar = 0.5mm in (A); and scale bar = 20µm in (B).   
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     WT                                                    ST3Gal4
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Table 3.6. Anatomical comparison of 18-month old wildtype and ST3Gal4
-/-
.  
 
 WT ST3Gal4
-/-
 
n 
 
4   
 
5 
 
  Body weight, g 47.0 ± 2.2 47.7 ± 3.9 
  Tibia Length, mm 18.4 ± 0.1 18.7 ± 0.1 
  Heart Weight, mg 177.8 ± 4.5 182.6 ± 10.4 
           HW/BW, mg/g 3.79 ± 0.09 3.87 ± 0.14 
           HW/TL, mg/mm 9.68 ± 0.27 9.78 ± 0.54 
  LV Weight, mg 118.0 ± 7.3 121.4 ± 8.4 
           LVW/BW, mg/g 2.51 ± 0.08 2.57 ± 0.12 
           LVW/TL, mg/mm 6.43 ± 0.41 6.50 ± 0.44 
  RV Weight, mg 25.0 ± 1.4 26.4 ± 1.9 
           RV/BW, mg/g 0.53 ± 0.01 0.56 ± 0.01 
           RV/TL, mg/mm 1.36 ± 0.08 1.41 ± 0.10 
  LA Weight, mg 5.0 ± 1.7 6.8 ± 1.0 
           LA/BW, mg/g 0.11 ± 0.04 0.15 ± 0.02 
           LA/TL, mg/mm 0.27 ± 0.09 0.36 ± 0.05 
  RA Weight, mg 5.5 ± 1.4 7.0 ± 1.1 
           RA/BW, mg/g 0.12 ± 0.04 0.15 ± 0.02 
           RA/TL, mg/mm 0.30 ± 0.08 0.37 ± 0.06 
 
† Values are presented as mean ± SEM.  
n, number of mice in each group; BW, body weight; TL, tibia length; HW, heart weight; LVW, 
left ventricular weight; RV, right ventricular weight; LA, left atrial weight; RA, right atrial 
weight.  
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ability of the heart to compensate for pathological stressors that are risk factors for DCM and HF 
in humans, we used a chronic pressure-overload model for stress-induced heart failure 
[161]
. 
16- to 20-week old male ST3Gal4
-/-
 and wildtype mice were randomly and blindly assigned to 
transverse aortic constriction (TAC)- or sham-operated groups.  At this age, there was no sign of 
altered cardiac structure or reduced systolic function in ST3Gal4
-/-
 (See Figure 3.3).  However, as 
described previously by us, 12- to 14-week old male ST3Gal4
-/-
 animals did display an increased 
susceptibility to arrhythmias caused by altered Nav and Kv gating 
[108, 110]
. At the baseline level (-
2 to -3 days), echocardiography showed no significant difference in systolic function, chamber 
dimension and aortic pressure between wildtype (n=7) and ST3Gal4
-/- 
(n=12) (See Figure 3.7-
3.8B-D; Table 3.7). Aortic peak pressure gradient of aortic constriction (AoPg) was measured 7 
days after surgery to determine the degree of pressure-load imposed by TAC. The AoPg of 
TAC’d ST3Gal4-/- and TAC’d WT were nearly identical (AoPg- TAC’d ST3Gal4-/- = 
85.9±0.7mmHg and TAC’d WT = 85.5±1.2mmHg, p>0.05), confirmed that the two groups 
received equivalent amount of pressure-loading (See Figure 3.7A; Table 3.8).  However, systolic 
function of TAC’d ST3Gal4-/-  declined rapidly, reaching statistical significance (as compared to 
TAC’d WT) within one week post-surgery that continued to deteriorate throughout the 
observation period, resulting in the development of left congestive heart failure by the sixth week 
post-surgery (6 weeks after TAC: TAC’d ST3Gal4-/-  EF% = 34 ± 5.2% and FS% = 16.9 ± 2.9%) 
(See Figure 3.7; Table 3.11).  Systolic function remained within the normal range for TAC’d WT 
(6 weeks after TAC: TAC’d WT EF%=53.8±7.4% and FS%=28.6±4.5%), and remained normal 
and relatively constant in sham WT (n=8) and sham ST3Gal4
-/-
(n=10) mice during the six week 
experiment (6 weeks after TAC: sham WT EF% = 68.9 ± 2.1% and FS% = 38.6 ± 1.6%; sham 
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ST3Gal4
-/-
 EF% = 59.2±1.5% and FS% = 31.2±1%) (See Figure 3.7; Table 3.11). No mortality 
was observed throughout 6-week TAC experiments.  
 
Insufficient LV Hypertrophy and Progressive Ventricular Dilation in TAC’d ST3Gal4-/-  
TAC’d WT left ventricular posterior wall thickness at diastole (LVPW;d) was nearly 
doubled after TAC, due to substantial left ventricular adaption (See Figure 3.7D&3.8A-B; Table 
3.7-3.11). However, TAC’d ST3Gal4-/- hearts presented only limited increase in left ventricular 
wall thickness with progressive left ventricular dilation, presented as attenuated LVPW;d,  
dilated left ventricular internal dimension at diastole (LVID;d),  and enlarged left ventricular 
end-diastolic volume (EDV) (See Figure 3.8; Table 3.7-3.11), with all parameters showing 
significant difference starting one week after TAC comparing to TAC’d WT.  No significant 
differences or changes were observed in LVPW;d, EDV and LVID;d of sham WT or sham 
ST3Gal4
-/-
 mice throughout the six-week experiment (See Figure 3.7D&3.8A-B; Table 3.7-3.11).  
Anatomical studies were performed at 6
th
 week post-surgery. Heart weight, left atrial 
weight, right atrial weight, left ventricle weight, right ventricle weight, lung weight, liver weight, 
tibia length were compared. Both TAC’d WT and TAC’d ST3Gal4-/- mice demonstrated 
significantly heavier left ventricular weight and heart weight when compared to sham WT and 
sham ST3Gal4
-/-
 mice, respectively (p<0.001) (See Table 3.12). However, TAC’d ST3Gal4-/- 
mice showed much heavier left atrial weight, lung weight, and right ventricle weight than those 
of TAC’d WT mice, supporting the left congestive heart failure findings in TAC’d ST3Gal4-/-.   
Together, the data showed that TAC’d ST3Gal4-/- hearts  exhibited inadequate adaptation 
and decompensate rapidly, deteriorating into left side heart failure under chronic stress 
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conditions, while TAC’d WT heart function remained within the normal range throughout the 
six-week period of chronic stress. 
 
Increased Susceptibility to Heart Failure Was Independent of Calcineurin Pathway in 
ST3Gal4
-/-
 
Activation of calcineurin/ NFAT pathway is one of the underlining mechanisms known to 
cause pathological cardiac hypertrophy and heart failure, especially in chronically stressed 
animal models 
[162]
. To investigate whether calcineurin pathway contributed to the observed heart 
failure in TAC’d ST3Gal4-/-, we examined calcineurin expression level from left ventricular 
protein extracts of TAC- or sham-operated mice 6 weeks after surgery.  An antibody against 
carboxyl terminal 349-505 amino acids of calcineurin subunit A (CnA) 
[156]
 was used, and 
GAPDH was served as the loading control (See Figure 3.9). CnA expressions were normalized to 
sham WT. Western blotting showed that calcineurin expressions were significantly lower (only 
about half compared to sham WT) in sham ST3Gal4
-/-
 (n=9) than in sham wildtype (n=6) 
(normalized CnA- sham WT = 1±0.17, sham ST3Gal4
-/-
 = 0.65±0.06, p<0.05) (See Figure 3.9). 
TAC increased calcineurin expression in both TAC’d WT (n=11) and TAC’d ST3Gal4-/- (n=6). 
However, TAC’d ST3Gal4-/- expressed much less calcineurin than TAC’d WT did (normalized 
CnA-TAC’d WT = 1.11±0.13, TAC’d ST3Gal4-/- = 0.83±0.18) (See Figure 3.9), excluded the 
possibility of calcineurin overexpression-induced heart failure in TAC’d ST3Gal4-/-.  
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Figure 3.7. TAC induced left congestive heart failure in 16- to 20-week old male ST3Gal4
-/-
. (Continued on Next Page) 
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Figure 3.7 (Continued) 
A. Equivalent pressure-overload was imposed on 16-20 week old ST3Gal4
-/-
 (85.9±0.7mmHg; n=12) and wildtype littermates 
(85.5±1.2mmHg; n=7), p>0.05. Shaded black bar, sham wildtype; solid black bar, TAC’d wildtype; shaded red bar, sham ST3Gal4-/-; 
solid red bar, TAC’d ST3Gal4-/-. B-C. EF% and FS% of TAC’d ST3Gal4-/- declined rapidly, reaching statistical significance within 
seven days post-surgery.  The systolic functions of TAC’d ST3Gal4-/- hearts continued deteriorating over time, developing congestive 
left heart failure by the sixth week post-TAC (EF% = 34 ± 5.2% and FS% = 16.9 ± 2.9%).  In comparison, TAC’d WT EF% and FS% 
were only marginally reduced, remaining significantly higher and within the normal range throughout the six-week experiment (6 
weeks after TAC surgery: EF%=53.8±7.3% and FS%=28.6±4.5%). Cardiac systolic function remained relatively constant and normal 
in sham wildtype (n=8) and sham ST3Gal4
-/-
(n=10) mice throughout the experiment (6 weeks after sham-surgery: sham WT EF% = 
68.9 ± 2.1% and FS% = 38.6 ± 1.6%, sham ST3Gal4
-/-
 EF% = 59.2±1.5% and FS% = 31.2±1.0%). WT, wildtype. Sham WT, black 
open circles/dashed lines; TAC’d WT, black solid circles/lines; Sham ST3Gal4-/-, red open squares/dashed lines; TAC’d ST3Gal4-/-, 
red solid squares/lines.  *, p<0.05; **, p<0.01; ***, p<0.001; NS, p>0.05 not statistical significant versus TAC’d WT. D. 
Representative 2D B-mode and M-mode echocardiography 6 weeks after TAC- or sham-surgery.  TAC’d ST3Gal4-/- hearts showed 
significantly thinner left ventricular walls, enlarged left ventricular internal dimension at systole and diastole, and reduced contractility 
when compared to TAC’d WT.  Green arrow, left ventricular internal dimension at diastole; Green open arrow, left ventricular internal 
dimension at systole; Red bar, left ventricular posterior wall at diastole.  
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Figure 3.8. Inadequate LV hypertrophy and progressive ventricular dilation in TAC’d ST3Gal4-/-. (Continued on Next Page) 
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Figure 3.8 (Continued) 
A. Gross morphology of the wildtype and ST3Gal4
-/-
 hearts 6 weeks after TAC- or sham-surgery. Scale bar, 1mm. B. The LVPW;d of 
TAC’d WT was significantly thicker than that of TAC’d ST3Gal4-/-, starting one week post-surgery. C-D. EDV and LVID;d were 
significantly enlarged in TAC’d ST3Gal4-/- mice compared to TAC’d WT mice, also starting one week post-surgery and progressively 
increasing throughout the 6-week experiment. Sham-operated animals showed no statistically significant changes in LVPW;d, EDV 
and LVID;d before or after sham-surgery. The mean ± SEM parameter values measured 6 weeks post-TAC: LVPW;d - TAC’d WT = 
1.15 ± 0.1 mm; TAC’d ST3Gal4-/- = 0.88±0.03 mm; p<0.01; LVID;d: TAC’d WT =4.17 ± 0.18 mm; TAC’d ST3Gal4-/- =4.8 ± 0.16 
mm; p<0.05; EDV: TAC’d WT =79.5 ± 8.31 µl; TAC’d ST3Gal4-/- = 109.63 ± 8.19 µl; p<0.05. WT, wildtype; LVPW;d, left 
ventricular posterior wall thickness at diastole; EDV, left ventricular end-diastolic volume; LVID;d, left ventricular internal dimension 
at diastole; *, p<0.05; **, p<0.01 versus TAC’d WT. TAC’d WT, black solid circles/lines; TAC’d ST3Gal4-/-, red solid squares/lines; 
Sham WT, black open circles/dashed lines; Sham ST3Gal4
-/-
, red open squares/dashed lines. 
 
 
88 
 
Table 3.7. Echocardiography of TAC- or sham-operated mice at baseline (-2 day) before surgery. 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n   8     7    10   12   
Body weight, g 31.8 ± 0.9 29.1 ± 1.1 30.8 ± 0.7 30.5 ± 0.9  
HR, beats/min 533 ± 6 525 ± 9 524 ± 3 536 ± 3  
Aortic pressure, mmHg 6.3 ± 1.0 5.3 ± 0.4 6.4 ± 0.3 6.4 ± 0.4  
Diastole                  
                      LVID, mm 4.14 ± 0.16 3.89 ± 0.13 4.17 ± 0.06 3.98 ± 0.05  
                      LVAW, mm 0.95 ± 0.02 0.96 ± 0.04 0.96 ± 0.03 0.87 ± 0.04  
                      LVPW, mm 0.76 ± 0.02 0.72 ± 0.03 0.70 ± 0.02 0.72 ± 0.01  
Systole                  
                      LVID, mm 2.70 ± 0.15 2.41 ± 0.16 2.83 ± 0.05 2.50 ± 0.06  
                      LVAW, mm 1.44 ± 0.04 1.39 ± 0.06 1.42 ± 0.05 1.41 ± 0.03  
                      LVPW, mm 1.17 ± 0.05 1.17 ± 0.05 1.07 ± 0.04 1.15 ± 0.02  
LVM, mg 109.6 ± 6.5 95.2 ± 5.3 110.2 ± 4.5 93.3 ± 3.2  
LVMi, mg/g 3.4 ± 0.1 3.3 ± 0.1 3.6 ± 0.1 3.1 ± 0.1  
EF, % 67.0 ± 3.3 71.4 ± 3.3 64.3 ± 0.7 70.2 ± 1.1  
FS, % 37.2 ± 2.4 40.6 ± 2.8 34.7 ± 0.5 39.3 ± 0.9  
CO, ml/min 27.8 ± 2.2 24.2 ± 0.7 25.9 ± 0.8 26.8 ± 0.9  
SV, µl 52.1 ± 4.3 45.9 ± 1.8 49.3 ± 1.6 50.0 ± 1.6  
EDV, µl 78.6 ± 7.1 65.4 ± 4.4 76.7 ± 2.2 71.4 ± 2.3  
ESV, µl 26.5 ± 4.0 19.5 ± 3.3 27.4 ± 0.9 21.4 ± 1.2  
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Table 3.7 (Continued) 
 
† Values are presented as mean ± SEM.  
n, number of mice in each group; WT, wildtype; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular 
anterior wall; LVPW, left ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index: 𝐿𝑉𝑀𝑖 =
𝐿𝑉𝑀
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; CO, cardiac output; SV, stroke 
volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic volume. 
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Table 3.8. Echocardiography of TAC- or sham-operated mice 1 week (7 days) after surgery. 
 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n   8     7   10    12   
Body weight, g 30.7 ± 0.6 27.9 ± 0.8
$
 30.8 ± 0.7 29.1 ± 1.0  
HR, beats/min 535 ± 4 541 ± 1 534 ± 5 531 ± 4  
AoPg, mmHg 7.2 ± 0.9 85.5 ± 1.2
$$$
 7.4 ± 0.6 85.9 ± 0.7
$$$
    
NS
  
Diastole                  
                      LVID, mm 4.25 ± 0.07 3.68 ± 0.10
$$$
 4.15 ± 0.06 3.99 ± 0.06      *  
                      LVAW, mm 0.94 ± 0.05 1.10 ± 0.03
$
 0.93 ± 0.04 1.12 ± 0.03
$$
  
                      LVPW, mm 0.73 ± 0.02 1.03 ± 0.08
$$
 0.73 ± 0.03 0.88 ± 0.03
$$
   *  
Systole                  
                      LVID, mm 2.73 ± 0.10 2.49 ± 0.14 2.91 ± 0.08 2.96 ± 0.10      *  
                      LVAW, mm 1.48 ± 0.04 1.59 ± 0.04 1.32 ± 0.06 1.51 ± 0.04
$$
  
                      LVPW, mm 1.16 ± 0.05 1.37 ± 0.04
$$
 1.04 ± 0.04 1.18 ± 0.02
$$
   ***  
LVM, mg 106.5 ± 4.5 119.4 ± 8.0 103.3 ± 4.5 126.2 ± 5.2
$$
  
LVMi, mg/g 3.4 ± 0.2 4.1 ± 0.2
$
 3.4 ± 0.1 4.1 ± 0.2
$$$
  
EF, % 67.7 ± 2.0 65.1 ± 3.2 61.1 ± 2.0 54.3 ± 2.6        *  
FS, % 37.5 ± 1.5 35.3 ± 2.4 32.6 ± 1.4 28.1 ± 1.8        *  
CO, ml/min 29.4 ± 0.9 19.8 ± 0.5
$$$
 25.7 ± 0.8 20.0 ± 0.9
$$$
  
SV, µl 56.5 ± 2.2 36.8 ± 0.9
$$$
 47.2 ± 1.0 37.6 ± 1.8
$$$
  
EDV, µl 83.7 ± 3.3 57.5 ± 3.7
$$$
 77.8 ± 2.7 69.7 ± 2.1
$
       **  
ESV, µl 27.3 ± 2.5 20.7 ± 3.2 30.6 ± 2.5 32.0 ± 2.3        *   
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Table 3.8 (Continued) 
 
† Values are presented as mean ± SEM. *, p<0.05 versus TAC’d WT; ** p<0.01 versus TAC’d WT; *** p<0.001 versus TAC’d WT; 
NS, p>0.05 not statistical significant versus TAC’d WT;  $, p<0.05 versus sham; $$, p<0.01 versus sham; and $$$, p<0.001 versus 
sham. 
n, number of mice in each group; WT, wildtype; HR, heart rate; AoPg, aortic peak pressure gradient of aortic constriction; LVID, left 
ventricular internal dimension; LVAW, left ventricular anterior wall; LVPW, left ventricular posterior wall; LVM, left ventricular 
mass;  𝐿𝑉𝑀 𝐼𝑛𝑑𝑒𝑥 =
𝐿𝑉𝑀
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; CO, cardiac 
output; SV, stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic volume. 
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Table 3.9. Echocardiography of TAC- or sham-operated mice 2 week (14 days) after surgery. 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n   8     7   10    12   
Body weight, g 31.1 ± 0.8 28.8 ± 0.8 30.2 ± 0.6 29.7 ± 1.0  
HR, beats/min 535 ± 3 529 ± 6 531 ± 3 536 ± 4  
Diastole                  
                      LVID, mm 4.35 ± 0.12 3.94 ± 0.11
$
 4.33 ± 0.06 4.30 ± 0.08     *  
                      LVAW, mm 0.98 ± 0.03 1.08 ± 0.03 0.95 ± 0.04 1.01 ± 0.03  
                      LVPW, mm 0.74 ± 0.03 1.00 ± 0.09
$$
 0.74 ± 0.03 0.89 ± 0.03
$$
  
Systole                  
                      LVID, mm 2.92 ± 0.08 2.86 ± 0.17 2.94 ± 0.08 3.35 ± 0.15
$
  
                      LVAW, mm 1.40 ± 0.04 1.54 ± 0.06 1.36 ± 0.05 1.38 ± 0.03     *  
                      LVPW, mm 1.10 ± 0.03 1.31 ± 0.11 1.09 ± 0.04 1.14 ± 0.02  
LVM, mg 116.8 ± 5.3 128.1 ± 7.2 111.0 ± 3.2 134.9 ± 7.4
$$
  
LVMi, mg/g 3.7 ± 0.1 4.4 ± 0.2
$
 3.6 ± 0.2 4.4 ± 0.2
$$
  
EF, % 65.4 ± 1.6 58.3 ± 4.5 62.0 ± 1.7 47.4 ± 3.8
$$
  
FS, % 35.8 ± 1.3 30.8 ± 2.8 33.3 ± 1.3 24.0 ± 2.3
$$
  
CO, ml/min 30.2 ± 2.1 21.2 ± 1.5
$$
 27.2 ± 1.3 20.6 ± 0.9
$$$
  
SV, µl 56.6 ± 3.9 39.7 ± 2.5
$$
 51.0 ± 2.2 38.5 ± 1.8
$$$
  
EDV, µl 86.4 ± 5.2 69.5 ± 4.3
$
 82.5 ± 3.3 84.1 ± 3.8       *  
ESV, µl 29.8 ± 2.1 29.8 ± 5.0 31.4 ± 2.3 45.6 ± 4.9
$
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Table 3.9 (Continued) 
 
† Values are presented as mean ± SEM. *, p<0.05 versus TAC’d WT;  $, p<0.05 versus sham; $$, p<0.01 versus sham; and $$$, p<0.001 
versus sham. 
n, number of mice in each group; WT, wildtype; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular 
anterior wall; LVPW, left ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index: 𝐿𝑉𝑀𝑖 =
𝐿𝑉𝑀
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; CO, cardiac output; SV, stroke 
volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic volume. 
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Table 3.10. Echocardiography of TAC- or sham-operated mice 3 week (21 days) after surgery. 
 
 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n   8     7   10    12   
Body weight, g 31.8 ± 0.6 28.9 ± 0.8
$
 30.4 ± 0.6 30.3 ± 0.9  
HR, beats/min 532 ± 4 534 ± 5 531 ± 5 535 ± 3  
Diastole                  
                      LVID, mm 4.31 ± 0.10 3.89 ± 0.14
$
 4.21 ± 0.07 4.55 ± 0.11
$
      **  
                      LVAW, mm 1.00 ± 0.05 1.12 ± 0.05 0.89 ± 0.03 1.03 ± 0.03
$$
  
                      LVPW, mm 0.73 ± 0.02 1.06 ± 0.09
$$
 0.72 ± 0.02 0.88 ± 0.03
$$$
   *  
Systole                  
                      LVID, mm 2.91 ± 0.12 2.85 ± 0.22 2.95 ± 0.07 3.67 ± 0.18
$$
     *  
                      LVAW, mm 1.40 ± 0.06 1.53 ± 0.07 1.28 ± 0.06 1.39 ± 0.04  
                      LVPW, mm 1.12 ± 0.04 1.41 ± 0.11
$
 1.09 ± 0.03 1.08 ± 0.04       **  
LVM, mg 116.9 ± 4.3 139.9 ± 9.6
$
 101.4 ± 3.0 146.8 ± 6.2
$$$
  
LVMi, mg/g 3.7 ± 0.1 4.8 ± 0.3
$$
 3.3 ± 0.1 4.8 ± 0.2
$$$
  
EF, % 63.7 ± 3.1 54.2 ± 4.7 58.8 ± 1.9 42.7 ± 4.6
$$
  
FS, % 34.7 ± 2.3 28.1 ± 3.0 31.0 ± 1.3 21.5 ± 2.7
$$
  
CO, ml/min 28.1 ± 1.4 18.4 ± 1.4
$$$
 24.0 ± 1.3 20.7 ± 1.3  
SV, µl 53.1 ± 2.6 34.7 ± 2.5
$$$
 45.3 ± 2.1 38.9 ± 2.5  
EDV, µl 84.0 ± 4.1 66.0 ± 5.6
$
 77.2 ± 3.1 96.6 ± 5.2
$$
      **  
ESV, µl 30.9 ± 3.3 31.3 ± 5.7 31.9 ± 2.1 57.7 ± 7.1
$$
      *  
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Table 3.10 (Continued) 
 
† Values are presented as mean ± SEM. *, p<0.05 versus TAC’d WT; ** p<0.01 versus TAC’d WT; $, p<0.05 versus sham; $$, p<0.01 
versus sham; and 
$$$
, p<0.001 versus sham. 
n, number of mice in each group; WT, wildtype; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular 
anterior wall; LVPW, left ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index: 𝐿𝑉𝑀𝑖 =
𝐿𝑉𝑀
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; CO, cardiac output; SV, stroke 
volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic volume. 
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Table 3.11. Echocardiography of TAC- or sham-operated mice 6 week (42 days) after surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n   8     7    10    12   
Body weight, g 32.3 ± 0.8 30.3 ± 0.9 31.2 ± 0.6 29.5 ± 0.8  
HR, beats/min 541 ± 2 535 ± 7 534 ± 3 532 ± 6  
Diastole                   
                      LVID, mm 4.37 ± 0.13 4.17 ± 0.18 4.24 ± 0.05 4.80 ± 0.16
$$
   *  
                      LVAW, mm 0.95 ± 0.02 1.12 ± 0.04
$$
 1.00 ± 0.04 0.98 ± 0.02      **  
                      LVPW, mm 0.72 ± 0.02 1.15 ± 0.10
$$
 0.73 ± 0.02 0.88 ± 0.03
$$$
  **  
Systole                   
                      LVID, mm 2.77 ± 0.14 3.13 ± 0.31 3.02 ± 0.04 4.10 ± 0.25
$$
  *  
                      LVAW, mm 1.44 ± 0.03 1.56 ± 0.10 1.35 ± 0.04 1.29 ± 0.05      *  
                      LVPW, mm 1.14 ± 0.04 1.48 ± 0.14 1.06 ± 0.02 1.07 ± 0.04      *  
LVM, mg 110.5 ± 7.2 162.4 ± 10.1
$$$
 110.2 ± 3.0 161.3 ± 11.2
$$$
  
LVMi, mg/g 3.5 ± 0.2 5.6 ± 0.4
$$$
 3.6 ± 0.1 5.3 ± 0.3
$$$
  
EF, % 68.9 ± 2.1 53.8 ± 7.3 59.2 ± 1.5 34.0 ± 5.2
$$$
    *  
FS, % 38.6 ± 1.6 28.6 ± 4.5 31.2 ± 1.0 16.9 ± 2.9
$$$
    *  
CO, ml/min 32.0 ± 1.8 21.1 ± 1.7
$$$
 25.6 ± 0.9 17.7 ± 1.5
$$$
  
SV, µl 59.0 ± 3.3 39.4 ± 2.9
$$$
 48.0 ± 1.8 33.1 ± 2.7
$$$
  
EDV, µl 86.7 ± 6.8 79.5 ± 8.3 81.0 ± 2.3 109.6 ± 8.2
$$
     *  
ESV, µl 27.7 ± 4.1 40.1 ± 10.3 33.1 ± 1.5 76.5 ± 10.3
$$
   *  
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Table 3.11 (Continued) 
 
† Values are presented as mean ± SEM. *, p<0.05 versus TAC’d WT; ** p<0.01 versus TAC’d WT; *** p<0.001 versus TAC’d WT; 
$
, p<0.05 versus sham; 
$$
, p<0.01 versus sham; and 
$$$
, p<0.001 versus sham. 
n, number of mice in each group; WT, wildtype; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular 
anterior wall; LVPW, left ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index: 𝐿𝑉𝑀𝑖 =
𝐿𝑉𝑀
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; CO, cardiac output; SV, stroke 
volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic volume. 
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Table 3.12. Anatomical comparison of TAC- or sham-operated mice 6 week after surgery. 
 
 
 
 WT ST3Gal4
-/-
 
  Sham  TAC Sham             TAC 
n  4    3   4    4   
  Baseline body weight, g 31.9 ± 0.6 31.8 ± 0.4 31.3 ± 1.8 33.0 ± 1.3  
  Tibia Length, mm 17.9 ± 0.3 18.1 ± 0.4 18.1 ± 0.1 18.0 ± 0.2  
  Heart Weight, mg 128.5 ± 2.3 219.7 ± 4.8
$$$
 138.5 ± 6.4 236.0 ± 12.6
$$
  
           HW/BW, mg/g 4.04 ± 0.07 6.90 ± 0.13
$$$
 4.45 ± 0.18 7.21 ± 0.61
$$
  
           HW/TL, mg/mm 7.16 ± 0.15 12.11 ± 0.02
$$$
 7.65 ± 0.32 13.13 ± 0.78
$$
  
  LV Weight, mg 90.5 ± 2.0 164.7 ± 3.8
$$$
 95.0 ± 5.6 165.0 ± 2.9
$$$
  
           LVW/BW, mg/g 2.84 ± 0.03 5.17 ± 0.07
$$$
 3.05 ± 0.12 5.03 ± 0.27
$$$
  
           LVW/TL, mg/mm 5.05 ± 0.13 9.08 ± 0.07
$$$
 5.24 ± 0.28 9.17 ± 0.20
$$$
  
  RV Weight, mg 22.8 ± 0.9 26.0 ± 2.1 23.3 ± 1.3 34.3 ± 5.3  
           RV/BW, mg/g 0.71 ± 0.03 0.82 ± 0.08 0.75 ± 0.03 1.05 ± 0.19  
           RV/TL, mg/mm 1.27 ± 0.04 1.44 ± 0.14 1.28 ± 0.07 1.91 ± 0.31  
  LA Weight, mg 3.0 ± 0.0 6.7 ± 0.9 2.5 ± 0.3 12.0 ± 2.4
$
  
           LA/BW, mg/g 0.09 ± 0.00 0.21 ± 0.03 0.08 ± 0.01 0.37 ± 0.08
$
  
           LA/TL, mg/mm 0.17 ± 0.00 0.37 ± 0.06 0.14 ± 0.02 0.67 ± 0.14
$
  
  RA Weight, mg 3.3 ± 0.3 4.3 ± 1.5 2.8 ± 0.3 6.5 ± 1.2
$
  
           RA/BW, mg/g 0.10 ± 0.01 0.14 ± 0.05 0.09 ± 0.01 0.19 ± 0.03
$
  
           RA/TL, mg/mm 0.18 ± 0.01 0.24 ± 0.09 0.15 ± 0.01 0.36 ± 0.07
$
  
Lung Weight, mg 213.5 ± 19.0 174.3 ± 2.9 234.8 ± 17.0 338.3 ± 97.7  
           Lung/BW, mg/g 6.74 ± 0.72 5.48 ± 0.11 7.63 ± 0.84 10.39 ± 3.07  
           Lung/TL, mg/mm 11.92 ± 1.09 9.62 ± 0.36 12.98 ± 0.96 18.94 ± 5.62  
Liver Weight, mg 1171 ± 60 1235 ± 124 1224 ± 71 1180 ± 24  
          Liver/BW, mg/g 36.7 ± 1.4 38.8 ± 4.1 39.2 ± 1.3 35.8 ± 1.2  
          Liver/TL, mg/mm 65.4 ± 4.4 67.9 ± 5.9 67.6 ± 3.5 65.6 ± 1.4  
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Table 3.12 (Continued) 
 
† Values are presented as mean ± SEM; $, p<0.05 versus sham; $$, p<0.01 versus sham; and $$$, p<0.001 versus sham. 
n, number of mice in each group; WT, wildtype; BW, baseline body weight; TL, tibia length; HW, heart weight; LVW, left ventricular 
weight; RV, right ventricular weight; LA, left atrial weight; RA, right atrial weight. 
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Figure 3.9. Increased susceptibility to heart failure was independent of calcineurin pathway 
in ST3Gal4
-/-
. 
A. Left ventricular tissue extracts were used to examine the calcineurin expression level from 
TAC- or sham-operated animals 6-week after surgery. GAPDH was used as the loading control. 
CnA expressions were normalized to sham WT. B. Calcineurin subunit A (CnA) expressions of 
sham ST3Gal4
-/-
 (n=9) were significantly lower (only about half compared to sham WT) than 
sham wildtype (n=6) (normalized CnA- sham WT = 1±0.17, sham ST3Gal4
-/-
 = 0.65±0.06, 
p<0.05). TAC induced CnA expression in both TAC’d WT (n=11) and TAC’d ST3Gal4-/- (n=6). 
However, TAC’d ST3Gal4-/- CnA level was much lower than TAC’d WT (normalized CnA-
TAC’d WT = 1.11±0.13, TAC’d ST3Gal4-/- = 0.83±0.18, p>0.05), excluded the possibility of 
calcineurin-overexpression induced heart failure in TAC’d ST3Gal4-/-. WT, wildtype; KO, 
ST3Gal4
-/-
; *, p<0.05. 
CnA 
GAPDH 
  Sham WT             Sham ST3Gal4
-/-
             TAC’d WT          TAC’d ST3Gal4-/- 
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Discussion 
In this study, we provided the first and the direct evidence of desialylation elicited 
idiopathic dilated cardiomyopathy (DCM), reporting the cardiac phenotype of ST3Gal4
-/-
 before 
and after chronic stress with aberrant ECG. Partial reduction of α2,3-sialylation achieved 
through ST3Gal4 gene deletion led to adult late-onset DCM and the rapid development of stress-
induced heart failure. The DCM symptoms progressed gradually and presented with thinner left 
ventricular walls and dilation of all four chambers (See Figure 3.3&3.5; Table 3.1-3.4), but with 
mostly preserved systolic function. However, under chronic stress conditions (pressure-overload), 
the hearts of 16- to 20-week old male ST3Gal4
-/-
 demonstrated reduced contractile reserve, 
manifested as inadequate adaptation, rapid decompensation with significantly (compare to 
wildtype) reduced systolic function by the end of week 1 that deteriorated into heart failure by 
the end of week 6 post-surgery (See Figure 3.7; Table 3.7-3.11).  In contrast to the negative 
impact of TAC surgery on the ST3Gal4
-/-
 heart, TAC’d WT showed the classic characteristics of 
stress-induced adaptation, observed as substantial thickening of the cardiac wall, and relatively 
maintained LVID;d, EDV, and contractile functions throughout the six-week experiment. 
Calcineurin expression was decreased in ST3Gal4
-/-
 (compared to TAC’d WT, See Figure 3.9), 
suggesting a calcineurin independent mechanism in TAC’d ST3Gal4-/-. These data suggest that 
α2,3-sialylation is a potential mechanism for idiopathic DCM and plays an essential role in 
cardiac adaptation and contractile function. 
Consistent with previous studies 
[152, 158]
, Maackia amurensis leukoagglutinin (MAL) and 
Maackia amurensis hemagglutinin (MAH) staining revealed that α2,3-sialylation is primarily 
present at sarcolemma and capillary endothelium & basal lamina of adult mouse heart (See  
102 
 
Figure 3.1). No intracellular structure was stained, supporting the hypothesis of sarcolemma 
associated glycoprotein mechanism for observed ST3Gal4
-/-
 phenotypes. In addition, ST3Gal4
-/-
 
seems to have increased capillarization (under MAH staining), thereby it is unlikely that the 
DCM and the increased susceptibility to heart failure in ST3Gal4
-/-
 were due to the insufficient 
tissue perfusion. Previous studies reported that ST3Gal4
-/-
 has increased bleeding time, decreased 
von Willebrand factor and platelet counts, decreased L-selectin binding and L-selectin-dependent 
leukocyte rolling, as well as the increased terminal galactose exposure 
[101, 103]
. Consistently, in 
this study, reduced α2,3-sialylation did not perturb cardiac development, vessel formation or 
skeletal growth (See Figure 3.5) 
[101, 103]
.  However, myocytes density as well as intercellular 
contacts were reduced (See Figure 3.5), suggesting a potential role of α2,3-sialylation in 
intercellular or cell-ECM communications.  
Because Masson’s trichrome staining did not detect any increased fibrosis in ST3Gal4-/- 
hearts when compared to wildtype littermates (See Figure 3.6), the mechanism of fibrosis-
induced arrhythmogenesis or conductive abnormality in ST3Gal4
-/-
 was unlikely 
[159]
.  
Although partial reduction of sialylation via ST3Gal4 gene deletion has provided us 
tremendous information regarding cardiac glycosylation, ST3Gal4
-/- 
is a global knockout. In 
order to better understand the role of glycosylation on cardiac function, we generated a 
cardiomyocyte specific knockout (αMHC-Cre) of glycosyltransferase which will be discussed in 
the next chapter.  
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CHAPTER FOUR  
CARDIAC DEFICIT OF COMPLEX N-GLYCOSYLATION CAUSES FATAL 
ARRHYTHMOGENIC DILATED CARDIOMYOPATHY 
 
Introduction 
Dilated cardiomyopathy (DCM) is a common cause of heart failure and sudden cardiac 
death 
[69]
. The mechanisms responsible for most forms of DCM, including the 30-40% congenital 
forms, are not fully determined 
[163-165]
. Risk factors such as alcohol abuse, obesity, smoking, and 
diabetes, contribute to DCM onset 
[166, 167]
.  The ~40 subtypes of human congenital disorders of 
glycosylation (CDG) result in modest but variable (among subtypes) reductions in glycosylation, 
and lead to multi-system effects, including cardiomyopathy. The mechanism responsible for 
CDG-associated cardiomyopathy is not understood. Furthermore, a clinical study using 
microarray analysis revealed a significant reduction in expression (nearly 2 fold reduction) of the 
glycosyltransferase responsible for production of complex and hybrid N-glycans, Mgat1, in 
idiopathic DCM patients’ LV tissues [69]. Screening for cardiac dysfunction in CDG patients, and 
for CDG in young cardiomyopathy patients of unknown etiology, is now recommended.  In 
addition, DCM risk factors contribute to altered glycosylation in non-DCM patients, and non-
congenital changes in glycosylation can occur with DCM 
[58]
.  
Previously we reported that the reduced glycoprotein sialylation that results from the 
global gene deletion of a cardiac expressing sialyltransferase, ST3Gal4
-/-
, contributed to mild 
adult late-onset DCM, reduced myocardial contractile reserve and increased susceptibility to 
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heart failure and arrhythmia. The main limitation of ST3Gal4
-/-
 is its lack of tissue-specificity. In 
order to study the cardiac effect of deglycosylation, we utilized Cre-lox system to delete N-
acetylglucosaminyltransferase I (Mgat1) specifically in cardiomyocytes, generated the first 
cardiac specific knockout of Mgat1
fx/fx/αMHC-Cre+ (Mgat1CKO). In contrast to ST3Gal 
sialyltransferase, the last step of glycosylation in Golgi apparatus, Mgat1 is a medial-Golgi 
enzyme catalyzes the synthesis of hybrid and complex N-linked glycosylation and is upstream to 
ST3Gal. Mgat1 gene is highly conserved between human and mouse and is located on the 
autosome chromosome (Chr) (on mouse Chr 11 and on human Chr 5, respectively) 
[126, 132]
. 
Previous study showed that Mgat1
-/+
 appears normal when observed up to postnatal day14 
[127]
. 
However, Mgat1
-/-
 is embryonically lethal in mice showing developmental retardation, open 
neuropore, reduced somites, anemia and etc, and embryos died between E9.5-E10.5 
[127]
.  
Here we questioned whether cardiomyocyte-specific (αMHC-Cre) deletion of Mgat1 that 
is  responsible for initiating synthesis of complex and hybrid N-glycans, contributes to the onset 
of dilated cardiomyopathy. 
 
Methods 
Survival study was performed using Kaplan-Meier methods with log-rank test. 
Echocardiography, histology and electrocardiogram were utilized to measure the cardiac effect 
of Mgat1CKO. Western blotting was conducted to probe the molecular mechanism of 
Mgat1CKO induced DCM. 
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Mortality Generated by Cardiac-Specific Deletion of N-Acetylglucosaminyltransferase I 
(Mgat1) in Mice 
Upon breeding Mgat1
fx/fx
 with Mgat1
fx/+
/αMHC-Cre+, four genotypes with identical 
genetic background were generated: Mgat1
fx/fx
/αMHC-Cre+ (Mgat1CKO), Mgat1fx/fx, Mgat1fx/+ 
(Mgat1 control) and Mgat1
fx/+
/αMHC-Cre+ (Mgat1Het) (See Figure 2.3 B). The breeding 
scheme produced normal litter size, Mendelian distribution of genotypes and a normal sex ratio/ 
each genotype, suggesting no mortality in utero. At birth, pups of all four genotypes were 
indistinguishable from each other, with no signs of cyanosis or dyspnea. Pup survival to weaning 
was normal, with both Mgat1CKO and Mgat1Het appearing normal, ad libitum, fully fertile, 
active, and having similar body size and weight to their littermate controls before the initial 
mortality at 32-week old (See Figure 4.1). No skeletal deformation, growth retardation was 
observed (See Figure 4.1&4.2).The male body weight (Mean±SEM) at 4-6 weeks old were: 
Mgat1 controls (n=10) = 17±0.9g, Mgat1Het (n=6) = 17.9±1.1g, Mgat1CKO (n=10) = 18.2±0.8g, 
p>0.05; at 8-9 weeks: Mgat1 controls (n=13) = 23.8±0.7g, Mgat1Het (n=6) = 26±0.9g, 
Mgat1CKO (n=9) = 24.9±0.7g, p>0.05; at 16-17 weeks: Mgat1 controls (n=14) = 32.3±1g, 
Mgat1Het (n=7) = 33.5±1.9g, Mgat1CKO (n=10) = 35.4±1.5g, p>0.05; and at 30-32 weeks: 
Mgat1 controls (n=16) = 42.1±0.8g, Mgat1Het (n=6) = 43.1±3.1g, Mgat1CKO (n=7) = 
43.6±2.4g, p>0.05 (See Figure 4.1).  
Next, we monitored the survival rate of Mgat1 offsprings. We found that all Mgat1CKO 
(homozygous for Mgat1 mutant gene) and Mgat1Het (heterozygous for Mgat1 mutant gene) 
have developed cardiac phenotypes (See Figure 4.3&4.5; Table 4.1) with 100% mortality by 67-
week old but varied severity of their disease symptoms and survival times (See Figure 4.2). Thus, 
a clear autosomal dominant inherence pattern with a complete penetrance and variable  
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Figure 4.1. Gross appearance and body weight comparison in male Mgat1 offsprings. 
A. Compared to Mgat1 controls, at 32-week old before the initial mortality, Mgat1CKO 
appeared normal, active and fully fertile without skeletal deformation or growth retardation. B. 
No significant difference was detected in male body weight among Mgat1 offsprings before 
postnatal 32 weeks. The male body weight (Mean±SEM) at 4-6 weeks old were: Mgat1 
controls (n=10) = 17±0.9g, Mgat1Het (n=6) = 17.9±1.1g, Mgat1CKO (n=10) = 18.2±0.8g, 
p>0.05; at 8-9 weeks: Mgat1 controls (n=13) = 23.8±0.7g, Mgat1Het (n=6) = 26±0.9g, 
Mgat1CKO (n=9) = 24.9±0.7g, p>0.05; at 16-17 weeks: Mgat1 controls (n=14) = 32.3±1g, 
Mgat1Het (n=7) = 33.5±1.9g, Mgat1CKO (n=10) = 35.4±1.5g, p>0.05; and at 30-32 weeks: 
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Figure 4.1 (Continued) 
Mgat1 controls (n=16) = 42.1±0.8g, Mgat1Het (n=6) = 43.1±3.1g, Mgat1CKO (n=7) = 
43.6±2.4g, p>0.05. N numbers were listed below the bar. Mgat1 control, Mgat1
fx/fx
 or 
Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
/αMHC-Cre+; Mgat1Het, Mgat1fx/+/αMHC-Cre+; Mgat1Ctrl, 
Mgat1 control; black bar, Mgat1 control; gray bar, Mgat1Het; and green bar, Mgat1CKO; wk, 
week.    
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expressivity was exhibited by Mgat1 colony. The initial mortality was observed in male 
Mgat1CKO at 32-week old. Kaplan-Meier survival analysis with log-rank test was performed 
and the survival time was expressed as median survival time with 95% confidence interval (CI). 
Kaplan-Meier test detected a significantly shorter survival time in male Mgat1CKO (n=10) than 
that in Mgat1Het (n=7): male Mgat1CKO = 37 weeks (95% CI, 32.4 to 41.6 weeks), male 
Mgat1Het = 48 weeks (95% CI, 37.7 to 58.3 weeks), p<0.01 (See Figure 4.2). Almost no 
mortality was detected in male Mgat1controls (n=13), suggesting an gene-dosage dependent 
effect on male Mgat1 survival time (See Chapter 1). In female, however, the same genotype 
produced much milder phenotype, demonstrated by significantly longer survival time, milder 
cardiac symptoms and later onset of mortality in female Mgat1CKO (n=11) than male 
Mgat1CKO (n=10) and in female Mgat1Het (n=7) than male Mgat1Het (n=7): female 
Mgat1CKO = 50 weeks (95% CI, 48 to 52.1 weeks), p<0.001 versus male Mgat1CKO; and 
female Mgat1Het = 52 weeks (95% CI, 49.4 to 54.6 weeks), p<0.05 versus male Mgat1Het (See 
Figure 4.2&4.5; Table 4.1). Moreover, the gene-dosage dependent effect on male Mgat1 survival 
was blunted on females, evidenced by similar cardiac phenotypes, median survival time and 95% 
CI when compared female Mgat1CKO (n=11) to female Mgat1Het (n=7), (p>0.05) (See Figure 
4.2). Additionally, female Mgat1CKO (n=11) was surviving at about male Mgat1Het level (n=7), 
as no significant difference in median survival time was detected between female Mgat1CKO 
and male Mgat1Het (p>0.05) (See Figure 4.2). Together, a clear sex-biased survival rate was 
observed in this cardiac specific deletion of an autosomal gene Mgat1, by which the survival 
time of female knockouts was much longer than that of male counterparts. Future studies are 
needed to elucidate the mechanisms underlying the sex difference of Mgat1 effect on murine 
hearts. 
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C.                                   Pairwise comparisons of log rank (Mantel-Cox) test 
 
Figure 4.2. Survival studies of Mgat1 colony. (Continued on Next Page) 
 
 
 
 
 
Medians for Survival Time 
Group 
Median 
Estimate 
95% Confidence Interval 
Lower Bound Upper Bound 
Male Mgat1CKO 37 32.4 41.6 
Male Mgat1Het 48 37.7 58.3 
Female Mgat1CKO 50 47.9 52.1 
Female Mgat1Het 52 49.4 54.6 
Male Mgat1Ctrl . . . 
Female Mgat1Ctrl . . . 
Overall 56 46.7 65.3 
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Figure 4.2 (Continued) 
A. All Mgat1CKO and Mgat1Het have developed cardiac phenotypes with 100% mortality by 
67-week old but varied severity of their disease symptoms and survival times. Thus, Mgat1 
colony displayed an autosomal dominant inherence pattern with a complete penetrance and 
variable expressivity. B-C. Kaplan-Meier survival analysis with log-rank test detected a 
significantly shorter survival time in male Mgat1CKO (n=10) than that in Mgat1Het (n=7), 
p=0.0045<0.01. Almost no mortality was detected in male Mgat1controls (n=13), suggesting an 
gene-dosage dependent effect on male Mgat1 survival time. The same genotype produced much 
milder phenotype in females, demonstrated by significantly longer survival time and later onset 
of mortality: female Mgat1CKO (n=11) versus male Mgat1CKO p=0.0001<0.001, and female 
Mgat1Het (n=7) versus male Mgat1Het p=0.0341<0.05. Female Mgat1CKO was surviving at 
about male Mgat1Het level, as no significant difference in median survival time was detected 
between female Mgat1CKO and male Mgat1Het (p=0.2759>0.05). Furthermore, the gene-dosage 
dependent effect was blunted on females, evidenced by similar cardiac phenotypes, median 
survival time and 95% CI when compared female Mgat1CKO to female Mgat1Het 
(p=0.9131>0.05). Together, a clear sex-biased survival rate was revealed in this cardiac specific 
deletion of an autosomal gene Mgat1. Mgat1 Ctrl, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
 
/αMHC-Cre+; Mgat1Het, Mgat1fx/+ /αMHC-Cre+; red line, male Mgat1CKO; black line, male 
Mgat1Het; blue line, male Mgat1Ctrl; orange line, female Mgat1CKO; gray line, female 
Mgat1Het; purple line, female Mgat1 Ctrl; CI, confidence interval. 
 
111 
 
Early-Onset of Dilated Cardiomyopathy with Severely Impaired Systolic and Diastolic 
Function in Mgat1CKO mice 
Before the initial mortality at 32-week, cardiac function was investigated in male Mgat1 
offsprings (Mgat1 control, Mgat1Het and Mgat1CKO) at 30- to 32-week old. Echocardiography 
of Mgat1CKO (n=7) showed a markedly enlarged left ventricle (LV) and left atria (LA) 
chambers with significantly thinner LV wall when compared to Mgat1 control (n=16): LVID;d-
Mgat1 control = 4.12±0.05mm, Mgat1CKO = 5.06±0.17mm, p<0.001; EDV-Mgat1 control = 
74.3±2.1µl, Mgat1CKO = 123.3±8.9µl, p<0.01; LA anteroposterior diameter-Mgat1 control = 
1.91±0.06mm, Mgat1CKO = 2.75±0.24mm, p<0.05; LVPW;d-Mgat1 control = 0.81±0.02mm, 
Mgat1CKO = 0.68±0.02mm, p<0.01 (See Figure 4.3A-C&G-I&O; Table 4.1). LV systolic 
function of Mgat1CKO (n=7) deteriorated into heart failure, presented as poor ejection fraction 
(EF%=40.0±3.8% ≤40%, p<0.001), fractional shortening (FS%=19.8±2.1%, p<0.001), cardiac 
output (CO=24.0±1.4ml/min, p<0.01) and stroke volume (SV=47.4±2.2µl, p<0.01) in 
comparison with Mgat1 control (n=16, EF% = 75.7±1.3%, FS% = 44.3±1.1%, CO = 
29.1±0.8ml/min, and SV = 56.1±1.6µl) (See Figure 4.3C&J-K; Table 4.1). Diastolic function of 
Mgat1CKO was also severely impacted, exhibiting grade III diastolic dysfunction evidenced by 
significantly elevated E/A ratio>2.0, greatly shortened E wave deceleration time (DT) and 
significantly enlarged left atrial (LA) diameter when compared to Mgat1 controls, indicating a 
restrictive LV filling pattern with a markedly elevated LA pressure. In addition, LV myocardial 
performance index (MPI) of Mgat1CKO (n=7) increased significantly (LV MPI= 0.77±0.07, 
p<0.01), consistent with the diagnosis of the end-stage dilated cardiomyopathy (DCM) in 
Mgat1CKO (See Figure 4.3D&L-O;Table 4.1). E/A ratio of Mgat1 control = 1.22±0.04, 
Mgat1CKO = 2.38±0.52, p<0.05; DT of Mgat1 control = 26.6±1.8ms, Mgat1CKO = 17.0±1.9ms, 
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p<0.01; LA diameter of Mgat1 control = 1.91±0.06mm, Mgat1CKO = 2.75±0.24mm, p<0.05; 
LV MPI of Mgat1 control = 0.55±0.02, Mgat1CKO = 0.77±0.07, p<0.01. The right ventricular 
(RV) function of male Mgat1 offsprings was also evaluated. Mgat1CKO (n=7) showed impaired 
RV systolic function, presented as significantly decreased RV CO (24.5±3.3ml/min, p<0.05) and 
RV SV (45.2±5.6µl, p<0.05) when compared to Mgat1 control (n=9) (See Figure 4.3P;Table 4.1). 
RV free wall thickness (RVFW) appeared to be thinner in Mgat1CKO (n=3) than Mgat1 control 
(n=7): RVFW of Mgat1 control = 0.46±0.03mm, and Mgat1CKO = 0.41±0.03mm, p>0.05) (See 
Figure 4.3E-F&Q; Table 4.1). No septal defect or great vessel abnormality were observed under 
echocardiography. Altered ECG waveform and frequent arrhythmia events were detected in 
Mgat1CKO mice during echocardiography (see Figure 4.3D), which will be studied in detail in 
the next section (See Figure 4.7-4.10;Table 4.5-4.6). Together, cardiac Mgat1 deletion caused 
global cardiac dilation with severely impaired systolic& diastolic function and frequent 
arrhythmia in 30-32 week old Mgat1CKO.  
Cardiac phenotype of Mgat1Het was much milder than that of Mgat1CKO with 
contractile functions being affected the most in Mgat1Het (See Figure 4.3; Table 4.1). 
Next, we investigated the DCM progression of male Mgat1 offsprings at 4-6 week, 8-9 
week, and 16-17 week.  Echocardiography revealed that, as early as 4-week old, Mgat1CKO 
(n=10) has developed significant LV dilation, evidenced by the significantly enlarged LVID;d 
and EDV when compared to Mgat1 controls (n=10): LVID;d at 4-6 week- Mgat1 control (n=10) 
= 3.43±0.08mm, and Mgat1CKO (n=10) = 3.86±0.09, p<0.01; EDV at 4-6 week- Mgat1 control 
(n=10) = 49.3±2.9µl, and Mgat1CKO (n=10) = 64.1±3.6µl, p<0.01 (See Figure 4.4A-B; Table 
4.2). Systolic function of Mgat1CKO was within the normal range (EF% = 60±2.0%, normal 
range=55-80%) at 4-6 week till 9 week old, excluded the possibility of the heart failure induced 
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chamber dilation. Cardiac chambers continued to dilate, become most prominent at 30-32 week 
just before mortality. Meanwhile, LVPW;d was slightly thinner in Mgat1CKO at 4-week (n=10, 
p>0.05), and reached the statistical significance at 30-32 week when compared to age-matched 
Mgat1 controls: LVPW;d at 4-6 week-Mgat1 control (n=10) = 0.64±0.02mm, Mgat1CKO (n=10) 
= 0.62±0.01mm, p>0.05; LVPW;d at 8-9 week-Mgat1 control (n=13) = 0.72±0.02mm, 
Mgat1CKO (n=9) = 0.67±0.04mm, p>0.05; LVPW;d at 16-17 week-Mgat1 control (n=14) = 
0.74±0.03mm, Mgat1CKO (n=10) = 0.68±0.04mm, p>0.05; and LVPW;d at 30-32 week- Mgat1 
control (n=16) = 0.81±0.02mm, Mga1CKO (n=7) = 0.68±0.02mm, p<0.01 (See Figure 4.4C; 
Table 4.1-4.4).  At 4-6 week old, a significant reduction of systolic function was detected in 
Mgat1CKO when compared (n=10) to Mgat1 controls (n=10): EF% - Mgat1 control = 
77.0±1.8%, and Mgat1CKO = 60.0±2 > 55%, p<0.001; FS% - Mgat1 control = 45.0±1.6%, 
Mgat1CKO = 31.6±1.4%, p<0.001.  Systolic function of Mgat1CKO continued to deteriorate 
and developed severe heart failure at 30-32 week old: EF% at 8-9 week old- Mgat1 control 
(n=13) = 74.2±1.2%, Mgat1CKO (n=9) = 57.5±3.4%, p<0.001; EF% at 16-17 week old- Mgat1 
control (n=14) = 72.9±1.3%, Mgat1CKO (n=10) = 48.7±4.7%, p<0.001; and EF% at 30-32 week 
old- Mgat1 control (n=16) = 75.7±1.3%, Mgat1CKO (n=7) = 40.0±3.8%, p<0.001 (See Figure 
4.4D-E; Table 4.1-4.4). Herein, data demonstrated an early-onset of dilated cardiomyopathy with 
systolic functional impairment initiated before 4-week-old in Mgat1CKO. On the other hand, 
diastolic function of Mgat1CKO was unaffected at 4-6 week old. The earliest sign of diastolic 
dysfunction was not detected until 8-week old, showing prolonged isovolumic relaxation time 
(IVRT): IVRT of Mgat1 control (n=8) = 18.5±0.5ms, Mgat1Het (n=2) = 21.0±0, p<0.05, and 
Mgat1CKO (n=4) = 20.1±0.5, p>0.05 (See Figure 4.4F-H; Table 4.1-4.4). This was followed by 
the significant changes in E/A ratio and DT at 16-week and 30-32 week old in Mgat1CKO when 
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compared with the age-matched Mgat1 controls (See Figure 4.4F-G; Table 4.1-4.4), suggesting 
the impairment of the diastolic function occurred after systolic dysfunction in Mgat1CKO. Again, 
no septal defect or great vessel abnormality was observed at any time points among Mgat1 
offsprings under echocardiography. 
In summary, cardiac-specific deletion of Mgat1 caused an end-stage dilated 
cardiomyopathy (DCM) in 30-32 week old mice. DCM of Mgat1CKO developed early, with 
systolic function affected firstly and mostly, followed by diastolic dysfunction.  
Compared with Mgat1CKO, Mgat1Het has much milder phenotype. From 4 to 32 week, 
echocardiography found only negligible LV dilation with insignificant LVPW;d in Mgat1Het 
when compared to age-matched Mgat1 controls (p>0.05) (See Figure 4.4A-C; Table 4.1-4.4). 
However, LA of Mgat1Het did significantly dilate at 30-32 week when compared to Mgat1 
control: 30-32 week LA anteroposterior diameter-Mgat1 control (n=16) = 1.91±0.06mm, 
Mgat1Het (n=5) = 2.17±0.08, p<0.05 (See Figure 4.3O; Table 4.1). Systolic function of 
Mgat1Het was mildly reduced and a statistical significance was only detected in 30-32 week old 
Mgat1Het when compared to age-matched Mgat1 control: 30-32 week EF%- Mgat1 control 
(n=16) = 75.7±1.3%, and Mgat1Het (n=6) = 61.3±2.8%, p<0.01 (See Figure 4.4D-E; Table 4.1-
4.4). Diastolic function changes of Mgat1Het were moderate and a significant IVRT 
prolongation was detected at 30-32 week old: 30-32 week IVRT- Mgat1 control (n=9) = 
16.9±0.5ms, and Mgat1Het (n=6) = 20.7±1.6ms, p<0.05 (See Figure 4.4F-H; Table 4.1-4.4). In 
general, Mgat1Het’s cardiac phenotype was much milder and was in between Mgat1 control and 
Mgat1CKO from 4-32 week postnatally. 
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Figure 4.3. Cardiac-specific deletion of Mgat1 lead to end-stage dilated cardiomyopathy 
with severely impaired systolic and diastolic function in postnatal 30- to 32-week old mice. 
(Continued on Next Page) 
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Figure 4.3 (Continued) 
Just before the initial mortality at 32-week old, echocardiography was performed to evaluate the 
cardiac function of male Mgat1 control, Mgat1Het and Mgat1CKO at 30- to 32-week old. At 
this age, all Mgat1Het and Mgat1CKO have developed cardiac phenotype. A. The 
representative image of 2D B-mode in parasternal long-axis view showed that Mgat1CKO had 
markedly enlarged left ventricle (LV) and left atrium (LA) chamber with significantly thinner 
left ventricular wall, when compared to Mgat1 control. Cardiac dilatation of Mgat1Het was in 
between Mgat1CKO and Mgat1 control. No septal defect or great vessel abnormality was 
observed among Mgat1 offsprings under echocardiography. B. The 2D B-mode of parasternal 
short-axis view at the mid-papillary muscle level from the same heart above showed 
consistently enlarged LV chamber and thinner LV wall in Mgat1CKO when compared to 
Mgat1 control. LV dilation of Mgat1Het was in between Mgat1CKO and Mgat1 control. C. The 
M-mode of the parasternal short-axis view from the same heart above showed markedly 
reduced contractility, enlarged LV internal dimension (LVID) and thinner LV anterior and 
posterior wall (AW and PW) in Mgat1CKO when compared to Mgat1 control. Such phenotype 
of Mgat1Het was again in between Mgat1CKO and Mgat1 control. AW, left ventricular anterior 
wall (LVAW); PW, left ventricular posterior wall (LVPW); single arrow, LVID at diastole or 
systole; double arrow, LVPW;d (LVPW at diastole); black bracket, LVAW; green bracket, 
LVPW. D. Diastolic function was assessed via interrogation of transmitral inflow using PW-
Doppler. Mgat1CKO exhibited significantly altered E and A waveform and E/A ratio when 
compared to Mgat1 control. ECG waveform (green line) of Mgat1CKO was dramatically 
altered too, accompanying with frequent arrhythmia events seen during echocardiography (See 
Figure 4.7, 4.10;Table 4.5-4.6). Such phenotypes were moderate in Mgat1Het and were in 
between Mgat1CKO and Mgat1 control. E-F. 2D B-mode and M-mode of right ventricle (RV) 
revealed a much thinner right ventricular free wall (RVFW, orange bar) in Mgat1CKO than that 
in Mgat1 control. Again, the RVFW thickness of Mgat1Het was in between Mgat1 control and 
Mgat1CKO. Compared with Mgat1 controls (n=16), Mgat1CKO (n=7) has significantly (G) 
enlarged left ventricular internal dimension at diastole (LVID;d), (H) increased end-diastolic 
volume (EDV), (L) thinner left ventricular posterior wall at diastole (LVPW;d), (J-K) and 
markedly reduced left ventricular systolic functions that reached heart failure in postnatal 30- to 
32-week old male Mgat1CKO. Such phenotypes of male Mgat1Het (n=6) were typically in 
between Mgat1CKO and Mgat1 control. LVID;d- Mgat1 control = 4.12±0.05mm; Mgat1CKO 
= 5.06±0.17, p<0.001; and Mgat1Het =  4.19±0.17mm, p>0.05. EDV- Mgat1 control = 
74.3±2.1µl; Mgat1CKO = 123.3±8.9µl, p<0.01; and Mgat1Het = 78.8±6.3µl, p>0.05. LVPW;d-
Mgat1 control = 0.81±0.02mm; Mgat1CKO = 0.68±0.02mm, p<0.01; and Mgat1Het = 
0.73±0.03mm, p>0.05. FS%- Mgat1 control = 44.3±1.1; Mgat1CKO = 19.8±2.1, p<0.001; and 
Mgat1Het = 32.8±1.9, p<0.001. EF%- Mgat1 control = 75.7±1.3; Mgat1CKO = 40.0±3.8, 
p<0.001; and Mgat1Het = 61.3±2.8, p<0.01. The left ventricular diastolic function was also 
examined. Mgat1CKO exhibited grade III diastolic dysfunction, evidenced by (L) markedly 
increased E/A ratio=2.38>2.0, (M) significantly shortened DT, and (O) greatly enlarged left 
atrial (LA) size when compared to Mgat1 control, indicating a restrictive LV filling pattern with 
a markedly elevated LA pressure. N. LV myocardial performance index (MPI) was 
significantly worsened in Mgat1CKO (0.77±0.07), confirming the diagnosis of end-stage 
dilated cardiomyopathy. The diastolic function of Mgat1Het was again in between Mgat1CKO 
and Mgat1 control. E/A ratio- Mgat1 control (n=9) = 1.22±1.04; Mgat1CKO (n=6)  
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Figure 4.3 (Continued) 
= 2.38±0.52, p<0.05; and Mgat1Het (n=5) = 1.13±0.06, p>0.05. DT- Mgat1 control (n=9) = 
26.6±1.8ms; Mgat1CKO (n=7) = 17.0±1.9, p<0.01; and Mgat1Het (n=6) = 28.4±2.2, p>0.05. 
LVMPI- Mgat1 control (n=9) = 0.55±0.02; Mgat1CKO (n=7) = 0.77±0.07, p<0.01; and 
Mgat1Het (n=6) = 0.6±0.04, p>0.05. LA anteroposterior diameter- Mgat1 control (n=16) = 
1.91±0.06mm; Mgat1CKO (n=7) = 2.75±0.24, p<0.05; and Mgat1Het (n=5) =2.17±0.08, 
p<0.05. P. In addition, right ventricular systolic function was estimated. RV cardiac output (RV 
CO) was significantly reduced in Mgat1CKOs (n=7) compared to Mgat1 controls (n=9). RV 
CO- Mgat1 control = 30.4±1.0ml/min; Mgat1CKO = 24.5±3.3ml/min, p<0.05; and Mgat1Het 
(n=6) = 27±2.8, p>0.05. Q. And right ventricular free wall (RVFW) appeared to be thinner in 
Mgat1CKO (n=3) than that in Mgat1 control (n=7), p>0.05.  RVFW- Mgat1 control (n=7) = 
0.46±0.03mm; Mgat1CKO (n=3) = 0.41±0.03, p>0.05; Mgat1Het (n=2) = 0.45±0.01, p>0.05. 
Sample numbers were listed within bar or legend. Data were presented as mean±SEM and the 
statistical significance was compared with Mgat1 control. *, p<0.05; **, p<0.01; *** p<0.001. 
Mgat1 Ctrl, Mgat1 control; Ctrl, Mgat1 control; Het, Mgat1Het; CKO, Mgat1CKO; Mgat1 
control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx 
/αMHC-Cre+; LV, left ventricle; RV, right ventricle; LA, left atrium; pm, papillary muscle; 
LVID, left ventricular internal dimension; black bar, Mgat1 control; gray bar, Mgat1Het; and 
green bar, Mgat1CKO. 
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Table 4.1. Echocardiography of male Mgat1 offsprings at 30- to 32-week old. 
 
  Mgat1 control      Mgat1Het     Mgat1CKO 
n   16    6   7  
Body weight, g 42 ± 1 43 ± 3 44 ± 2 
HR, beats/min 520 ± 4 517 ± 10 510 ± 8 
Left Ventricle             
     Diastole          
                  LVID, mm 4.12 ± 0.05 4.19 ± 0.17 5.06 ± 0.17*** 
                  LVAW, mm 0.99 ± 0.04 0.94 ± 0.04 0.83 ± 0.05* 
                  LVPW, mm 0.81 ± 0.02 0.73 ± 0.03 0.68 ± 0.02** 
     Systole            
                  LVID, mm 2.38 ± 0.06 2.88 ± 0.16** 4.13 ± 0.22*** 
                  LVAW, mm 1.53 ± 0.04 1.36 ± 0.07* 1.09 ± 0.07*** 
                  LVPW, mm 1.34 ± 0.03 1.08 ± 0.05*** 0.86 ± 0.04*** 
     LVM, mg 115.7 ± 4.6 109.6 ± 8.7 126.1 ± 6.6 
     LVMi, mg/g 2.75 ± 0.11 2.56 ± 0.13 2.93 ± 0.19 
     EF, % 75.7 ± 1.3 61.3 ± 2.8** 40.0 ± 3.8*** 
     FS, % 44.3 ± 1.1 32.8 ± 1.9*** 19.8 ± 2.1*** 
     SV, µl 56.1 ± 1.6 47.7 ± 3.1* 47.4 ± 2.2** 
     CO, ml/min 29.1 ± 0.8 24.3 ± 1.6** 24.0 ± 1.4** 
     COi, ml/min/g 0.70 ± 0.02 0.57 ± 0.03** 0.56 ± 0.04** 
     EDV, µl 74.3 ± 2.1 78.8 ± 6.3 123.3 ± 8.9** 
     ESV, µl 18.2 ± 1.2 31.1 ± 3.9*** 75.9 ± 9.8** 
Mitral Valve            
     E/A 1.22 ± 0.04 1.13 ± 0.06 2.38 ± 0.52* 
     DT, ms 26.6 ± 1.8 28.4 ± 2.2 17.0 ± 1.9** 
     IVCT, ms 6.95 ± 0.38 8.50 ± 0.14** 10.24 ± 1.15* 
     IVRT, ms 16.9 ± 0.5 20.7 ± 1.6* 25.2 ± 1.5*** 
     AET, ms 43.1 ± 0.8 47.1 ± 1.6* 46.3 ± 1.3* 
     NFT, ms 66.6 ± 1.0 75.3 ± 1.3*** 81.7 ± 1.6*** 
     LV MPI 0.55 ± 0.02 0.60 ± 0.04 0.77 ± 0.07** 
RV           
     PA VTI, cm 3.5 ± 0.1 3.5 ± 0.1 3.1 ± 0.2 
     PAT, ms 14.3 ± 0.7 15.3 ± 1.0 14.7 ± 1.3 
     PET, ms 47.5 ± 1.1 51.7 ± 1.4* 53.3 ± 1.3** 
     PAT/PET, % 30.4 ± 1.9 29.7 ± 2.0 27.8 ± 2.6 
     RV SV, µl 60.2 ± 1.8 49.6 ± 4.6* 45.2 ± 5.6* 
     RV CO, ml/min 30.4 ± 1.0 27.0 ± 2.8 24.5 ± 3.3* 
     RVFW, mm 0.46 ± 0.03 0.45 ± 0.01 0.41 ± 0.03 
Left Atria           
     LAd, mm 1.91 ± 0.06 2.17 ± 0.08* 2.75 ± 0.24* 
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Table 4.1 (Continued) 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 
controls and denoted as: *, p<0.05; ** p<0.01; *** p<0.001.  
n, number of mice in each group; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 
/αMHC-Cre+; Mgat1CKO, Mgat1fx/fx /αMHC-Cre+; HR, heart rate; LVID, left ventricular 
internal dimension; LVAW, left ventricular anterior wall; LVPW, left ventricular posterior 
wall; LVM, left ventricular mass; LVMi, left ventricular mass index =
𝐿𝑉𝑀
𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left 
ventricular ejection fraction; FS, left ventricular fractional shortening; CO, left ventricular 
cardiac output; COi, left ventricular cardiac output index =
𝐶𝑂
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
; SV, left ventricular 
stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic 
volume; IVCT, left ventricular isovolumic contraction time; IVRT, left ventricular isovolumic 
relaxation time; AET, aortic ejection time; NFT,  left ventricular non-filling time; LV MPI,  left 
ventricular myocardial performance index (Tei index); E/A, ratio of mitral valve E to A; DT, E 
wave deceleration time; RV, right ventricle; PA VTI, pulmonary artery velocity time integral; 
PAT, pulmonary acceleration time; PET,  pulmonary ejection time; PAT/PET, the ratio of PAT 
to PET(%)=
𝑃𝐴𝑇
𝑃𝐸𝑇
× 100%; RV SV, right ventricular stroke volume; RV CO, right ventricular 
cardiac output; RVFW, right ventricular free wall thickness; LAd, left atrial anteroposterior 
diameter. 
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Figure 4.4. Early-onset of dilated cardiomyopathy and systolic dysfunction in Mgat1CKO. (Continued on Next Page) 
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Figure 4.4 (Continued) 
We investigated the cardiac structural and functional changes in male Mgat1 offsprings from postnatal 4-week to 32-week old. A-B. 
Mgat1CKO (n=10) displayed a significantly enlarged left ventricular internal dimension at diastole (LVID;d) and left ventricular 
end-diastolic volume (EDV) at 4-6 week old when compared with Mgat1 controls (n=10): LVID;d of Mgat1 control = 
3.43±0.08mm, and Mgat1CKO = 3.86±0.09mm, p<0.01; EDV of Mgat1 control =  49.3±2.9µl, and Mgat1CKO = 64.1±3.6µl, 
p<0.01. Cardiac chamber of Mgat1CKO continued to dilate and was statistically significant at all time points observed: 8-9 week, 
16-17 week and 30-32week. On the other hand, male Mgat1Het cardiac chamber size did not differ significantly when compared 
with Mgat1 controls from 4-32 week postnatally. The observed significant chamber dilation of Mgat1CKO at 4-6 week suggested 
that the dilated cardiomyopathy phenotype started before 4-week old in male Mgat1CKOs.  C. Left ventricular posterior wall 
thickness at diastole (LVPW;d) was also thinner in Mgat1CKO (n=10) and reached statistical significance at 30-32 week when 
compared with age-matched Mgat1 controls (See also Table 4.2-4.4 & Table 4.1). LVPW;d of Mgat1Het, however, was similar to 
Mgat1 controls throughout the entire 4-32 week (See also Table 4.2-4.4 & Table 4.1).  D-E. Furthermore, the cardiac systolic 
function was adversely impacted. Starting from 4-6 week old, EF% and FS% of Mgat1CKO (n=10) were significantly reduced 
when compared to age-matched Mgat1 controls (n=10): EF% of 4-6 week Mgat1 control = 77±1.8 versus Mgat1CKO = 60±2.0, 
p<0.001; FS% of 4-6 week Mgat1 control = 45±1.6 versus Mgat1CKO = 31.6±1.4, p<0.001. Although systolic function was still 
within the normal range (55-80%) from 4-9 week, EF% and FS% of Mgat1CKO continued to deteriorate, developing severe heart 
failure at 30-32 week old (See also Figure 4.3; Table 4.1). However, EF% and FS% of Mgat1Het did not differ significantly from 
Mgat1 controls until later in the adulthood at 30-32 week, and their values were always in between Mgat1CKO and Mgat1 control. 
The diastolic function was probed in 4-32 week old Mgat1 offsprings and the preliminary data showed that (F-H) at 4-week old, 
there was no statistical significance in E/A ratio, deceleration time (DT) and isovolumic relaxation time (IVRT) of Mgat1CKO 
(n=4) when compared to Mgat1 controls (n=4), p>0.05, suggesting an unaffected diastolic function in 4-6 week old Mgat1CKO.  
The earliest sign of IVRT prolongation was detected only at 8-9 week old in Mgat1Het and Mgat1CKO followed by the significant 
changes of E/A ratio and DT in Mgat1CKO on and after 16-week old (See also Table 4.2-4.4 & Table 4.1). No septal defect or great 
vessel abnormality was observed at any time points among Mgat1 offsprings under echocardiography. Together, the data 
demonstrated the early development of dilated cardiomyopathy and systolic dysfunction before 4-week old in male Mgat1CKO, 
followed by the diastolic dysfunction observed after 6-week old. Sample numbers were listed below the bars. Data were presented 
as mean±SEM and the statistical significance was compared with Mgat1 control. *, p<0.05; **, p<0.01; *** p<0.001. Mgat1 Ctrl, 
Mgat1 control; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx /αMHC-Cre+; 
black bar, Mgat1 control; gray bar, Mgat1Het; and green bar, Mgat1CKO.  
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Table 4.2. Echocardiography of male Mgat1 offsprings at 4- to 6-week old. 
 
 
 
 
  Mgat1 control      Mgat1Het     Mgat1CKO 
n  10    6   10  
Body weight, g 17 ± 1 18 ± 1 18 ± 1 
HR, beats/min 531 ± 5 534 ± 3 527 ± 4 
Diastole           
               LVID, mm 3.43 ± 0.08 3.56 ± 0.05 3.86 ± 0.09** 
               LVAW, mm 0.80 ± 0.03 0.77 ± 0.02 0.70 ± 0.03* 
               LVPW, mm 0.64 ± 0.02 0.64 ± 0.03 0.62 ± 0.01 
Systole           
               LVID, mm 1.98 ± 0.09 2.20 ± 0.06 2.76 ± 0.11*** 
               LVAW, mm 1.26 ± 0.06 1.18 ± 0.04 1.05 ± 0.04** 
               LVPW, mm 1.08 ± 0.04 1.05 ± 0.05 0.89 ± 0.02*** 
LVM, mg 63.7 ± 3.8 65.5 ± 3.7 68.7 ± 3.4 
LVMi, mg/g 3.74 ± 0.11 3.67 ± 0.12 3.78 ± 0.09 
EF, % 77.0 ± 1.8 72.1 ± 1.3 60.0 ± 2.0*** 
FS, % 45.0 ± 1.6 40.5 ± 1.1 31.6 ± 1.4*** 
SV, µl 37.7 ± 2.0 39.3 ± 1.6 37.9 ± 1.4 
CO, ml/min 20.1 ± 1.1 20.9 ± 1.0 20.1 ± 0.7 
COi, ml/min/g 1.19 ± 0.04 1.18 ± 0.07 1.12 ± 0.05 
EDV, µl 49.3 ± 2.9 54.6 ± 2.1 64.1 ± 3.6** 
ESV, µl 11.5 ± 1.4 15.3 ± 1.0 26.1 ± 2.6*** 
Mitral Valve            
               E/A 1.39 ± 0.08 1.44 ±  1.55 ± 0.10 
               DT, ms 22.8 ± 2.1 25.0 ±  23.3 ± 1.0 
               IVCT, ms 6.0 ± 0.5 5.7 ±  7.9 ± 0.8 
               IVRT, ms 17.2 ± 0.9 17.4 ±  18.0 ± 0.6 
               AET, ms 39.5 ± 1.2 40.6 ±  35.5 ± 0.9* 
               NFT, ms 62.7 ± 2.4 63.7 ±  61.4 ± 1.4 
               LV MPI 0.59 ± 0.02 0.57 ±   0.73 ± 0.01** 
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Table 4.2 (Continued) 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** 
p<0.01; *** p<0.001.  
n, number of mice in each group; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx 
/αMHC-Cre+; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular anterior wall; LVPW, left 
ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index =
𝐿𝑉𝑀
𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, left ventricular cardiac output; COi, left ventricular cardiac output index 
=
𝐶𝑂
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
; SV, left ventricular stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic 
volume; E/A, ratio of mitral valve E to A; DT, E wave deceleration time; IVCT, left ventricular isovolumic contraction time; IVRT, 
left ventricular isovolumic relaxation time; AET, aortic ejection time; NFT,  left ventricular non-filling time; LV MPI,  left 
ventricular myocardial performance index (Tei index).  
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Table 4.3. Echocardiography of male Mgat1 offsprings at 8- to 9-week old. 
 
 
 
 
 
  Mgat1 control      Mgat1Het     Mgat1CKO 
n  13    6   9  
Body weight, g 24 ± 1 26 ± 1 25 ± 1 
HR, beats/min 534 ± 3 531 ± 4 529 ± 4 
Diastole           
               LVID, mm 3.56 ± 0.07 3.82 ± 0.09 4.11 ± 0.12*** 
               LVAW, mm 0.89 ± 0.04 0.81 ± 0.03 0.90 ± 0.04 
               LVPW, mm 0.72 ± 0.02 0.74 ± 0.03 0.67 ± 0.04 
Systole           
               LVID, mm 2.18 ± 0.07 2.51 ± 0.15* 3.02 ± 0.16*** 
               LVAW, mm 1.35 ± 0.05 1.24 ± 0.06 1.27 ± 0.07 
               LVPW, mm 1.18 ± 0.02 1.11 ± 0.04 0.95 ± 0.06*** 
LVM, mg 79.0 ± 3.7 82.8 ± 3.5 96.3 ± 6.0* 
LVMi, mg/g 3.32 ± 0.13 3.19 ± 0.08 3.85 ± 0.15* 
EF, % 74.2 ± 1.2 68.3 ± 3.9 57.5 ± 3.4*** 
FS, % 42.5 ± 1.1 38.1 ± 3.0 30.3 ± 2.2*** 
SV, µl 41.5 ± 1.7 44.3 ± 3.0 44.2 ± 2.0 
CO, ml/min 22.2 ± 0.9 23.8 ± 1.6 23.6 ± 1.1 
COi, ml/min/g 0.93 ± 0.03 0.93 ± 0.08 0.95 ± 0.03 
EDV, µl 56.2 ± 2.5 65.1 ± 3.2 78.7 ± 5.2*** 
ESV, µl 14.7 ± 1.1 20.8 ± 3.0 34.6 ± 4.9*** 
Mitral Valve            
               E/A 1.32 ± 0.06 1.39 ± 0.05 1.28 ± 0.07 
               DT, ms 23.5 ± 1.6 22.5 ± 3.0 25.6 ± 2.4 
               IVCT, ms 8.5 ± 0.7 10.9 ± 1.7 13.7 ± 3.8 
               IVRT, ms 18.5 ± 0.5 21.0 ± 0.0* 20.1 ± 0.5 
               AET, ms 39.2 ± 0.6 37.5 ± 0.0 36.3 ± 1.0* 
               NFT, ms 66.3 ± 1.4 69.4 ± 1.7 70.1 ± 4.7 
               LV MPI 0.69 ± 0.02 0.85 ± 0.04* 0.93 ± 0.10** 
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Table 4.3 (Continued) 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** 
p<0.01; *** p<0.001.  
n, number of mice in each group; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx 
/αMHC-Cre+; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular anterior wall; LVPW, left 
ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index =
𝐿𝑉𝑀
𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, left ventricular cardiac output; COi, left ventricular cardiac output index 
=
𝐶𝑂
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
; SV, left ventricular stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic 
volume; E/A, ratio of mitral valve E to A; DT, E wave deceleration time; IVCT, left ventricular isovolumic contraction time; IVRT, 
left ventricular isovolumic relaxation time; AET, aortic ejection time; NFT,  left ventricular non-filling time; LV MPI,  left 
ventricular myocardial performance index (Tei index). 
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Table 4.4. Echocardiography of male Mgat1 offsprings at 16- to 17-week old. 
 
 
 
 
 
  Mgat1 control      Mgat1Het     Mgat1CKO 
n  14    7   10  
Body weight, g 32 ± 1 33 ± 2 35 ± 1 
HR, beats/min 526 ± 5 525 ± 9 518 ± 5 
Diastole           
               LVID, mm 4.04 ± 0.08 3.88 ± 0.11 4.75 ± 0.17** 
               LVAW, mm 0.97 ± 0.04 1.00 ± 0.06 0.79 ± 0.04** 
               LVPW, mm 0.74 ± 0.03 0.80 ± 0.04 0.68 ± 0.04 
Systole           
               LVID, mm 2.41 ± 0.09 2.51 ± 0.19 3.63 ± 0.26*** 
               LVAW, mm 1.52 ± 0.05 1.44 ± 0.10 1.15 ± 0.07*** 
               LVPW, mm 1.21 ± 0.03 1.19 ± 0.06 0.94 ± 0.06** 
LVM, mg 102.9 ± 6.0 106.5 ± 8.0 115.5 ± 4.9 
LVMi, mg/g 3.22 ± 0.19 3.21 ± 0.23 3.30 ± 0.16 
EF, % 72.9 ± 1.3 67.6 ± 4.3 48.7 ± 4.7*** 
FS, % 41.7 ± 1.1 37.7 ± 3.2 25.2 ± 2.9*** 
SV, µl 52.1 ± 2.0 43.5 ± 1.9* 47.6 ± 2.2 
CO, ml/min 27.2 ± 1.0 23.1 ± 1.1* 24.6 ± 1.3 
COi, ml/min/g 0.85 ± 0.04 0.71 ± 0.05* 0.70 ± 0.04* 
EDV, µl 71.7 ± 3.2 65.5 ± 3.9 104.2 ± 8.9** 
ESV, µl 19.7 ± 1.5 21.9 ± 4.0 56.7 ± 9.3** 
Mitral Valve            
               E/A 1.16 ± 0.01 1.29 ±  15.25 ± 3.19* 
               DT, ms 32.6 ± 1.7 22.7 ±  19.0 ± 1.8* 
               IVCT, ms 9.8 ± 0.9 5.6 ±  12.2 ± 1.7 
               IVRT, ms 17.2 ± 0.6 16.8 ±  20.8 ± 0.9 
               AET, ms 39.1 ± 2.9 44.8 ±  37.8 ± 2.6 
               NFT, ms 66.0 ± 4.3 67.3 ±  70.7 ± 5.1 
               LV MPI 0.69 ± 0.01 0.50 ±   0.87 ± 0.01** 
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Table 4.4 (Continued) 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** 
p<0.01; *** p<0.001.  
n, number of mice in each group; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx 
/αMHC-Cre+; HR, heart rate; LVID, left ventricular internal dimension; LVAW, left ventricular anterior wall; LVPW, left 
ventricular posterior wall; LVM, left ventricular mass; LVMi, left ventricular mass index =
𝐿𝑉𝑀
𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
; EF, left ventricular ejection 
fraction; FS, left ventricular fractional shortening; CO, left ventricular cardiac output; COi, left ventricular cardiac output index 
=
𝐶𝑂
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
; SV, left ventricular stroke volume; EDV, left ventricular end-diastolic volume; ESV, left ventricular end-systolic 
volume; E/A, ratio of mitral valve E to A; DT, E wave deceleration time; IVCT, left ventricular isovolumic contraction time; IVRT, 
left ventricular isovolumic relaxation time; AET, aortic ejection time; NFT,  left ventricular non-filling time; LV MPI,  left 
ventricular myocardial performance index (Tei index). 
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Histological examination was performed on 31-week old male and 35-week old female 
Mgat1 offsprings. Both male and female Mgat1CKOs developed cardiac phenotypes, manifested 
as significantly enlarged right ventricle (RV) and left ventricle (LV) when compared with their 
littermate controls, consistent with previous echocardiography findings (See Figure 4.2&4.5A-B; 
Table 4.1). Male Mgat1CKO also developed drastically enlarged left atrium (LA) and right 
atrium (RA) at 31-week, suggesting a very high risk of atrial arrhythmia. The apparently milder 
cardiac phenotype in female Mgat1CKO than that in male Mgat1CKO hearts also was in 
agreement with previous survival study findings (See Figure 4.2&4.5A-B). No structural defect 
or major vessel deformation was detected in both female and male Mgat1CKO. Consistently, 
H&E staining of 35-week female Mgat1CKO exhibited the greatly dilated RV and LV with a 
much thinner LV wall (See Figure 4.5C). No septal valvular or great vessel defect was seen in 
Mgatg1CKO, suggesting cardiac-specific deletion of Mgat1 did not perturb murine cardiogenesis 
(See Figure 4.5A-C). Under the light microscope, myocyte density was significantly reduced in 
Mgat1CKO, with markedly increased interstitial tissues. Mgat1CKO myocytes were highly 
disorganized with notable atrophic appearance (See Figure 4.5D). The normal striation pattern 
and intercalated disc structures were largely diminished and disrupted with heavy accumulation 
of vacuoles in Mgat1CKO myocytes, suggesting the high probability of impaired contractility, 
obstructive conductivity and severe arrhythmia (See Figure 4.5D-E). No sign of 
narrowing/obstruction of coronary artery lumen, inflammation or cell infiltration were observed 
in Mgat1CKO, consistent with the diagnosis of idiopathic DCM (See Figure 4.5C-D). Masson’s 
trichrome staining of 35-week old female Mgat1CKO revealed a substantial interstitial and 
perivascular fibrosis in cardiac tissue, consistent with the diagnosis of end-stage DCM (See 
Figure 4.6).  
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D.  
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Figure 4.5. Histological examination of male and female Mgat1 control and Mgat1CKO 
hearts. 
A. At 31-week old just before the initial male mortality, hearts from male Mgat1 control (left) 
and male Mgat1CKO (right) were examined. 31-week old male Mgat1CKO displayed marked 
enlargement of all 4 cardiac chambers: right atrium (RA), left atrium (LA), right ventricle (RV) 
and left ventricle (LV). LA was dramatically dilated with apparent thrombosis within, 
suggesting a high risk of atrial arrhythmia in male Mgat1CKO. No cardiac structural defects or 
major vessel deformation was found in Mgat1CKO. Scale bar, 1mm. B. The hearts from 35-
week old female Mgat1 control (left) and Mgat1CKO (right) were also examined. Female 
Mgat1CKO had milder cardiac phenotype than male Mgat1CKO, showing enlarged RV and 
LV, but not LA and RA. No structural defects or major vessel deformation was seen in female 
Mgat1CKO too. The apparently milder cardiac phenotype found in female Mgat1CKO than that 
 
 
 
 
Female Mgat1 control Female Mgat1CKO 
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Figure 4.5 (Continued) 
in male Mgat1CKO was consistent with the previous survival studies (See Figure 4.2). Scale 
bar, 1mm. C. H&E staining of the same 35-week old female hearts (X12.5) showed the 
consistent enlargement of both RV and LV and much thinner LV wall, confirmed the 
echocardiography findings of end-stage dilated cardiomyopathy (See Figure 4.3). No septal, 
valvular or great vessel defect was found, indicating that Mgat1 deletion in murine heart did not 
perturb cardiogenesis. Scale bar, 500µm. D. Under light microscope at higher magnification 
(X400), female Mgat1CKO myocytes were extremely disorganized with notable atrophic 
appearance. Myocyte density was significantly reduced with markedly increased interstitial 
tissues (arrowhead) in female Mgat1CKO. The characteristic striation pattern and intercalated 
discs were severely diminished and greatly disrupted in female Mgat1CKO myocytes, 
suggesting the high probability of impaired contractility, obstructive conductivity and severe 
arrhythmia. No sign of narrowing/obstruction of coronary artery lumen, inflammation or cell 
infiltration were observed, consistent with the diagnosis of idiopathic DCM. Scale bar, 20µm. 
E. At X1000 magnification, female Mgat1CKO myocytes had heavy vacuoles accumulation 
(arrow) with greatly diminished striation and intercalated discs when compared to female 
Mgat1 control cardiomyocytes. Scale bar, 5µm. Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; 
Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+. 
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Figure 4.6. Substantial fibrosis was present in female Mgat1CKO hearts. 
A. (X12.5) Masson’s Trichrome staining was performed on 35-week old female Mgat1 control 
(left) and Mgat1CKO (right) hearts. Internal positive controls (e.g. valves) were stained blue. 
Scale bar, 500µm. Female Mgat1CKO hearts presented with substantial interstitial and 
perivascular fibrosis (arrowhead), mostly obvious in apex (B, X200 from solid box in A) and 
LV free wall (C, X200 from dashed box in A). Scale bar, 30µm. The extensive collagen 
deposition (blue) was also clearly seen under higher magnification (X1000) in both apex (D) 
and LV free wall (E) of female Mgat1CKO, suggesting a severe cardiac dysfunction. Scale bar, 
5µm. Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+. 
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Altered ECG with Frequent Arrhythmia Was Observed in 34-42 Week Mgat1CKO Hearts. 
First, we investigated the ECG changes by performing lead II surface ECG on 35-week 
old female Mgat1 offsprings under light anesthesia. The ECG waveform of sinus rhythm showed 
the significantly prolonged and notched P in 35-week old female Mgat1CKO, indicating an 
enlarged RA and LA in female Mgat1CKO. P duration- female Mgat1 control (n=6) = 8±0.4ms; 
and female Mgat1CKO (n=4) = 17±2.3ms, p<0.01 (See Figure 4.7; Table 4.5). Female 
Mgat1CKO QRS complex was prolonged, suggesting a slowed conductance within female 
Mgat1CKO hearts. R voltage in female Mgat1CKO was diminished, consistent with observed 
DCM phenotype. QRS duration- female Mgat1 control = 11±0.4ms; and female Mgat1CKO = 
18±1.2ms, p<0.001. R amplitude- female Mgat1 control = 798±75.6µV; and female Mgat1CKO 
= 426±43.6µV, p<0.01 (See Figure 4.7; Table 4.5). In addition, J wave in female Mgat1CKO 
was depressed, with prolonged QT and QTc intervals. J amplitude- female Mgat1 control = 
217±16.2µV; and female Mgat1CKO = -5±10.5µV, p<0.001. In comparison, female Mgat1Het 
(n=4) had only mild changes in its ECG waveform from sinus rhythm and the values were in 
between female Mgat1 control and female Mgat1CKO (See Figure 4.7; Table 4.5). Next, lead II 
telemetry ECG recording on conscious, unrestrained 34- to 42-week old male Mgat1CKO was 
conducted. ECG waveform from sinus rhythm of 34-42 week male Mgat1CKO had similar 
changes as those of 35-week female Mgat1CKO (n=4), including a prolonged and notched P, 
extremely low QRS voltage, prolonged QRS complex and depressed J when compared to 34-42 
week Mgat1 controls (n=3) (See Figure 4.8; Table 4.6). In addition, long-term telemetry ECG 
recording showed frequent and various arrhythmia in 34-42 week male Mgat1CKO, ranging 
from spontaneous PVC, isolated of sustained ectopic atrial beats, sustained junctional 
tachycardia to even ventricular tachycardia, where atrial and AV nodal arrhythmia were mostly 
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often (See Figure 4.9). And as disease progresses, arrhythmia in male Mgat1CKO appeared to 
worsen, shifting from primary atrial arrhythmia to junctional or even ventricular arrhythmia. 
Male Mgat1CKO eventually die due to myocardial failure (data not shown). Interestingly, 34-42 
week male Mgat1CKO (n=3) showed a significantly elevated basal HR and greatly depressed 
HRV in 24 hour simultaneous telemetry ECG  recording when compared to male Mgat1 control 
(n=3). This type of HRV changes is often seen in end-stage myocardial dysfunction with 
implication of poor prognosis, consistent with echocardiography and histology findings of male 
Mgat1CKO. Basal HR- male Mgat1 control = 491±8bpm; male Mgat1CKO = 550±9bpm, 
p<0.01. SDNN- male Mgat1 control = 22.5±0.4ms; male Mgat1CKO = 12.2±3.6ms, p<0.05. 
pNN6%- male Mgat1 control = 22.2±2.7%, male Mgat1CKO = 4.3±2.0%, p<0.01 (See Figure 
4.10).  
Very preliminary data also detected a reduction of alpha-dystroglycan protein expression 
in male Mgat1CKO when compared to male Mgat1 control (data not shown), indicating a 
potential mechanism of DCM development via disruption of dystrophin associated glycoprotein 
complex in Mgat1CKO. However, future study is needed to elucidate the molecular mechanism 
of cardiac-specific deficit of complex and hybrid N-glycan induced arrhythmogenic DCM. 
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Figure 4.7. Significantly altered surface ECG waveform in 35-week female Mgat1CKO. 
Lead II surface ECG was recorded under light anesthesia in 35-week old female Mgat1 offsprings. A-B &F. The averaged ECG 
waveforms from sinus rhythms of female Mgat1 control (A), female Mgat1CKO (B) and female Mgat1Het (F) respectively. Noted 
that the P wave of Mgat1CKO was notched and prolonged, indicating the dilated RA and LA in Mgat1CKO. Mgat1CKO had very 
low QRS voltage which was consistent with the severe DCM observed above. In addition, J waves in both Mgat1CKO and 
Mgat1Het were depressed, but most severe in Mgat1CKO. Mgat1 control ECG waveform was normal. Bar, interval length. C. RR 
intervals were similar among 35-week female Mgat1 control (n=6), Mgat1CKO (n=4) and Mgat1Het (n=4) (p>0.05). D. ECG 
measurements showed consistently low R peak (p<0.001) and J wave (p<0.001) in female Mgat1CKO with (E) significantly 
prolonged QRS complex (p<0.001), P (p<0.01), QT and QTc intervals (p<0.01). Prolonged QRS complex also suggested a reduced 
conductance within Mgat1CKO heart. In comparison, Mgat1Het had only moderate changes in ECG, such as mild prolongation of 
QT and QTc intervals (p<0.05) and moderately depressed J wave (p<0.001). See Table 4.5 for raw ECG values. QTc, corrected QT 
interval for heart rate. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** p<0.01; *** 
p<0.001. Mgat1Ctrl, Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; Mgat1CKO, Mgat1fx/fx /αMHC-
Cre
+
.  
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Table 4.5. Quantitative comparison of lead II surface ECG from female 35-week old Mgat1 offsprings. 
 
  Female Mgat1Ctrl Female Mgat1Het Female Mgat1CKO 
n  6    4   4  
Body weight (g) 35 ± 2.3 31 ± 1.9 34 ± 2.6 
Heart rate (bpm) 547 ± 9.6 544 ± 13.7 536 ± 5.2 
RR interval (ms) 110 ± 2.0 111 ± 3.4 112 ± 1.1 
P amplitude (µV) 104 ± 13.5 131 ± 6.2 90 ± 5.9 
P duration (ms) 8 ± 0.4 12 ± 2.5 17 ± 2.3** 
PR interval (ms) 34 ± 1.4 34 ± 0.7 37 ± 1.2 
R amplitude (µV) 798 ± 75.6 830 ± 157.2 426 ± 43.6** 
QRS interval (ms) 11 ± 0.4 11 ± 1.3 18 ± 1.2*** 
J  amplitude (µV) 217 ± 16.2 69 ± 21.1*** -5 ± 10.5*** 
JT interval (ms) 36 ± 0.7 37 ± 1.6 33 ± 2.7 
QT interval (ms) 49 ± 0.5 53 ± 1.4* 58 ± 2.2** 
QTc (ms) 47 ± 0.7 50 ± 0.8* 55 ± 2.1** 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** 
p<0.01; *** p<0.001.  
n, number of mice in each group; Mgat1Ctrl, Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1Het, Mgat1
fx/+
 /αMHC-Cre+; 
Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+; QTc, corrected QT interval for heart rate. 
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Figure 4.8. Significantly altered telemetry sinus ECG waveform in male 34- to 42-week Mgat1CKO. (Continued on Next 
Page)  
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Figure 4.8 (Continued) 
The simultaneous lead II telemetry ECG was recorded from 34- to 42-week old conscious unrestrained male Mgat1CKO (n=4) and 
Mgat1 control (n=3). A-B. The representative 1-second ECG (left) and 60-second averaged ECG waveform (right) of sinus rhythm 
from male Mgat1 control (A) or male Mgat1CKO (B) were presented here. Male Mgat1CKO showed the significantly prolonged P 
wave with two prominent peaks, suggesting the severely dilated RA and LA in male Mgat1CKO, consistent with previous 
echocardiography and autopsy findings (See Figure 4.3&4.5A). Mgat1CKO QRS voltage was extremely low, in agreement with the 
end-stage DCM phenotypes. The prolonged QRS complex of male Mgat1CKO also indicated a slower conductance within male 
Mgat1CKO hearts. Bar, interval length. C. The resting heart rate (HR) of male Mgat1CKO was higher than that of male Mgat1 
control (p>0.05). D-E. Consistently, ECG measurements showed the significantly low R peak (p<0.001), depressed J (p<0.05) with 
significantly prolonged P (p<0.01) and QRS complex (p<0.05) in male Mgat1CKO. QT and QTc of male Mgat1CKO were slightly 
prolonged but insignificant (p>0.05), probably due to the faster resting HR in Mgat1CKO. In general, the telemetry sinus ECG 
waveform changes of male Mgat1CKO was in line with the surface ECG changes of 35-week old female Mgat1CKO, suggesting 
the shared sinus electrophysiological phenotype between male and female Mgat1CKOs. See Table 4.6 for raw telemetry ECG 
values. QTc, corrected QT interval for heart rate. Statistical significance was compared with Mgat1 controls and denoted as: *, 
p<0.05; ** p<0.01. Mgat1Ctrl, Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; and Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+. 
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Table 4.6. Quantitative comparison of telemetry sinus ECG from male 34- to 42-week Mgat1 control and Mgat1CKO. 
 
 
Male Mgat1 control Male Mgat1CKO 
n  3    4  
Body weight (g) 42 ± 2.8 40 ± 3.0 
Heart rate (bpm) 504 ± 13 540 ± 19 
RR interval (ms) 119 ± 3.0 112 ± 3.9 
P amplitude (µV) 71 ± 15.0 64 ± 14.4 
P duration (ms) 11 ± 1.3 24 ± 1.5** 
PR interval (ms) 35 ± 2.4 41 ± 1.3 
R amplitude (µV) 707 ± 86.3 291 ± 79.9* 
QRS interval (ms) 12 ± 1.2 21 ± 2.3* 
J  amplitude (µV) 72 ± 24.6 -15 ± 7.1* 
JT interval (ms) 48 ± 1.5 40 ± 5.4 
QT interval (ms) 63 ± 2.8 67 ± 2.6 
QTc (ms) 57 ± 2.0 63 ± 1.4 
 
† Values were presented as mean ± SEM. Statistical significance was compared with Mgat1 controls and denoted as: *, p<0.05; ** 
p<0.01.  
n, number of mice in each group; Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+; QTc, corrected QT 
interval for heart rate. 
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Figure 4.9. Frequent and sustained arrhythmia was detected in male 34- to 42-week Mgat1CKO. (Continued on Next Page) 
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Figure 4.9 (Continued) 
Lead II ambulatory telemetry ECG was recorded from 34- to 42-week old conscious unrestrained male Mgat1CKO (n=4) and 
Mgat1 control (n=3). A. The representative 2-second telemetry ECG from male Mgat1 control showed normal sinus rhythm with 
normal ECG waveform. No ventricular arrhythmia was detected in any male Mgat1 controls. However, wide range of atrial and 
ventricular arrhythmia was detected in male Mgat1CKO including: (B) spontaneous premature ventricular contraction (PVC, 
arrow); (C-D) sustained atrial arrhythmia where atrial ectopic beats from different origins retrogradely activated atria, producing the 
negative P waves; (E) sustained junctional tachycardia; and (F) a train of ventricular tachycardia, characterized as AV dissociation, 
capture beat (asterisk) and fusion complex. Arrhythmia in male Mgat1CKO deteriorated progressively, from atrial arrhythmia to 
frequent junctional arrhythmia and even ventricular arrhythmia. However, the main cause of death for male Mgat1CKO was 
myocardial failure. Sustained atrial ectopic beats in male Mgat1CKO was also consistent with the enlarged RA and LA seen in male 
Mgat1CKO. Mgat1 control, Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+.   
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Figure 4.10. Elevated basal heart rate (HR) and depressed HRV in 34- to 42-week male Mgat1CKO mice. (Continued on 
Next Page)  
 
 
Male Mgat1 control Male Mgat1CKO 
n  3    3  
Body weight (g) 42 ± 3.5 38 ± 4.9 
NN Interval (ms) 126.3 ± 2.0 110.8 ± 2.4** 
NN Rate (bpm) 491 ± 8 550 ± 9** 
SDNN (ms) 22.5 ± 0.4 12.2 ± 3.6* 
RMSSD (ms) 6.9 ± 1.0 2.4 ± 0.6* 
pNN6 (%) 22.2 ± 2.7 4.3 ± 2.0** 
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Figure 4.10 (Continued) 
Simultaneous 24-hour continuous telemetry ECG recording was performed on 34-to 42- week male Mgat1 control (n=3) and 
Mgat1CKO (n=3). Only the sinus beats without arrhythmia, ectopic beats or artifacts were included for HRV analysis, as described 
previously (See Chapter Two). A. The representative RR tachogram of male Mgat1Control showed normal RR interval variations 
with mean normal-to-normal heart rate (NN rate) = 491±8 bpm. Black dashed line: mean NN Interval. B. However, male 
Mgat1CKO presented with significantly elevated basal HR (550±9 bpm, p<0.01) and markedly reduced RR interval variations when 
compared to male Mgat1 controls. Black dashed line: mean NN Interval. C. HRV results averaged from n=3 of Mgat1 control and 
Mgat1CKO were tabulated here. Male Mgat1CKO showed greatly depressed HRV, evidenced by significantly reduced SDNN, 
RMSSD and pNN6% in male Mgat1CKO when compared to Mgat1 controls, which is often seen in end-stage myocardial 
dysfunction, indicating a poor prognosis for male Mgat1CKO. Indeed, male Mgat1CKO deceased rapidly due to myocardial failure 
(See survival study in Figure 4.2). HRV, heart rate variability; NN interval, normal-to-normal interval; NN rate, normal-to-normal 
heart rate; SDNN,  the standard deviation of all NN interval; RMSSD, the square-root of the mean of square successive differences 
between successive NN intervals; pNN6 (%), percentage of normal consecutive NN intervals differing by >6 ms. Mgat1 control, 
Mgat1
fx/fx
 or Mgat1
fx/+
; Mgat1CKO, Mgat1
fx/fx
 /αMHC-Cre+.   
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Discussion 
In current study, we investigated the impact of cardiac complex and hybrid N-glycan in 
murine heart via cardiac-specific knockout of Mgat1 (Mgat1CKO). Mgat1CKO developed the 
early-onset of DCM, late adult mortality, severely impaired cardiac systolic and diastolic 
function, and frequent arrhythmia. Mgat1 did not disrupt murine cardiogenesis, evidenced by 
normal litter size, Mendelian distribution of genotypes, no sign of cyanosis or dyspnea at birth 
and no septal defect or vessel deformation detected by autopsy or echocardiography, similar to 
ST3Gal4. Moreover, a striking sex-differential phenotype was observed in this autosomal gene 
deletion of Mgat1, in which female Mgat1CKO had much milder cardiac phenotype and 
significantly longer survival time than those in male Mgat1CKO. The clear gene-dosage 
dependent effect observed in male Mgat1 offsprings was blunted in females. As a matter of fact, 
the sex-biased cardiac effect was also seen in the autosomal gene deletion of ST3Gal4 (ST3Gal4
-
/-
), where under pressure over-load, female ST3Gal4
-/-
 hearts did not develop heart failure and 
their cardiac function did not differ from wild type littermates (data not shown), unlike  male 
ST3Gal4
-/-
. Future studies are needed to investigate the mechanisms of this glyco-dependent sex-
differential cardiac phenotype.  
Mgat1 knockout affected cardiac systolic function the most, in concurrent with DCM 
development, showing the early-onset of systolic dysfunction before 4-week old. Diastolic 
dysfunction developed later after postnatal 6 weeks in male Mgat1CKO. Histological 
examination confirmed the DCM phenotype, showing dilation of all 4 cardiac chambers (RA, 
LA, RV and LV) with substantial tissue fibrosis in Mgat1CKO. Arrhythmia was also readily 
seen in adult Mgat1CKO and the severity was parallel to its disease stages. The earliest ECG 
waveform changes and arrhythmia were detected at postnatal week 7 in male Mgat1CKO. 
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Furthermore, the very preliminary data showed a marked reduction of α-dystroglycan (α-DG) 
protein expression in male Mgat1CKO, supporting the mechanism of disrupted Dystrophin-
associated protein complex (DAPC) induced DCM in Mgat1CKO. Future studies are needed to 
elucidate the molecular mechanisms underlying cardiac deficit of complex and hybrid N-glycan 
induced arrhythmogenic DCM. 
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CHAPTER FIVE  
DISCUSSION 
 
Our lab is the pioneer in the field of glyco-dependent cardiac electrophysiology. 
Previously, we showed that cardiac glycome is variable and changes differentially during the 
development of atria and ventricles 
[105]
. Experimental prevention or removal of sialic acids 
altered the voltage sensitivity of NaV and KV gating, through direct, isoform-specific, 
electrostatic mechanisms 
[25-31, 105-122]
. We also found that adult ventricular cardiomyocytes of 
ST3Gal4
-/-
 have altered AP waveforms, characterized by slow depolarization, extended 
repolarization and reduced refractory period (See Ednie A.R. et al., 2013 and 2015) 
[108, 110]
. 
These AP waveform changes were attributed to the depolarizing shift in NaV, Ito and IK, slow 
gating, increased rate of NaV recovery from fast inactivation, and a rightward shift of NaV 
window current. All of which contributed to the reduced cellular refractory periods, prolonged 
QT interval and increased susceptibility to arrhythmia in ST3Gal4
-/-
 hearts 
[108, 110]
. In addition, 
the very preliminary data from Mgat1CKO ventricular myocytes showed similar but more severe 
changes of AP waveform when compared to ST3Gal4
-/-
, displaying a much more prolonged AP 
duration, marked depolarizing shift of NaV gating and NaV window current, and faster NaV 
recovery rate. However, it is not known whether and how sialic acid or N-glycosylation impact 
cardiac function in vivo.  
Here, we reported that the partial reduction of N-linked α2,3-sialylation achieved through 
ST3Gal4 gene deletion led to later onset of dilated cardiomyopathy (DCM) (See Figure 3.3; 
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Table 3.1-3.4). The DCM symptoms developed gradually, starting after postnatal 9-month in 
ST3Gal4
-/-
, presenting with thinner LV walls and dilation of all four chambers, but with 
preserved systolic function and the lack of fibrosis, indicating a modest DCM in ST3Gal4
-/-
(See 
Figure 3.3&3.5-3.6; Table 3.1-3.4). At 16-20 week old, before the cardiac structural and 
functional changes in ST3Gal4
-/-
, pressure-overload (TAC) was imposed on both ST3Gal4
-/-
 and 
WT littermates (See Figure 3.7A). No mortality was found in all groups. TAC’d WT hearts 
showed the classic characteristics of stress-induced adaptation, demonstrating substantial 
thickening of the LV wall, and relatively maintained cardiac chamber size and contractile 
functions throughout the six-week experiment (See Figure 3.7-3.8; Table 3.7-3.11). TAC’d 
ST3Gal4
-/-
 mice, however, displayed insufficient LV adaptation and rapid cardiac 
decompensation, presenting significantly (compared to WT) reduced systolic function by the end 
of week 1 that deteriorated into heart failure by the end of week six post-surgery, suggesting an 
increased susceptibility to heart failure in ST3Gal4
-/-
(See Figure 3.7-3.8; Table 3.7-3.11). 
Furthermore, both sham and TAC’d ST3Gal4-/- hearts had less calcineurin protein expression 
when compared to sham or TAC’d WT (See Figure 3.9), suggesting the increased susceptibility 
to heart failure was not due to the increased calcineurin levels in ST3Gal4
-/-
. ST3Gal4
-/-
 did not 
perturb cardiogenesis, evidenced by normal litter size and lack of cardiac or vessel defect in 
ST3Gal4
-/-
(See Figure 3.2&3.5). These data showed, for the first time, that α2,3-sialylation plays 
an essential role in cardiac adaptation and contractile function, reporting at the first time the 
cardiac phenotype of ST3Gal4
-/-
 under normal and stressed conditions.  
More severe than ST3Gal4
-/- 
phenotypes, removal of cardiomyocyte complex and hybrid 
N-glycan via gene deletion of cardiac Mgat1 (Mgat1CKO) resulted in an early-onset of DCM, 
late adult mortality and severely impaired cardiac systolic and diastolic function with frequent 
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arrhythmia in mice (See Figure 4.3-4.4&4.7-4.9; Table 4.1-4.6). Moreover, a striking sex-
differential phenotype was observed in this autosomal gene deletion of Mgat1, in which female 
Mgat1CKO had much milder cardiac phenotype and significantly longer survival time than male 
Mgat1CKO (See Figure 4.2). The clear gene-dosage dependent effect observed in male Mgat1 
offsprings was blunted in females (See Figure 4.2). Histological examination confirmed the 
DCM findings, showing dilation of all 4 cardiac chambers (RA, LA, RV and LV) with 
substantial tissue fibrosis in Mgat1CKO (See Figure 4.5-4.6). In addition, Mgat1 knockout 
affected cardiac systolic function the most, in concurrent with DCM development, showing the 
early-onset of systolic dysfunction before 4-week old. Diastolic dysfunction developed later after 
postnatal 6 weeks in male Mgat1CKO (See Figure 4.4; Table 4.1-4.4). Arrhythmia was also 
readily seen in adult Mgat1CKO (See Figure 4.7-4.9). Mgat1 did not disrupt murine 
cardiogenesis, evidenced by normal litter size, Mendelian distribution of genotypes, no sign of 
cyanosis or dyspnea at birth and no septal defect or vessel deformation detected by autopsy or 
echocardiography, similar to ST3Gal4 (See Figure 4.1, 4.3&4.5). The cardiac phenotype of 
Mgat1CKO is align with the cardiac phenotype resulted from reduced sialylation (ST3Gal4
-/-
), 
indicating a broad implication of glycosylation in DCM etiology. Future studies are needed to 
investigate the mechanisms of glyco-dependent DCM in Chagas disease, CDG and other 
idiopathic DCMs.  
 
Desialylation and Idiopathic Dilated Cardiomyopathy 
We, as well as previous studies, found that α2,3-sialylation is primarily expressed at 
sarcolemma, capillary endothelium and the basal lamina of adult murine cardiac tissues (See 
Figure 3.1) 
[158]
. No intracellular staining was observed (See Figure 3.1). It suggests that the 
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sarcolemma glycoprotein(s) are probably the main contributors to the cardiomyocyte phenotypes 
observed in ST3Gal4
-/-
. Previous studies reported that ST3Gal4
-/-
 appear normal, fully fertile, 
well-nourished with no growth retardation or skeletal deformation 
[101] [103]
. Consistent with these 
studies, we also found that reduced N-α2,3-sialic acid did not perturb cardiogenesis, evidenced 
by normal litter size, Mendelian distribution of genotypes, normal lifespan with no cardiac defect 
or major vessel deformation under echocardiography and autopsy examination (See Figure 
3.2&3.5). In addition, cardiomyocyte density was reduced in 1.5-year ST3Gal4
-/-
, suggesting a 
modest degenerative effect or abated proliferation upon ST3Gal4 deletion (See Figure 3.5). 
Future studies are needed to examine the cardiomyocytes proliferation and apoptosis in ST3Gal4
-
/-
. The myocyte-myocyte connection and myocyte-ECM contact appeared reduced, a potential 
role of α2,3-sialic acid in intercellular and cell-ECM communication is implicated (See Figure 
3.5). Moreover, there appears increased capillary density in adult ST3Gal4
-/-
 cardiac tissue (data 
not shown), thus excluded the deficient tissue oxygenation or perfusion as a reason for observed 
DCM and reduced myocyte density in ST3Gal4
-/-
.  
Under echocardiography, young 16-20 week-old ST3Gal4
-/-
 (n=12) has slight but 
statistically non-significant elevation of basal aortic pressure gradient (6.39±0.39mmHg) than its 
wild-type littermates (n=7) (5.31±0.37mmHg), p>0.05 (See Table 3.7). The reason for this slight 
increase of basal blood pressure and its effect on cardiac function are unknown. However, the 
cardiac systolic function was preserved in ST3Gal4
-/-
. In this study, we have stringently 
controlled pressure-load by using the same gauge needle during TAC ligation, followed by 
recruitment criteria of AoPg=85±5mmHg. No statistical significance was found in AoPg 
between TAC’d WT and TAC’d ST3Gal4-/- (AoPg of TAC’d WT=85.5±1mmHg and TAC’d 
ST3Gal4
-/-
 =85.9±1mmHg, p>0.05; noted the narrow standard error of AoPg), ensured equivalent 
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amount of pressure-overload imposed on TAC’d WT and TAC’d ST3Gal4-/- mice (See Figure 
3.7; Table 3.8).  
There is an implication of desialylation-induced idiopathic DCM. Previous studies 
reported a correlation between altered sialylation and aberrant cardiac function.  For example, 
each subtype of >45 CDG results in modest but variable (among subtypes) reduced glycoprotein 
glycosylation, with nearly all subtypes resulting in reduced levels of sialic acids and dramatic 
multi-system effects including cardiomyopathy with related arrhythmias and a high infant 
mortality rate 
[48-51, 168]
. We showed here and previously that a mild perturbation in the sialylation 
pathway (i.e., gene deletion of ST3Gal4) that results in a modest reduction in sialic acid of only 
some glycoproteins is sufficient to induce rather strong cardiac phenotypes 
[108, 110]
. In addition, 
altered sialylation/ glycosylation occurs with environmental/metabolic risk factors for DCM 
including smoking, excessive drinking, and diabetes 
[68, 71]
. Interestingly, non-congenital changes 
in sialylation occur in humans with DCM and heart failure 
[56, 69, 70]
, but whether altered 
sialylation is pathogenic or subsequent to DCM onset has not been determined. Relevant 
examples showed mRNA levels for the galactotransferase, β4galT1 (acts to attach penultimate 
galactose to N-/O-glycans, required for the addition of the terminal sialic acids), a putative 
sialyltransferase, and the CMP sialic acid transporter, were lower in end stage human DCM 
[56, 69, 
70]
.  In addition, patients suffering from heart failure secondary to idiopathic DCM have reduced 
α2,3-sialylation but not α2,6-sialic acid in their cardiac tissues [72]. These studies, in agreement 
with the current work, suggest a correlation between congenital and non-congenital changes in 
sialylation and reduced cardiac function that contribute to DCM and heart failure.   
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Another relevant disease is Chagas disease, caused by the infection of parasite T. Cruzi. . 
The characteristic of this disease is the parasitic secretion of the trans-sialidase that transfers 
α2,3-sialic acid specifically from host cell surface to parasitic mucins due to  the incapacity of 
producing sialic acid by the parasite itself 
[76]
. Cardiomyocyte is its primary target 
[76]
. As a result, 
chronically infected patients develop dilated cardiomyopathy and/or megacolon/ 
megaoesophagus 
[73]
,  with most of them die from DCM, heart failure, fatal arrhythmia and 
cardiac sudden death.  Although, it is highly suspected that the removal of α2,3-sialic acid 
contributed to the characteristic heart and GI track dilation 
[73]
, no direct evidence is available. 
Here we, at the first time, demonstrated that partial removal of N-linked α2,3-sialic acid directly 
caused DCM, abnormal ECG and reduced cardiac adaptation to stress in vivo.  
 
Channelopathy as a Potential Mechanism for Dilated Cardiomyopathy 
The cellular mechanisms by which idiopathic and even many congenital forms of DCM 
contribute to disease etiology, including CDG-related DCM, remain unknown. Previous studies 
from our laboratory demonstrated that ST3Gal4 
-/- 
has reduced cardiac NaV and KV channel 
sialylation, altered cardiac NaV and KV gating,  and increased susceptibility to arrhythmias 
[108, 
110]
. A very recent study  provided some insight and elegantly showed that incomplete Na
+
 
channel inactivation that leads to an extended AP and prolongation of the ECG QT segment was, 
“…sufficient to drive structural alterations, including atrial and ventricular enlargement,” 
providing convincing evidence that aberrant NaV gating that extends the AP/QT segment can 
contribute directly to cardiomyopathy 
[169]
. The data presented here combined with our previous 
efforts provide a possible mechanistic link between reduced sialylation, aberrant electrical 
signaling, idiopathic DCM and heart failure 
[108, 110]
. That is, we previously showed in this same 
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ST3Gal4
-/-
 strain, that reduced cardiomyocyte NaV sialylation resulted in altered NaV gating and 
arrhythmogenic activities similar to that described for the aforementioned heart failure model, 
SCN5A mutations correlated to DCM in humans 
[110, 164, 170-174]
. Using statistical in silico 
modeling, we recently verified that these sialic acid-dependent Nav gating changes directly 
contribute to arrhythmogenic activity 
[109]
. In addition, we reported significant effects on 
sialylation and gating of Kv isoforms, reduced cellular and ventricular refractory periods, as well 
as AP/QT segment prolongation in ST3Gal4
-/-
 hearts that would likely exacerbate the arrhythmic 
behavior 
[108, 110]
. We also showed that ST3Gal4 expression had no measurable impact on 
voltage-gated Ca
2+
 channel (CaV) activity. Thus, the extended AP/QT (due to loss of KV 
functions and altered NaV activities during AP) and the shorter refractory period (due to faster 
recovery of NaV) likely contribute to the increased arrhythmogenic activity that is similar to that 
observed in humans with NaV1.5-correlated congenital arrhythmic DCM, in the previously 
discussed mouse model for heart failure, and in the recent study that shows aberrant Na
+
 influx is 
sufficient to induce cardiomyopathy 
[164, 169-174]
. Here, we show that the same animals that are 
susceptible to arrhythmias, present at an older age with dilated chambers and thinner-walled left 
ventricles and they are highly susceptible to chronic stress-induced heart failure. Masson’s 
trichrome staining did not detect any increased fibrosis in 1.5-year old ST3Gal4
-/-
 hearts when 
compared to wildtype littermates (See Figure 3.6), therefore the mechanism of fibrosis-induced 
arrhythmogenesis or conductive abnormality in ST3Gal4
-/-
 was unlikely 
[159]
.  
Potential cellular mechanisms responsible for human congenital arrhythmic DCM as 
described by others (for e.g., see 
[165, 170, 175-178]
) include: 1) disruption or weakening of 
cytoskeletal components or of interacting voltage-gated ion channel auxiliary proteins 
[165, 175]
, 
and 2) altered Ca
2+
 homeostasis secondary to aberrant electrical signaling that impacts 
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electromechanical activity 
[170, 177, 178]
.  While we cannot definitively rule out involvement of 
cytoskeletal components, we see no evidence to support a mechanism that involves disruption of 
proteins interacting with voltage-gated ion channel alpha subunits, as no change in current 
densities of any cardiomyocyte voltage-gated ionic current was observed 
[108, 110]
.  Thus, aberrant 
Ca
2+
 homeostasis that occurs in the absence of altered CaV activity appears to be the most likely 
potential mechanism as also suggested by Wan et al.
[169]
. That is, reduced sialic acid levels 
attached to cardiomyocyte NaV and KV directly cause a change in channel gating that is 
responsible for aberrant electrical signaling as described above
 [108-110]
, and this likely leads to 
altered cardiomyocyte Ca
2+
 homeostasis 
[178]
.  While reduced glycoprotein sialylation could 
impact numerous cellular pathways, sialo-dependent arrhythmias induced by changes in NaV and 
KV gating resulting in altered cytosolic Ca
2+
 is one viable mechanism that links aberrant 
sialylation, altered electrical signaling, idiopathic DCM, and chronic stress-induced heart failure 
which will be the focus of future experimental and in silico studies.  
 
Dystrophin-Associated Protein Complex and DCM 
Various gene mutations cause human DCM 
[179, 180]
. So far, about 50 DCM-causing genes 
were discovered, such as, Fukutin, Fukutin-related protein, dolichol kinase (DOLK), 
acetylglucosaminyltransferase-like protein (LARGE), dystrophin, dystroglycans, sarcoglycans, 
Lamin A/C (LMNA) and etc. 
[60, 61, 78, 181-183]
. Some of those genes translate cytoskeletal proteins. 
Others encode glycosyltransferases (e.g. Fukutin, Fukutin-related protein, DOLK, LARGE and 
etc.) which belongs to the subtypes of a larger group of inherited disease, human congenital 
disorders of glycosylation (CDG). DCM patients can also have reduced glycosylation in their 
hearts 
[69, 72]
. For example, patients suffering from heart failure secondary to idiopathic DCM 
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have reduced α2,3-sialylation but not α2,6-sialic acid in their cardiac tissues [72]. The microarray 
analysis of idiopathic DCM patients’ LV tissues also revealed a significant reduction in Mgat1 
expression (nearly 2 fold reduction) when compared to the non-failing hearts 
[69, 70]
, indicating 
the bidirectional communication between glycosylation and DCM. 
Dystrophin-associated protein complex (DAPC) is a collection of glycoproteins located 
in between the extracellular matrix and intracellular cytoskeleton, mediating cellular interactions 
with extracellular matrix, and is essential for membrane stabilization, force transmission and 
synapses formation 
[78]
. DAPC is heavily glycosylated 
[78]
. Interruption of DAPC glycosylation 
leads to DCM, such as dolichol kinase-congenital disorder of glycosylation, Fukuyama-type 
congenital muscular dystrophy, limb-girdle muscular dystrophy, Duchenne muscular dystrophy 
and Becker muscular dystrophy 
[60, 61, 78, 182]
. DAPC also participates in the transduction of 
extracellular-mediated signals to the muscle cytoskeleton 
[80, 165]
, in which DAPC binds and 
regulates multiple ion channels (e.g. Nav, TRPC, sarcolemmal calcium pump, mechanosensitive 
Na
+
 channels and etc.),  G proteins, neuronal nitric oxide synthase (nNOS) and etc. for signal 
conduction 
[80]
. It is not clear whether ST3Gal4 deletion altered DAPC sialylation, which in turn 
interrupted nNOS signaling that can lead to elevated basal blood pressure in ST3Gal4
-/-
 
[184]
. 
Additionally, the very preliminary data showed a marked reduction of α-dystroglycan (α-DG) 
protein expression in male Mgat1CKO, supporting the mechanism of disrupted Dystrophin-
associated protein complex (DAPC) induced DCM in Mgat1CKO.  
SCN5A participates in murine cardiogenesis at early gestational stages and SCN5A
-/-
 is 
embryonically lethal in mice 
[185]
. Knockdown of SCN5Laa and SCN5Lab (the human SCN5A 
homologs) in zebrafish also exhibited severe cardiac defects with reduced cardiogenic genes 
expression (e.g. nkx2.5, gata4 and hand2) that was independent of electrophysiological effects, 
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suggesting sodium channel regulates early cardiac development via interaction with other 
proteins but not sodium current 
[113]
. Interestingly, the knockdown of zebrafish ether-à-go-go-
related gene potassium channel failed to interrupt cardiogenesis 
[113]
.There is an ongoing debate 
on whether NaV dysfunction is the cause or the result of DCM 
[164, 165, 172, 173, 186-188]
. Some of 
those studies screened the DCM-causing genes such as nkx2.5, LMNA and gap junction encoding 
genes such as Cx43, Cx40 and Cx45; and stated that all of those genes were intact except for the 
detected SCN5A mutations. However, those studies did not examine DAPC or glycogenes 
expressions. It is hypothesized that NaV and or KV associate with syntrophin-dystrophin complex 
at the lateral sarcolemma and synapse-associated protein 97 (SAP97) at the gap junction of 
cardiomyocytes 
[165, 175, 189]
. The interruption of DAPC lead to altered NaV and/or KV gating 
which contributes to the severe arrhythmia in DCMs of Duchenne muscular dystrophy, Becker 
muscular dystrophy and etc. 
[165, 189]
. However, future studies need to be done to evaluate the 
expression and activity of DAPC in ST3Gal4
-/-
 and Mgat1CKO. 
 
Future Studies 
The current and previous studies have shown that reduced glycosylation altered voltage-
gated ion channel gating (e.g. NaV and KV gating) and AP waveform in cardiomyocytes, causing 
subsequent arrhythmia and ECG changes 
[27-30, 105, 107, 108, 110-112, 114-121]
. It is reported that 
prolonged AP duration increased intracellular [Ca
2+
], therefore disrupted [Ca
2+
] homeostasis 
[171]
. 
Voltage-gated ion channel, such as NaV, was also shown to interfere with downstream Ca
2+
 
signaling. However, it is not known if intracellular [Ca
2+
] was indeed changed in ST3Gal4
-/-
 or 
Mgat1CKO cardiomyocytes. Future studies are needed to evaluate intracellular [Ca
2+
] in 
ST3Gal4
-/-
 and Mgat1CKO via Ca
2+
 imaging. The traditional Ca
2+
 imaging is soon be replaced 
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with the high speed Ca
2+
 imaging technique using Nipkow-type spinning-disk confocal 
microscopy (Olympus “live cell” DSU) with Fluo-4 AM calcium indicator. This new technology 
provides up to 2000 fps on a 2D whole cell level, with high signal-to-noise ratio, fast “on” and 
“off” kinetics and high sensitivity provided by the new dye, better suited for studying the fast 
intracellular event like Ca
2+
 events in cardiomyocytes 
[190, 191]
. Optical mapping is another 
extremely power tool to study arrhythmogenesis. It provides 3D evaluation on the whole heart 
level for intracellular [Ca
2+
] and AP propagation, in conjunct with different stimulation protocols 
and pseudo-ECG recording, providing a comprehensive image for heart excitation, signaling 
propagation and conduction velocity 
[192-194]
.   
Calcineurin was implied in the pro-survival signaling pathways previously 
[85]
. In young 
16- 20 week old ST3Gal4
-/-
 before cardiac structural and functional changes, calcineurin 
expression was reduced in left ventricles of ST3Gal4
-/-
 (See Figure 3.9). In addition, 
cardiomyocytes appears atrophic in ST3Gal4
-/-
 and Mgat1CKO (See Figure 3.5&4.5). Future 
studies are also needed to examine the cell apoptosis to determine if ST3Gal4 or Mgat1 is 
involved in cardiomyocytes’ survival.  
Because the gene deletion of ST3Gal4 and Mgat1 in ST3Gal4
-/-
 and Mgat1CKO started in 
utero and resulted in significant DCM phenotype which can cause arrhythmia. In order to better 
understand glyco-dependent arrhythmogenesis, we could use inducible animal model to turn on 
and off ST3Gal4 or Mgat1 in a short period of time, circumventing the cardiac structural effect. 
Last but not the least, the striking sex-differential phenotype in Mgat1CKO needs to be 
studied. Mgat1 is an autosomal gene, yet Mgat1 deletion produced a significant difference in 
cardiac phenotype between female and male Mgat1CKO. Whether and how hormones affected 
the glyco-dependent cardiac phenotype is not clear. Even though most of dystroglycanopathies 
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are caused by X-linked chromosomal gene mutations, the similarity between dystroglycanopathy 
and our animals prompted the question whether DAPC expression or its glycosylation was 
affected by ST3Gal4 or Mgat1. In addition, Mgat1 protein expression level needs to be checked 
in both male and female Mgat1CKOs.  
In general, the translatable knowledge obtained above will not only further our 
understandings in the causes and mechanisms of clinical DCM and heart failure, but also provide 
prognostic tools and therapeutic targets for disease diagnosis and treatments.  
 
 
 
 
164 
 
SUMMARY 
 
α2,3-sialylation and complex N-glycosylation are essential in cardiac function. 
Interruption of sialylation or complex N-glycosylation renders heart developing dilated 
cardiomyopathy, contractile dysfunction and arrhythmia. Both ST3Gal4 and Mgat1 did not 
participate in murine cardiogenesis, as no sign of cardiac defects under autopsy or 
echocardiography. Sex difference in cardiac phenotype was most obvious in Mgat1CKO. Future 
studies are needed to elucidate its mechanisms. In general, the current study is the first and direct 
evidence of desialylation-elicited idiopathic dilated cardiomyopathy (DCM), reporting the 
cardiac phenotype of ST3Gal4
-/-
and cardiac-specific knockout of Mgat1. The study provided new 
targets for therapeutic and preventive interventions in addition to fundamentally advancing the 
fields of glyco-dependent DCM, such as metabolic cardiomyopathy, human congenital disorders 
of glycosylation, Chagas disease, and sudden cardiac death.  
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